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Metastasis, the spread of cancer cells from a primary tumor to a distal organ,
represents the predominant cause of mortality in patients with solid tumors. However, the
molecular mechanisms underpinning this multistep progression are poorly defined.
Successful metastasis requires a cancer cell to acquire multiple capabilities, including the
ability to migrate, invade, and co-opt the microenvironment in the distal organ for
colonization. Many of these phenotypes require the actions of a family of lipids called
phosphoinositides (PIs). Although structurally small molecules and minor components of
the cellular lipidome, PIs are critical mediators of many cellular processes through their
localization, abundance, and recruitment of effector proteins. The actions of PIs are
orchestrated by PI regulator proteins that bind to or act upon each PI. Identifying and
characterizing PI regulator proteins that promote metastasis could elucidate novel cellular
pathways and enable the development of therapeutic approaches targeting mechanisms
unique to metastatic disease.
In this thesis, I describe work delineating the molecular mechanisms of three PI
regulator proteins in promoting breast cancer metastasis. These proteins were initially
identified as putative targets of the metastasis suppressor miRNAs, miR-126 and miR335. We identify PITPNC1 as amplified in nearly half human breast cancers, and

overexpressed in metastatic melanoma, breast, and colon cancer. Biochemical and cellbiological experiments reveal that PITPNC1 binds to phosphatidyl inositol 4-phosphate
(PI4P) in the Golgi. Through this binding, PITPNC1 recruits RAB1B to the Golgi, which
in turn recruits GOLPH3. GOLPH3 facilitates elongation of the Golgi structure,
enhancing vesicular release. Through this pathway, PITPNC1 increases the secretion of a
set of pro-angiogenic and pro-invasive proteins including ADAM10, FAM3C, HTRA1,
MMP1, and PDGFA.
In the second half of this thesis, I characterize the molecular mechanism of
PTPRN2 and PLCβ1 in driving breast cancer metastasis by enhancing cellular migration.
I find that increased expression of PTPRN2 and PLCβ1 associates with human metastatic
relapse. PTPRN2 and PLCβ1 enzymatically reduce plasma membrane phosphatidyl
inositol 4,5-bisphosphate (PI(4,5)P2) through two independent mechanisms. Reduction of
plasma membrane PI(4,5)P2 abundance releases the PI(4,5)P2-binding protein cofilin
from its membrane-bound inactive state into the cytoplasm. Cytoplasmic cofilin binds
and severs actin, generating free barbed ends in actin filaments and inducing actin
polymerization. PTPRN2 and PLCβ1-mediated actin remodeling dynamics increase
cellular migration, a key metastatic phenotype.
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CHAPTER I: INTRODUCTION

Breast Cancer in the United States: Subtyping and Staging
The American Cancer Society estimates that more than 230,000 new cases of
invasive breast cancer will be diagnosed in women in the United States in 2015, making
breast cancer the most common type of cancer among women in the United States. It is
estimated that one in eight women in the U.S. will develop invasive breast cancer during
her lifetime. Breast cancer is the second most common cancer-related cause of death
among women after lung cancer, with approximately 40,000 deaths per year. Breast
cancer can also afflict men although with a 100-fold lower incidence rate. An estimated
2,300 men will be diagnosed with breast cancer in 2015 and 400 will die from breast
cancer. Additionally, approximately 60,000 women will be diagnosed with carcinoma in
situ (CIS), a non-invasive form of breast cancer with a survival rate of essentially 100%
(The American Cancer Society, 2015).
Breast cancer is defined as neoplastic growth in the epithelial cells of the lobules
and ducts in the breast. Brest cancer is clinically heterogeneous disease with many
histopathological subtypes identified. The most common histopathological presentation is
invasive ductal carcinoma, which represents 50-80% of breast cancer cases (Polyak,
2011). Other less common subtypes include lobular carcinoma, tubular carcinoma,
mucinous carcinoma, medullary carcinoma, and inflammatory breast cancer. Histological
typing alone has proven to be a poor prognostic marker for survival and metastatic
relapse in patients (Ellis et al., 1992), indicating a role for molecular drivers of breast
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cancer progression that are independent of the morphological features of the tumor as
defined by these subtypes.
Advances in cellular expression profiling using high-throughput microarray-based
technology enabled the identification of molecular subtypes of breast cancer with
improved prognostic ability and prediction of effective treatment. Based on these studies,
four major subtypes have been identified and are now utilized in clinical diagnosis:
luminal-A, luminal-B, HER2 amplified, and basal-like (Perou et al., 2000; Sorlie et al.,
2001; Sotiriou and Pusztai, 2009). Luminal subtypes A and B are characterized by their
expression of the estrogen receptor and/or progesterone receptor, and comprise
approximately 70% of diagnosed malignancies (Sotiriou and Pusztai, 2009) . An
estimated 30% of patients with luminal B tumors also overexpress HER2. The luminal A
subtype is less proliferative than the luminal B subtype as measured by Ki67 staining,
and consequently patients whose tumors are luminal B subtype have a poorer prognosis
(Cheang et al., 2009).
HER2 amplified tumors exhibit high expression of HER2 and low expression of
the estrogen and progesterone receptors. They represent approximately 15% of invasive
breast cancers, and have a poorer prognosis than the luminal subtypes (Slamon et al.,
1987). Due to genomic amplification, breast cancers may have 25-50 copies of the HER2
gene resulting in 40-100-fold increases in HER2 protein levels (Kallioniemi et al., 1992;
Venter et al., 1987). HER2 encodes the human epidermal growth factor receptor, an
oncogene that when overexpressed promotes tumorigenesis through several pathways
including inducing mitosis and preventing apoptosis leading to deregulated cellular
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proliferation, disrupting cell adhesion and polarity, and enhancing invasive capacity
(Moasser, 2007).
Basal-like tumors are characterized by high expression of basal epithelial genes
and basal cytokeratins and low expression of estrogen receptor, progesterone receptor,
and HER2. The basal subtype is correlated with mutations in the BRCA1 gene, a tumorsuppressor gene involved in the repair of DNA double-strand breaks (Rakha and Ellis,
2009). Basal-like tumors grow at a more rapid rate than other types, and are more likely
to occur in women under age 50. Additionally these tumors are more likely to present as
a higher histological grade indicating that the cancer cells are dividing more rapidly
(higher mitotic index), are poorly differentiated, and show marked morphological
variation from normal breast cells. Basal-like tumors are characterized as triple-negative
breast cancer (TNBC) when they are negative for immunohistochemical expression of the
estrogen receptor, progesterone receptor, and HER2. TNBC represent 12-17% of women
diagnosed with breast cancer (Foulkes et al., 2010).
Breast cancer is diagnosed as four stages. Stages I through III are characterized by
the size of the tumor and whether the tumor has spread to nearby lymph nodes. Stage IV
is characterized as the spread of the tumor to a distant organ, or the process of metastasis.
The five-year survival rate for women diagnosed with breast cancer varies widely
depending on the tumor stage at diagnosis. According to the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) data, the five-year relative survival
rate for breast cancer when the tumor is confined to the primary site is approximately
99%. When the tumor has spread to regional lymph nodes, the survival rate decreases to
72-90%, depending on tumor size and number of cancer-positive lymph nodes. However,
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when the cancer has metastasized to a distal site, the survival rate drops dramatically to
22% (National Cancer Institute, 2015). For the vast majority of breast cancer-related
deaths, it is not the primary tumor but the occurrence of distal metastasis that is the
primary cause of death.

Treatments for Breast Cancer
Current treatment for breast cancer depends upon the subtype and stage at
diagnosis. Primary therapy for breast cancer involves surgical removal of the tumor,
unless the tumor is too large to be surgically resected. Adjuvant therapies are then
administered to prevent cancer recurrence, and these include radiation therapy and
chemotherapy. Additional adjuvant therapies are targeted depending on the breast cancer
molecular subtype. For breast cancers with overexpression of the estrogen or
progesterone receptors, endocrine therapy is administered that specifically targets these
receptors. Endocrine therapy primarily comprises two classes: selective estrogen
receptor modulators and aromatase inhibitors. Selective estrogen receptor modulators
such as tamoxifen bind the estrogen receptor competitively and prevent binding by
estrogens, inhibiting cancer cell growth. Tamoxifen administration reduces the relative
risk of death from breast cancer by 30% (Yeo et al., 2014). Aromatase inhibitors reduce
estrogens by blocking the aromatase enzyme from producing estrogens. As with the
selective estrogen receptor modulators, aromatase inhibitors reduce cancer cell growth by
lowering the amount of estrogens that reaches the cancer cell (Smith and Dowsett, 2003).
For patients whose tumors exhibit HER2 amplification, the primary targeted adjuvant
therapy is trastuzumab. Trastuzumab, marketed as Herceptin, is a monoclonal antibody
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that binds to the HER receptors to inhibit their ability to induce cellular growth and
progression. Trastuzumab slow disease progression and reduces the risk of death from
breast cancer by 20% in patients (Slamon et al., 2001).
There are currently no targeted biological therapeutics for women with TNBC.
Given their low expression of estrogen and progesterone receptors, these tumors to not
respond to endocrine therapy. Approximately 20% of women with TNBC will respond to
chemotherapy, however the majority shows no response (Foulkes et al., 2010). TNBC
patients with BRCA gene mutations may benefit from poly-ADP ribose polymerase
(PARP) inhibitors. Cells with BRCA mutations are highly sensitive to PARP activity, a
base-excision enzyme in DNA double-strand break repair. Addition of PARP inhibitors
to these cells induces chromosomal instability and results in apoptosis (Farmer et al.,
2005). Various PARP inhibitor compounds are currently undergoing clinical trials in
breast cancer patients. Identifying additional genes that are critical for TNBC tumor
growth and disease progression has the potential to identify novel targeted therapeutics
for this patient population.
Since metastasis is the predominant cause of mortality in breast cancer patients,
identifying therapeutic targets of metastatic progression represents an unmet clinical need
of high importance.
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Molecular Mechanisms of Metastasis
In order to treat or prevent the process of metastasis, it is necessary to understand
the molecular mechanisms of metastasis and determine key mediators of metastatic
progression. Metastasis requires a cascade of steps, each requiring distinct phenotypes
and molecular capacities of a cancer cell. A cancer cell in the primary tumor must
migrate out of the primary tumor site, intravasate into the vasculature, survive in the
blood vessels, arrest in capillary beds, extravasate out of the vasculature, and inhabit a
distal organ. Each step in the metastatic cascade is highly inefficient and may be ratelimiting, such that only an estimated 0.01% of all disseminated cancer cells ultimately
successfully colonize a secondary site (Fidler, 1970).
The primary tumor is composed of a heterogeneous population of cells, likely
driven by the selective pressure placed on the tumor, such as lack of nutrients, lack of
oxygen, or low pH in combination with the genetic instability frequently present within
cancer cells. Genetic instability in cancer cells can be due to mutations in DNA repair
proteins, telomeric dysfunction, or abnormal mitosis (Chiang and Massague, 2008), and
this increases the frequency of alterations that produce varied cellular phenotypes. Cancer
cells must be able to overcome many barriers in order to survive and grow, such as the
ability to sustain proliferation, resist cell death, evade the immune system, and induce
angiogenesis (Hanahan and Weinberg, 2011). However, in addition to these capabilities
to survive in the primary tumor, metastatic cells must possess additional abilities in order
to metastasize. The molecular and phenotypic variation in the primary tumor cells
produces a subpopulation of cells capable of completing the metastatic cascade.
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The first step of the metastatic cascade requires that a cancer overcome cellintrinsic and cell-extrinsic barriers to leave the primary tumor site. Metastatic cancer cells
exhibit reduced cellular adhesion, a necessary quality for a cancer cell to leave the tumor
colony. This reduced cellular adhesion is often a result of a loss of E-cadherin, a
transmembrane protein that tethers cells together forming junctions (Perl et al., 1998).
Additionally, cancer cells may recruit stromal cells, which secrete proteinases capable of
cleaving cell-adhesion integrins, enabling cancer cells to dissociate from the primary
tumor (Kessenbrock et al., 2010).
Another phenotype that is required for metastasis in increased migratory capacity,
enabling cancer cells to traffic throughout the body. Through advances in in vivo imaging
of invasive cancer cells it was noted that cancer cells migrate at high speed along
collagen fibers in the extracellular matrix, and this phenotype correlated with the
metastatic capacity of these cells (Condeelis and Segall, 2003). The enhanced migratory
capacity of cancer cells is mediated by changes in the actin cytoskeleton, cell adhesion
contact disassembly, and factors in the microenvironment that induce signal transduction
(Condeelis et al., 2005). Cancer cells migrate towards growth factors, a process known as
chemotaxis. For example, tumor-associated macrophages secrete epidermal growth factor
(EGF), which stimulates cancer cell migration by binding to the EGF receptor and
inducing actin polymerization and motility (Wyckoff et al., 2004). The RHO family of
small GTPases have also been shown to be necessary for cancer cell motility. Both RHO
and RAC proteins have been identified as overexpressed in various cancers, and this
overexpression correlates with worse patients outcomes (Sahai and Marshall, 2002).
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In addition to migration, metastatic cells must also be able to invade through
tissue in order to metastasize. Cancer cells need to overcome components of the tumor
microenvironment that act to limit invasion, such as the extracellular matrix and
basement membrane. The extracellular matrix (ECM) is composed of proteoglycans, and
fibers such as collagens, elastins, fibronectins, and glycoproteins such as laminins. The
basement membrane is layers of ECM that separate the endothelium from deeper tissues.
Invasive cancer cells form membrane protrusions called invadopodia to move through the
ECM and penetrate the basement membrane to gain access to the vasculature.
Invadopodia formation is mediated by WASP proteins and the Arp2/3 protein complex,
which are required for invasion in breast cancer cells (Gligorijevic et al., 2012). Invasive
cancer cells degrade the extracellular matrix by secreting proteinases, such as matrix
metalloproteinase 1 (MMP1). The degradation of the ECM is also facilitated by MMPs
secreted by stromal cells including tumor-associated macrophages and fibroblasts
(Kessenbrock et al., 2010). The degradation of the ECM by cancer cells and the ability to
coordinate cellular migration and invasion are necessary features for cancer cells to begin
the metastatic process.
Once cancer cells have migrated away from the primary tumor site and invaded
through the ECM, they next invade into the vasculature, a process called intravasation.
Cancer cells must then survive in the circulation, where they are subjected to sheering
forces as part of hemodynamic flow. During travel through the circulation, cancer cells
are not adhered to the ECM, a condition that triggers programmed cell death in normal
cells (a mechanism referred to as anoikis). Cancer cells are able to resist anoikis, although
the mechanism of this ability is not yet described. Additionally, cancer cells have been
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found to bind to platelets. Binding to platelets protects cancer cells from turbulent blood
flow and shields these cells from immune surveillance (Nash et al., 2002). These
mechanisms enhance the ability of metastatic cells to survive in travel to a secondary site
in the organism.
Cancer cells in the circulation frequently arrest in capillary beds, where a subset
of cells are able to invade out of the blood vessel in the process of extravasation to arrive
at a secondary organ. However, the location of metastatic colonies is not sufficiently
explained by blood flow patterns. In early clinical studies of metastasis, it was noted that
metastatic nodules form preferentially in specific organs, leading Stephen Paget to
propose his “seed and soil” hypothesis, suggesting that cancer cells (“seeds”)
preferentially grow in specific compatible microenvironments (“soil”) (Paget, 1889). The
most common sites of breast cancer metastasis are the brain (10%), lung (20%), liver
(30%), and bone (40%). However in TNBC, the rates of distal metastasis are higher in the
brain and lung (30% and 40%, respectively) and lower in in the bone (10%) (Foulkes et
al., 2010). The organ specificity of metastasis for various cancers highlights the
importance of the interactions between cancer cells and their microenvironment. The
distal organs must facilitate the initial survival of the extravasated cancer cells, and the
cancer cells must be able to co-opt this novel organ site for their growth.
In the distal organ, the cancer cells initiate colonies that proliferate to form
metastatic nodules, hindering the organ’s structure and function until organ failure
occurs. However, this process may happen acutely, or cancer cells may enter dormancy
for a period of years. Consequently a cancer patient may remain in remission for several
years before the onset of metastatic relapse. Patients with HER2-amplified tumors or
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TNBC tend to relapse within five years, while patients with luminal tumor subtypes
demonstrate a constant rate of relapse over 10 to 15 years (Smid et al., 2008). Recent
studies have indicated that cancer cells undergo cell cycle arrest upon entering the distal
organ and require cell-extrinsic and cell-intrinsic signals to reactivate (Giancotti, 2013).
For example, a secreted antagonist of TGFβ ligands, Coco, accumulates on the surface of
metastatic cancer cells in the lung and shields them from the inhibitory action of growthsuppressing proteins (Gao et al., 2012).
It is clear from the complexity of the metastatic cascade that the coordinated
action of many genes is required for its completion. Full dissection of the molecular
mechanisms governing these processes has yet to be achieved, and given the molecular
heterogeneity in patients’ primary tumors, may involve a multitude of gene pathways
each capable of generating a given metastatic phenotype. One mechanism by which
cancer cells coordinate the expression of a network of metastatic gene products is posttranscriptional regulation carried out by small noncoding microRNAs.

Regulation of Metastasis by MicroRNAs
MicroRNAs or miRNAs are small noncoding RNAs that are processed through
cleavage events to generate 21-26-nucleotide miRNA duplexes (Kim, 2005; Winter et al.,
2009). One strand of the miRNA duplex is loaded into the RNA-induced silencing
complex (RISC), and the miRNA guides the binding of the RISC complex to messenger
RNAs (mRNAs) with sequence complementarity (Liu et al., 2004). Binding of mRNAs
by the RISC leads to translational repression, reducing gene and protein expression of a
given miRNA’s target transcript (Filipowicz et al., 2008). miRNAs may share sequence

10

complementarity with multiple genes, enabling a single miRNA to regulate the
expression of several genes concurrently. Deregulated miRNA expression as a
mechanism to modulate the expression of a gene network is an established feature of
metastasis in multiple cancers, including breast, colorectal, gastric cancers, melanoma,
and hepatocellular carcinoma (Li et al., 2011b; Loo et al., 2015; Pencheva et al., 2012;
Tavazoie et al., 2008; Wong et al., 2011).
To identify miRNA regulators of metastasis, poorly metastatic MDA-MB-231 and
CN34 breast cancer cell populations were subjected to in vivo selection to enrich for
subpopulations with the ability to colonize the lungs (Pollack and Fidler, 1982). The
resulting LM2 and CNLM1a1 sublines exhibit increased lung metastatic capacity relative
to their respective parental populations (Minn et al., 2005; Tavazoie et al., 2008). Small
RNA profiling of the in vivo-selected highly metastatic breast cancer cells and their
poorly metastatic parental cell populations revealed miR-126 and miR-335 as silenced in
the highly metastatic sublines. Depletion of these miRNAs increased the metastatic
capacity of breast cancer cells while overexpression of either miRNA abrogated
metastatic colonization capacity, establishing miR-126 and miR-335 as functional
suppressors of breast cancer metastasis. Breast cancer patients whose primary tumors’
express low levels of miR-126 and miR-335 have worse overall survival and relapse-free
survival compared to patients whose primary tumors’ express high levels of these
miRNAs (Tavazoie et al., 2008). Interestingly, miR-126 has now been identified as a
tumor suppressor miRNA in lung, cervical, pancreatic, colorectal, and gastric cancers as
well (Feng et al., 2010; Guo et al., 2008; Hamada et al., 2012; Wang et al., 2008;
Yanaihara et al., 2006). miR-335 has also been identified as a suppressor of metastasis in
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small cell lung, gastric, and ovarian cancers (Cao et al., 2013; Gong et al., 2014; Yan et
al., 2012).
These microRNAs mediate their effects through their downstream gene targets. In
highly metastatic breast cancer cells, silencing of these miRNAs de-represses the
expression of a set of pro-metastatic genes. miR-126 was demonstrated to repress the
expression of IGFBP2, MERTK, and PITPNC1, which enhance metastasis through the
recruitment of endothelial cells (Png et al., 2012). miR-335 represses the expression of
several pro-metastatic genes, including SOX4, TNC, PTPRN2 and PLCB1 (Tavazoie et
al., 2008). We were intrigued by the finding that three of these putative targets of miR126 and miR-335, PITPNC1 (phosphatidyl inositol transfer protein cytoplasmic 1),
PTPRN2 (phosphotyrosine phosphatase receptor type N 2), and PLCβ1 (phospholipase C
beta 1), shared a common functional characterization as regulators of phosphoinositides.

Phosphoinositides in Normal and Metastatic Cell Processes
Phosphoinositides (PIs) are key regulators of many cellular functions in both
normal and malignant cells. PIs are the major determinants of membrane identity and
regulate membrane trafficking in both normal and disease states (Balla, 2013; Vicinanza
et al., 2008). PIs consist of an inositol ring linked to a diacylglycerol backbone through a
phosphodiester linkage. These lipids are synthesized in the endoplasmic reticulum by PI
synthase enzymes and distributed throughout the cell through vesicular traffic and PI
transfer proteins (Agranoff et al., 1958). The function and localization of PIs differ
greatly depending on the phosphorylation state of the hydroxyl groups on the inositol
ring, which are metabolically interconverted to different phosphorylated states by PI
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kinases and PI phosphatases, or reduced to second messengers through PI hydrolyzers.
The inositol ring may be phosphorylated at the 3’, 4’ and 5’ positions. Through the
advent of novel biochemical and cell-biological methods, the cellular roles of various PIs
and their protein regulators in secretion, endocytosis, actin dynamics, and intracellular
signaling have begun to be elucidated (Mayinger, 2012). Although the roles of
phosphatidyl inositol 5-phosphate (PI5P) and phosphatidyl inositol 3,4-bisphosphate
(PI(3,4)P2) are still unclear, functions of the other five PIs have been delineated in
multiple pathways as described below. These PIs govern cellular functions through
recruiting proteins to specific cellular locations. To modulate these processes, protein
regulators of PIs may increase or decrease the abundance of a PI or change the location of
a PI.
Phosphatidyl inositol 3-phosphate (PI3P) is mainly located in endosomes where it
mediates several steps of endocytic membrane trafficking. Endocytic vesicles fuse with
early endosomes that then combine to form multivesicular bodies and then late
endosomes. The contents of late endosomes are either sorted for recycling back to the
Golgi or sorted for degradation in lysosomes. PI3P recruits proteins involved in endocytic
vesicle fusion to early endosomes such as Rab5 and EEA1 (Simonsen et al., 1998). PI3P
is phosphorylated to phosphatidyl inositol 3,5-bisphosphate (PI(3,5)P2) in late
endosomes by the 5’ kinase PIKfyve. PI(3,5)P2 has been implicated in regulating the
localization and size of late endosomes and lysosomes, however PI(3,5)P2 effector
proteins have yet to be identified (Dove et al., 2009). Therefore both PI(3,5)P2 and PI3P
regulate endocytosis, a process which is disrupted in cancer cells. Improper endocytic
trafficking of growth receptors can lead to prolonged growth signaling. Improper
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endocytosis of cell surface marker leads to loss of cell polarity, a hallmark of tumor cells
(Mosesson et al., 2008).
Phosphatidyl inositol 4-phosphate (PI4P) is the most abundant PI within the cell.
It is mainly localized in the Golgi, the organelle responsible for vesicular sorting,
however a pool of PI4P also exists in the plasma membrane (Balla et al., 2005). The role
of PI4P in the plasma membrane is less well described, although PI4P may serve as a
precursor for PI(4,5)P2 in the plasma membrane. PI4P is synthesized from PI by PI4kinases which are present in the trans Golgi network (TGN), the Golgi stacks closer to
the plasma membrane rather than the cis stacks closer to the endoplasmic reticulum
(Balla et al., 2002). PI4P is essential for the Golgi’s function in exocytosis, as it recruits
proteins such as AP-1 and FAPP-2 that are critical for vesicle budding from the TGN
(Godi et al., 2004; Wang et al., 2003). Additionally, PI4P maintains Golgi structure
through the PI4P-binding protein GOLPH3 linked to the actin cytoskeleton (Dippold et
al., 2009). Since secretion is necessary for metastatic invasion, angiogenesis, and
remodeling of the metastatic niche, regulation of Golgi PI4P is an important process in
metastatic cancer cells.
Phosphatidyl inositol 4,5-bisphosphate (PI(4,5)P2) is present mainly in the plasma
membrane where it performs a myriad of functions including membrane trafficking,
signaling, and actin dynamics. This lipid has been implicated in regulated exocytosis by
recruiting the CAPS protein (calcium-activated protein for secretion) to the plasma
membrane where it facilitates secretory vesicle fusion to the plasma membrane. PI(4,5)P2
has also been shown to be involved in clathrin-mediated endocytosis by recruiting the
clathrin adaptor protein AP-2, which aids in the formation of clathrin-coated pits
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necessary for endocytic vesicle formation. However, PI(4,5)P2 must then be removed
from endocytic vesicles after membrane fission or the vesicles become coated with actin
and aggregate in the cytoplasm (Brown et al., 2001). PI(4,5)P2 is involved in cellular
signaling through its hydrolysis to generate the second messengers diacylglycerol (DAG)
and inositol triphosphate (IP3), which activate protein kinase C signal transduction
cascades. Additionally PI(4,5)P2 has recently been found to regulate the activity of ion
channels and transporters in the plasma membrane, although the mechanism of activation
and physiological relevance have yet to be determined (Suh and Hille, 2008). This lipid
also regulates actin dynamics by recruiting multiple actin remodeling proteins including
cofilin, WASP, and ERM proteins to differentially activate or inhibit their activity.
Modulating actin dynamics is required for cancer cell motility. PI(4,5)P2 is also the
precursor to phosphatidyl inositol 3,4,5-trisphosphate (PI(3,4,5)P3 or PIP3), a key
molecule in cancer cell proliferation.
PIP3 is generated by PI3-kinase when the kinase is activated through extracellular
signaling via growth factors, hormones, or cytokines. PIP3 then recruits the kinase Akt to
the plasma membrane where Akt is dually phosphorylated and becomes activated. Active
Akt phosphorylates many downstream substrates including mTOR, which promotes cell
growth and cell cycle progression. Because PIP3 is preferentially generated near sites on
the plasma membrane where signaling by extracellular factors has occurred, PIP3 plays a
key role in membrane polarization and chemotaxis.
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Phosphoinositides and Their Regulators in Cancer and Other Diseases
PIP3 is the best-characterized PI in cancer development and progression. PIP3
and the PI3-kinase signaling pathway effect multiple pro-tumorigenic cellular processes,
including cell growth, survival, adhesion, and motility. PIP3 levels are stringently
regulated by both PI3-kinase and PTEN, the phosphatase which dephosphorylates PIP3
back to its precursor, PI(4,5)P2. Mutations in PTEN and the alpha catalytic subunit of
PI3K (PI3KCA) are among the most common genetic changes in a broad spectrum of
cancers including up to 25% of breast cancers, up-regulating the activity of PI3-kinase or
abrogating the activity of PTEN to sustain PIP3 signaling (Samuels et al., 2004).
Additionally, inhibitory mutations in another PIP3 phosphatase, SHIP1 that
dephosphorylates PIP3 to PI(3,4)P2, have been identified in leukemia (Luo et al., 2003).
Given the importance of PIP3 signaling in cancer, PI3-kinase represents an attractive
target for the development of therapeutic anti-cancer agents (Liu et al., 2009).
Several protein regulators of PI(4,5)P2 have also been implicated in cancer.
PI(4,5)P2 is synthesized from PI4P by PIPKI, and mutations in the PIPKIγ isoform have
been identified in gastric cancer. Loss of PIP5KIγ activity in these cancer cells reduced
PI(4,5)P2 levels and weakened cell-cell junctions, enabling cells to dissociate from the
primary tumor as part of the beginning of the metastatic cascade (Yabuta et al., 2002).
PI(4,5)P2 is hydrolyzed by the phospholipase C family of enzymes. PLCγ expression is
increased in several cancers including breast, colorectal, prostate, and head and neck
cancer. PLCγ has been shown to enhance cancer cell motility following stimulation by
epidermal growth factor (EGF) in the tumor microenvironment (Bunney and Katan,
2010).
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A protein regulator of PI4P, GOLPH3, has also recently been identified as an
oncogene. GOLPH3 bridges PI4P and actin, inducing tensile forces that facilitate the
elongated ribbon morphology of the Golgi. Interestingly, copy number analysis revealed
GOLPH3 expression is frequently amplified in multiple solid tumor cancers, including
one-third of breast cancers and melanomas. Overexpression of GOLPH3 has been shown
to enhance cellular proliferation in cancer cells in vitro, although the precise mechanism
is unclear (Scott et al., 2009). The identification of GOLPH3 as a clinically relevant
cancer promoter further underlines the significance of PI4P in mediating cancer
phenotypes.

Other pathologies associated with protein regulators of PIs are X-linked, meaning
they are inherited through the X chromosome and thus predominantly afflict male
offspring of asymptomatic female carriers. These diseases may affect females as well, but
much more rarely since both parents must be carriers for the disease to manifest in female
offspring. X-linked agammaglobulinemia is disorder that afflicts patients with mutations
in their Btk gene. The encoded protein, Btk, contains a plekstrin homology (PH) domain
that binds to PIP3. Binding to PIP3 activates Btk’s kinase activity, enabling it to
phosphorylate phospholipase C, which in turn hydrolyzes PI(4,5)P2. Hydrolysis of
PI(4,5)P2 generates DAG and IP3, which mediate B cell signaling and maturation
(Conley et al., 2000). Patients with mutations in Btk thus do not generate mature B cells,
a key immune cell type responsible for the generation of antibodies in response to
infection. These patients develop persistent and recurrent infections unless treated with
intravenous infusion of immunoglobulin (IVIG).
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Oculocerebrorenal syndrome (also called Lowe syndrome) is also an X-linked
disorder caused by mutations in the OCRL1 gene. OCRLI is an inositol polyphosphate-5phosphatase, which dephosphorylates PI(4,5)P2 to generate PI4P, and loss of this protein
leads to elevated PI(4,5)P2 levels. OCRL1 has been demonstrated to localize to clathrincoated pits and early endosomes, indicating a role for this protein in endocytosis.
Additionally, fibroblasts from Lowe syndrome patients show defects in the actin
cytoskeleton and consequently impaired cell adhesion and migration. OCRL1 thus
impacts multiple aspects of membrane trafficking, which leads to a multifaceted clinical
presentation. Patients with Lowe syndrome display kidney function defects, cataracts,
glaucoma, hypotonia, and cognitive impairment (Mehta et al., 2014).
Myotubular myopathy and Charcot-Marie-Tooth Neuropathy Type 4 are both
caused by mutations in the MTM (myotubular myopathy) family of phosphatases, which
dephosphorylate PI3P. Myotubular myopathy is caused by mutations in the MTM1 gene
and manifests as mild to severe skeletal muscle weakness. MTM1 localizes to the PI3Prich endosomes in cells, but the mechanistic link between the role of MTM1 in
endosomal dynamics and muscle degeneration has yet to be determined (Tsujita et al.,
2004). Charcot-Marie Tooth (CMT) Neuropathy is caused by mutations in the MTMR2
gene, and is distinct from the above pathologies through its autosomal inheritance pattern.
Patients with CMT exhibit distal muscle weakens and sensory loss due to axonal
demyelinating and neurodegeneration. MTMR2 dephosphorylates both PI3P and
PI(3,5)P2, although the direct link between these PIs and myelination is unknown.
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Phosphoinositide Regulator Proteins as Drivers of Cancer Metastasis
Given the significance of phosphoinositide dysregulation in cancer and other
diseases, PI regulator proteins are potent mediators of pathogenesis. We sought to
determine the function of three proteins identified as putative targets of metastasis
suppressor miRNAs (PITPNC1, PTPRN2, and PLCβ1) in regulating PIs to promote
breast cancer metastasis. PITPNC1 is a member of the RdgB (Retinal Degeneration type
B) family of PI transfer proteins. This protein family was named after its founding
member RdgB when it was discovered that flies with mutations in this gene exhibit
impaired response to light and photoreceptor cell degeneration through vesiculation of
the rhabdomeric membranes (Harris and Stark, 1977). From these defects, it is postulated
that the function of RdgB is to bring PI to the rhabdomeric membranes where it is
synthesized to PI(4,5)P2, a key molecule in the light detection pathway (Harris and Stark,
1977). PITPNC1 (also known as RdgBβ) is a much smaller soluble homolog of RdgB,
and its function in mammalian cells is unknown.
PTPRN2 was initially identified as an auto-antigen in type I diabetes and is
predominantly present in neuroendocrine cells (Lan et al., 1996; Lu et al., 1996;
Wasmeier and Hutton, 1996). As a transmembrane protein, PTPRN2 shuttles between
secretory vesicles and the plasma membrane. Due to its presence in neurosecretory
vesicles, PTPRN2 has been implicated in insulin and neurotransmitter exocytosis,
however the precise role of PTPRN2 in the secretory pathway is unknown (Cai et al.,
2011). PTPRN2 belongs to the protein tyrosine phosphatase family, but does not exhibit
activity against phosphoprotein substrates due to several critical mutations in the PTP
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domain (Magistrelli et al., 1996). Recently, PTPRN2 was found to exhibit
phosphatidylinositol phosphatase (PIP) activity against PI(4,5)P2 (Caromile et al., 2010).
PLCβ1 belongs to the family of PLC enzymes, which hydrolyze PI(4,5)P2 to
generate the second messengers diacylglycerol (DAG) and inositol triphosphate (IP3)
(Rhee, 2001). PLCβ1 localizes mainly to the inner leaflet of the plasma membrane, where
it is activated by the Gaq family of G proteins, although a subset of the protein is found in
the cytoplasm and nucleus (Smrcka et al., 1991; Taylor et al., 1991).
In this thesis, I describe findings toward delineating the molecular mechanisms of
these three PI regulator proteins in breast cancer metastasis. Through molecular,
biochemical, cell-biological, and in vivo experiments as well as analysis of clinical
datasets, I describe roles for PITPNC1 in driving metastatic secretion through binding
PI4P (Chapters II and III) and for PTPRN2 and PLCβ1 in promoting metastatic migration
through modulating PI(4,5)P2 (Chapter IV). In Chapter V, I discuss the biological
implications of these findings for metastatic disease.
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CHAPTER II: CLINICAL RELEVANCE AND MECHANISTIC
CHARCTERIZATION OF PITPNC1 IN METASTASIS

Identification of Multiple Mechanisms of PITPNC1 Regulation in Breast Cancer
We began our mechanistic studies on PITPNC1 by seeking to identify pre- and
post-transcriptional mechanisms that augment PITPNC1 expression in highly metastatic
breast cancer cells. Kim Png and Nils Halberg had previously identified PITPNC1 as
target of miR-126, leading to increased PITPNC1 expression in highly metastatic cells
with silenced miR-126 (Png et al., 2012). Nils Halberg and I further identified a second
mechanism of post-transcriptional regulation of PITPNC1. We identified several regions
of sequence complementarity between the PITPNC1 coding sequence and the seed
sequence of another established metastasis suppressor miRNA in breast cancer, miR-335
(Figure 2.1). This sequence complementarity suggested that miR-335 might also be
capable of regulating PITPNC1 expression in breast cancer via miRNA-mediated gene
silencing through translational repression.
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To test this hypothesis, I performed heterologous luciferase reporter assays
wherein the coding sequence (CDS) and 3’ untranslated region (3’ UTR) of the PITPNC1
gene were cloned into a luciferase reporter vector, and these constructs were transfected
into MDA-MB-231 cells. The effect of miR-335 on the expression of its putative target
PITPNC1 was examined by measuring luciferase activity read-out after addition of the
luciferase substrate, luciferin. I tested whether decreasing expression of miR-335 by
transfecting cells with locked nucleic acid (LNA) targeting miR-335 would increase
PITPNC1-driven luciferase activity in these cells. Addition of LNA targeting miR-335
did not increase PITPNC1 CDS-driven luciferase activity compared to addition of a
control LNA, however PITPNC1-3’UTR-driven luciferase activity increased 1.5-fold
(Figure 2.2). These results were consistent with our analysis of putative miRNA target
sites in the PITPNC1 gene (Figure 2.1), which did not reveal miR-335 target sequences
with PITPNC1’s CDS, only within its 3’UTR. This suggests that miR-335 may repress
PITPNC1 translation through binding to PITPNC1’s 3’UTR. I performed site-directed
mutagenesis to mutate the 8-nucleotide sequence within PITPNC1’s 3’UTR
complementary to the seed sequence of miR-335. Importantly, mutating the miRNAcomplementarity sequence abrogated the miRNA-mediated regulation (Figure 2.2a),
consistent with direct targeting of PITPNC1 by miR-335.
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Figure 2.2. miR-335 directly regulates PITPNC1 through targeting its 3’UTR.
Heterologous reporter assays measuring luciferase activity driven off of PITPNC1’s wildtype or miR-335 target site mutant CDSs and 3’UTRs in MDA-MB-231 cells treated with
LNA targeting miR-335 or control LNA. n = 4. Data are represented as mean ± S.E.M.
**p < 0.01.
Given that miRNA silencing reduces translation of a gene target, we next
examined PITPNC1 protein levels in breast cancer cells with altered levels of miR-335.
Western blot analysis of PITPNC1 in LM2 cells with retroviral-induced overexpression
of miR-335 revealed reduced protein levels of PITPNC1 compared to cells
overexpressing a control vector (Figure 2.3a). Conversely, MDA-MB-231 cells treated
with LNA targeting miR-335 exhibited increased protein levels of PITPNC1 compared to
cells treated with control LNA (Figure 2.3b). These complementary experiments indicate
that miR-335 regulates the protein level of PITPNC1 in breast cancer cells, and reveal an
additional mechanism of post-transcriptional regulation of this gene in breast cancer
metastasis.
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Figure 2.3. miR-335 expression inversely correlates with PITPNC1 protein levels.
a. Western blot analysis of PITPNC1 levels in three biological replicates of LM2 cells
overexpressing miR-335 or a control vector.
b. Western blot analysis of PITPNC1 levels in three biological replicates of MDA-MB231 cells treated with LNA targeting miR-335 or a control LNA.
Western blot analysis of GAPDH was used as the loading control.
Consistent with loss of both miRNA-126 and miRNA-335 in the in vivo-selected
highly metastatic derivative sublines, PITPNC1 protein expression is higher in the LM2
and CNLM1a1 cells compared to their poorly metastatic parental populations, MDAMB-231 and CN34 respectively (Figure 2.4). Together these findings reveal PITPNC1’s
protein abundance is increased in highly metastatic breast cancer cells in part due to
silenced regulation by miR-126 and miR-335.
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Figure 2.4. PITPNC1 protein abundance in highly metastatic and poorly metastatic
breast cancer cells.
Western blot analysis of PITPNC1 levels in MDA-MB-231, LM2, CN34, and
CN34LM1a1 cells. Western blot analysis of GAPDH was used a loading control.
Nils Halberg analyzed genomic copy number data from 244 human breast cancer
cell lines and tumors from the Broad Institute’s Tumorscape (Beroukhim et al., 2010) and
found PITPNC1 to be significantly amplified in 46% of these samples
(q = 2.32 x 10-15) (Figure 2.5). Copy number variation has been found across many
cancers, due mainly to the genomic instability that is an established feature of malignancy
(Hanahan and Weinberg, 2011). Thus genomic amplification represents a third
mechanism by which breast cancer cells upregulate PITPNC1 expression, further
underlining its relevance in breast cancer metastasis.

Figure 2.5. Genomic amplification of PITPNC1 in breast cancer.
Genomic copy number analysis of 244 breast tumors and cell lines. Data from
Tumorscape (Beroukhim et al., 2010).
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Clinical Relevance of PITPNC1 in Breast Cancer, Colon Cancer, and Melanoma
We next sought to determine if PITPNC1 expression was clinically correlated
with breast cancer progression. We measured PITPNC1 cDNA levels in a commercially
available collection of human breast cancers, and found PITPNC1 expression increased
in cancerous tissue relative to normal breast tissue (Figure 2.6a). Consistent with a role
for PITPNC1 in promoting metastasis, PITPNC1 expression increased with breast cancer
stage, with the highest expression in stage IV (distal metastasis). Notably, in this dataset
and the Tumorscape dataset, PITPNC1 expression was higher in patients with triplenegative breast cancer (TNBC) (Figure 2.6b, c). Together these date support the
conclusion that increased PITPNC1 expression clinically correlates with breast cancer
progression, and may be particularly significant in TNBC.

Figure 2.6. PITPNC1 expression increases with breast cancer stage and correlates
with triple-negative breast cancer status.
a. PITPNC1 expression analysis of human breast cancers (stages I-IV) and normal
epithelial breast tissue (Non-Tumor) was performed using TissueScan qPCR Array
Breast Cancer Panels I, II, and III (Origene).
b, c. Data from Figure 2.5 and (a) were segregated based on their status as triple-negative
breast cancer (TNBC) or non-TNBC.
Data are represented as mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001.
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Given the data supporting regulation of PITPNC1 expression by miR-126 and
miR-335—two microRNAs that have been established as metastasis suppressors in
multiple cancers—we questioned if PITPNC1 was clinically correlated with metastatic
progression in other cancer types. PITPNC1 expression in patients’ primary melanoma
tumors and primary colorectal tumors was significantly correlated with metastatic
progression outcomes, indicating that PITPNC1 may promote metastasis in these cancers
in addition to breast cancer (Figure 2.7a, b).

Figure 2.7. Clinical correlation of PITPNC1 with metastatic outcomes in colorectal
cancer and melanoma.
a. Kaplan-Meier curve representing metastasis-free survival cohort of colorectal patients
(N=177) as a function of their primary tumor’s PITPNC1 expression levels (Data from
GSE17536). Patients whose primary tumors’ PITPNC1 expressions levels were greater or
lower than the median for the population were classified as PITPNC1 positive (red) or
negative (blue), respectively.
b. PITPNC1 expression levels in normal skin, patients’ primary melanoma lesions, and
patients’ distal metastatic lesions (Haqq et al., 2005). N = 37. Data are represented as
mean ± S.E.M. *p < 0.05, **p < 0.01.
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To determine whether PITPNC1 is a functional promoter of metastasis, we
depleted PITPNC1 in highly metastatic cells, injected these cells into the tail vein of
NOD SCID mice, and measured the ability of these cells to colonize the lungs. Png and
Halberg previously performed this assay in the highly metastatic derivative LM2 breast
cancer cells, and found that depletion of PITPNC1 significantly reduced the ability of
these cells to colonize the lungs (Png et al., 2012). Halberg and I depleted PITPNC1
using short hairpin RNA-mediated gene silencing in an additional highly metastatic
derivative breast cancer cell line, CNLM1a1, and again found that PITPNC1 expression
was necessary for these cells to maximally colonize the lungs of mice (Figure 2.8a, b).

Figure 2.8. Functional validation of PITPNC1 in breast cancer metastasis.
a. Western blot analysis of PITPNC1 levels in CNLM1a1 cells expressing a short hairpin
targeting PITPNC1 or a control hairpin. GAPDH was used as a loading control.
b. Bioluminescence imaging quantification of lung colonization by 40,000 CNLM1a1
cells as in (a). N=5 mice/group. Error bars represent SEM.

The LM2 and CNLM1a1 cell lines are derived from cells collected from human
breast cancer patients, so the metastatic assays must be performed in an immunodeficient
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background. We tested the role PITPNC1 in a syngeneic mouse model of spontaneous
breast cancer metastasis by depleting PITPNC1 in highly metastatic murine breast cancer
cells, 4T1. 4T1 cells were in vivo-selected for the ability to spontaneously metastasize to
the lungs of mice and form metastatic colonies (Aslakson and Miller, 1992). PITPNC1
knockdown in 4T1 cells also reduced the ability of these cells to metastasize in
immunocompetent mice, indicating that PITPNC1’s effects are independent of the
immune capacity of the host (Figure 2.9a, b). These findings establish PITPNC1 as a
robust mediator of breast cancer metastasis.

Figure 2.9. PITPNC1 drives metastasis in a syngeneic model of breast cancer
metastasis.
a. Western blot analysis of PITPNC1 levels in murine 4T1 cells transduced with short
hairpins targeting PITPNC1 or a control hairpin. Western blot analysis of GAPDH was
used as a loading control.
b. Bioluminescence imaging quantification of lung metastatic colonization by 50,000 4T1
breast cancer cells expressing a control or PITPNC1 targeting hairpins. N=5/group.
Right, representative lung histology. Data are represented as mean ± S.E.M. *p < 0.05.
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To functionally validate the role of PITPNC1 in colorectal cancer and melanoma,
we performed similar in vivo metastasis assays. For colorectal cancer, we depleted
PITPNC1 in the high metastatic colon cancer subline LS-174T-LvM3, derived from the
LS-174T human colon cancer cell line (Loo et al., 2015). This cell line possesses a
mutated form of the KRAS oncogene, which is mutated in 35-50% of colon cancers and
thus is relatively representative of human colorectal cancer (Wilson et al., 2010). Since
colorectal cancer predominantly metastasizes to the liver, these cells were injected
intrasplenically and liver colonization was measured. LS-174T-LvM3 with PITPNC1
depletion exhibited 15-fold reduced liver metastasis capacity compared to LS-174TLvM3 control cells (Figure 2.10a, b).

Figure 2.10. Functional validation of PITPNC1 as driver of colorectal cancer
metastasis.
a. LS174T-LvM3 colon cancer cells were transduced with a control hairpin or hairpins
targeting PITPNC1. PITPNC1 expression levels were determined by qRT-PCR.
b. Bioluminescence imaging quantification of liver colonization by 80,000 cells in (a).
Right, luciferase signal from ex vivo livers at day 21. N=6/group. Data are represented as
mean ± S.E.M. *p < 0.05.
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To test the role of PITPNC1 in melanoma metastasis, we depleted PITPNC1 in
the highly metastatic MeWo melanoma line (Pencheva et al., 2012) and tested the ability
of these cells to metastasize to the lungs. These cells were injected via the tail vein, and
MeWo cells with PITPNC1-knockdown showed 8-fold reduced lung colonization
capacity compared to control cells (Figure 2.11a, b). Together these data indicate
PITPNC1 is functionally required in colorectal cancer and melanoma metastasis.

Figure 2.11. Functional validation of PITPNC1 as driver of melanoma metastasis.
a. MeWo melanoma cells were transduced with lentivirus expressing a control hairpin or
hairpins targeting PITPNC1. PITPNC1 expression levels were determined by qRT-PCR.
b. Bioluminescence imaging quantification of lung colonization by 40,000 cells in (a).
Right, representative lung histology. N=5/group. Data are represented as mean ± S.E.M.
*p < 0.05.
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Identification of the Metastatic Phenotypes Mediated by PITPNC1
To investigate the mechanism by which PITPNC1 promotes metastasis, we next
sought to determine the metastatic phenotypes it governs. Png and Halberg previously
demonstrated that depletion of PITPNC1 in LM2 cells significantly inhibited in vitro
invasion of these cells though Matrigel, a gelatinous protein mixture that mimics the
extracellular matrix in tissue. Invasion is a necessary feature of highly metastatic cells, as
they must possess the capacity to invade through surrounding tissue, extravasate from the
primary site, and intravasate at a secondary site (Chiang and Massague, 2008).
Additionally, Png and Halberg found that depletion of PITPNC1 in LM2 cells
significantly reduced the ability of these cells to recruit endothelial cells (Png et al.,
2012). Recruitment of endothelial cells is a necessary precursor for the formation of new
blood vessels to supply nutrients to the tumor. However, Png and Halberg found that
recruiting endothelial cells aided in tumor growth at early stages of colonization, prior to
vasculature development, indicating that endothelial interaction may play a role in
metastatic initiation as well.
I tested the role of PITPNC1 in these metastatic phenotypes in several other cell
lines to confirm that PITPNC1 was required for these processes in multiple cancers.
Depletion of PITPNC1 using two independent short hairpin RNAs in CNLM1a1, HCC1806, BT-549, and 4T1 breast cancer cells all reduced the ability of these cells to invade
through Matrigel and recruit endothelial cells compared to cells transduced with a control
hairpin (Figure 2.12a, b). These human breast cancer cell lines all represent TNBC,
consistent with our clinical findings for a role for PITPNC1 in driving TNBC. The
requirement for PITPNC1 expression in these metastatic phenotypes was also observed in
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melanoma and colon cancer cells. PITPNC1 depletion in Mewo-LM2 melanoma cells
and 6513-LvM3B cells, a colon cancer cell line in vivo-selected for liver metastatic
capacity, reduced their invasive and endothelial recruitment capacities (Figure 2.12a, b).

Figure 2.12. PITPNC1 promotes Matrigel invasion and endothelial recruitment in
multiple cancer types.
a. Matrigel invasion by 50,000 LM2, 4T1, HCC-1806, BT-549, CN34LM1a1, MeWo or
LS174T-LvM3 cells expressing short hairpins targeting PITPNC1 or a control hairpin.
Data normalized to control group values. N=4/group.
b. Trans-well recruitment of 80,000 human umbilical vein endothelial cells (HUVEC) by
cancer cells as in (a). Data normalized to control group values. N=4/group.
Data are represented as mean ± S.E.M. ***p < 0.001.
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Depletion of PITPNC1 did not affect two additional metastatic phenotypes, in
vitro migration and proliferation. Cancer cells frequently demonstrate increased motility
(Condeelis et al., 2005), thus we tested in vitro migration by allowing breast, colon, and
melanoma cancer cells to migrate through a porous trans-well membrane. Depletion of
PITPNC1 did not affect the migratory capacity of breast, melanoma, or colon cancer cells
(Figure 2.13), indicating that the inhibitory effects we find in the Matrigel invasion assay
are not due to decreased migratory capacity of PITPNC1-knockdown cells, but instead
due to an inability to breakdown the Matrigel to enable movement—a process which
requires secreted factors.

Figure 2.13. PITPNC1 is not required for migration capacity in multiple cancer
types.
Trans-well migration of 20,000 LM2, MeWo, or LS174T-LvM3 cells expressing
PITPNC1 knockdown or control hairpin. Values were normalized to those of shControl
cells. N=4/group. Error bars represent S.E.M.

Additionally, the effects of PITPNC1-knockdown on in vivo metastasis, invasion,
and endothelial recruitment are not due to decreased proliferation, as these cells display
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similar growth rates to control cells (Png et al., 2012) (Figure 2.14a-c). These findings
reveal that the phenotypic effects of PITPNC1 depletion are selective and do not result
from reduced cellular viability.

Figure 2.14. Depletion of PITPNC1 does not affect cellular proliferation.
a-c. Proliferation of 20,000 MDA-MB-231 (a), 4T1 (b), and CN34LM1a1 (c) cells
expressing short hairpins targeting PITPNC1 or a control hairpin. N=3/group. Error bars
represent S.E.M.
Since depletion of PITPNC1 in highly metastatic cells revealed this gene as
necessary for maximal metastasis, invasion, and endothelial recruitment capacities, we
questioned if increased expression of PITPNC1 in poorly metastatic cells was sufficient
to augment these phenotypes. Indeed, overexpression of PITPNC1 in MDA-MB-231
cells was sufficient to enhance in vitro invasion and endothelial recruitment, as well as
metastatic colonization (Figure 2.15a-c). Therefore, PITPNC1 is both necessary and
sufficient for metastatic capacity.
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Figure 1.15. PITPNC1 is sufficient to promote breast cancer metastasis.
a, b. 50,000 MDA-MB-231 cells transduced with PITPNC1 overexpression or a control
vector were subjected to the Matrigel invasion assay (a) and endothelial recruitment
assay (b). N = 4/group.
c. Bioluminescence imaging quantification of lung colonization by 40,000 cells in (a).
N = 6/group. Right, representative lung histology.
Data are represented as mean ± S.E.M. **p < 0.01, ***p < 0.001.

Characterization and Mechanistic Role of PITPNC1’s Lipid-Binding Activity
To elucidate the molecular mechanism by which PITPNC1 regulates metastatic
colonization, we sought to determine the role of its phosphatidyl inositol transfer protein
(PITP) lipid-binding and transferring domain. This N-terminal domain comprises
approximately 80% of the PITPNC1 protein, with the remainder composed of a Cterminal unstructured tail. To perform lipid biochemistry experiments with PITPNC1, I
first expressed and purified recombinant PITPNC1 protein using an E. Coli IPTGinduced expression system. Although PITPNC1 was not expressed at high levels in the E.
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Coli, I was able to collect sufficient protein by expressing a GST-tagged fusion protein
and purifying the protein using glutathione-based affinity purification (Figure 2.16a).
To identify PITPNC1’s lipid substrate, Halberg first performed a lipid-overlay
assay in which a broad range of lipids were spotted on a membrane and blotted with
purified recombinant PITPNC1 protein. Bound PITPNC1 was detected using an antiGST antibody. These lipid-blot assays revealed that PITPNC1 binds most strongly to
Phosphatidyl inositol 4-phosphate (PI4P), with weaker binding to PIs containing a single
phosphate head group, namely phosphatidyl inositol 3-phosphate (PI3P) and phosphatidyl
inositol 5-phosphate (PI5P) (Figure 2.16b). To test this interaction in a more
physiological context, Halberg then conducted a vesicular pull-down experiment. In this
experiment, liposomes that contain the PI of interest are incubated with recombinant
PITPNC1 protein. The liposomes mimic the membranes in which these lipids would be
located in the cell, and thus binding is more biologically relevant compared to isolated
lipids. Following incubation, the liposomes are pelleted and the fraction of PITPNC1
protein bound to liposomes is compared to the fraction of PITPNC1 protein remaining in
the supernatant (unbound protein). Consistent with the lipid overlay assay, PITPNC1 was
found to bind to vesicles containing PI4P to a greater extent than to those containing
PI3P, PI5P, phosphatidyl inositol 3,4-bisphosphate (PI(3,4)P2), or phosphatidic acid (PA)
(Figure 2.16c).
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Figure 2.16. PITPNC1 binds to PI4P in vitro.
a. Gel electrophoresis of GST-tagged recombinant PITPNC1 protein stained with
colloidal blue (predicted molecular weight: 68 kD).
b. Lipid overlay assay. Lipid-bound recombinant PITPNC1-GST was detected with antiGST antibody. The experiment was repeated 3 times.
c. Vesicle pull-down assay of recombinant PITPNC1 using vesicles containing PI3P,
PI4P, PI5P, PI(3,4)P2, or PA. Pelleted vesicle fraction (P) and supernatant fraction (S)
were subjected to 1-D gel electrophoresis. Right, densitometry analysis of gel image
indicating percent of total PITPNC1 in pelleted fraction. N=3/group. Data are represented
as mean ± S.E.M. ***p < 0.001.

Having observed lipid binding towards PI4P in the above biochemical
experiments, we next sought to verify the physiological relevance of this binding. I
performed immunofluorescence microscopy experiments to elucidate the cellular
localization of PITPNC1 in breast cancer cells and determine if lipid-binding activity is
necessary for this localization. I observed that GFP-tagged PITPNC1 displays diffuse
cytoplasmic staining as previously described (Takano et al., 2003), but intriguingly
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showed most intense staining in perinuclear regions that co-stained with p230, a marker
of the trans Golgi network (TGN) (Figure 2.17a). The Golgi is the sorting hub for
vesicles traveling to the plasma membrane or endosomal compartments, and these
functions are dependent on resident PI4P (Mayinger, 2012). Although some PI4P is
localized to the plasma membrane as well, the TGN is the predominant location of PI4P
in the cell. Additionally, co-staining of PITPNC1 and PI4P using the PI4P-specific PHdomain of FAPP1 confirmed that PITPNC1 accumulates in PI4P-positive areas of the
Golgi (Figure 2.17b). This data supported our hypothesis derived through biochemical
experiments that PITPNC1 binds PI4P in vivo.

Figure 2.17. PITPNC1 co-localizes with trans Golgi and PI4P markers.
a. MDA-MB-231 cells expressing GFP-tagged PITPNC1 (green) co-stained with antip230 antibody (red) and 4',6-diamidino-2-phenylindole (DAPI, blue) were analyzed by
immunofluorescence microscopy.
b. MDA-MB-231 cells expressing GFP-tagged PITPNC1 (green) co-stained with DAPI
(blue), and FAPP-PH for the detection of PI4P (red).

39

To further validate PIPTNC1’s binding of PI4P, we sought to abrogate lipidbinding capacity by mutating the PITP domain. Previous studies have shown that the
T59E and N90F mutations of PITPα, another PITP domain family member that binds PI
and phosphatidylcholine in vitro, inhibits lipid binding (Milligan et al., 1997; Tilley et al.,
2004; Yoder et al., 2001). Although the PITP domains of PITPα and PITPNC1 are only
approximately 40% similar overall, homology analysis revealed these residues are
conserved across these PITP domains (Figure 2.18a). I performed site-directed
mutagenesis of the corresponding residues in PITPNC1 (T58 and N88) to generate
putative lipid-binding mutants forms of PITPNC1. These lipid-bindings mutants forms
were expressed at equivalent levels with wild-type PITPNC1, such that any effects
observed were due to lipid-binding activity rather than protein expression level (Figure
2.18b). We verified that these mutations abrogated lipid-binding capacity in the vesicular
pull-down assay. Both mutations revealed reduced ability of recombinant PITPNC1 to
bind PI4P-containing vesicles (Figure 2.18c).
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Figure 2.18. Mutations of PITPNC1 T58 and N88 abrogate lipid-binding capacity.
a. Diagram of PITPNC1 isoform A protein structure. Sequence alignment of PITPα (top)
and PITPNC1A (bottom) indicating conserved threonine and asparagine residues in the
lipid-binding domain.
b. Western blot analysis of PITPNC1 levels in MDA-MB-231 cells transduced with
PITPNC1WT, PITPNC1T58E, and PITPNC1N88F . GAPDH was used a loading control.
c. Vesicle pull-down assay of recombinant wild-type or mutant PITPNC1 using vesicles
containing PI4P. Pelleted vesicle fraction (P) and supernatant fraction (S) were subjected
to 1-D gel electrophoresis. Right, densitometry analysis of gel image indicating percent
of total PITPNC1 in pelleted fraction. N=3/group. Data are represented as mean ± S.E.M.
**p < 0.01.

To determine if PI4P binding was required for Golgi localization of PITPNC1, I
then expressed Flag-tagged wild-type or lipid-binding mutant PITPNC1 in breast cancer
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cells and performed immunofluorescence analysis between PITPNC1-Flag and the Golgi
marker Giantin. These studies revealed that PITPNC1N88F showed reduced localization to
the Golgi compared to PITPNC1WT, indicating that Golgi localization is dependent upon
PI4P binding (Figure 2.19).

Figure 2.19. PITPNC1’s ability to bind PI4P is required for its Golgi localization.
MDA-MB-231 cells with stable expression of Flag-tagged wild-type or N88F mutant
PITPNC1 co-stained with anti-Flag and anti-Giantin were analyzed by
immunofluorescence microscopy. The intensity of Flag immunoreactivity in areas
positive for Giantin was considered as the Golgi signal. The Golgi signal was normalized
to total cellular levels of PITPNC1 to control for differences in expression levels among
individual cells. N=30/group. The upper and lower bars in box and whiskers plots show
minimum and maximum data points. ***p < 0.001.

We next asked if PI4P binding is required for the pro-metastatic phenotypes
mediated by PITPNC1. I overexpressed either wild-type or the two lipid binding mutant
forms of PITPNC1 in MDA-MB-231 cells and found that PITPNC1WT, but neither of the
lipid binding mutants, was sufficient to promote Matrigel invasion and endothelial
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recruitment (Figure 2.20a, b). Similarly, neither PITPNC1N88F nor PITPNC1T58E were
sufficient to increase metastatic colonization, suggesting that PITPNC1’s lipid binding
activity is required for metastasis (Figure 2.20c).

Figure 2.20. PITPNC1’s lipid binding domain is required for metastasis.
a, b. 50,000 MDA-MB-231 cells expressing PIPTNC1WT, PITPNC1T58E, PITPNC1N88F, or
control vector were subjected to the Matrigel invasion assay (a) and endothelial
recruitment assay (b). N=4/group. Data are represented as mean ± S.E.M.
c. Bioluminescence imaging plot by 40,000 MDA-MB-231 cells in (a). N=6/group.
Right, representative lung histology. *p < 0.05, **p < 0.01.
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To further support our findings in a complementary experiment, we asked if
reducing TGN PI4P levels would change the localization of PITPNC1 and abrogate its
promotion of metastatic phenotypes. To decrease TGN PI4P levels, I transfected breast
cancer cells with a TGN-localized PI4P phosphatase Sac1K2A, previously developed for
this purpose (Rohde et al., 2003). The Sac1K2A construct localized exclusively to the
Golgi in breast cancer cells (Figure 2.21a), and its expression significantly reduced TGN
PI4P levels (Figure 2.21b). In accordance with PITPNC1 binding to TGN PI4P,
expression of Sac1K2A significantly reduced PITPNC1-Flag localization to the Golgi
(Figure 2.22a). Consistent with a required role for TGN PI4P in PITPCN1 function,
reduction of PI4P by Sac1K2A abrogated the ability of PITPNC1 overexpression to
enhance invasion and endothelial recruitment (Figure 2.22b, c). Overall, these findings
reveal that the interaction between PI4P and PITPNC1 in the TGN is required for
PITPNC1’s promotion of metastasis.
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Figure 2.21. Use of Sac1K2A to selectively deplete Golgi PI4P.
a. MDA-MB-231 were transfected with GFP-SAC1K2A and subjected to
immunofluorescence analysis for GFP, p230 (red) and DAPI (blue) 48 hours posttransfection. Arrows indicate signal overlap between GFP and the trans-Golgi marker
p230.
b. MDA-MB-231 cells were transfected with Sac1K2A and subjected to
immunofluorescence analysis for FAPP-PH (green), p230 (red), and DAPI (blue). Right,
quantification of PI4P in the Golgi as measured by FAPP-PH signal in p230-postive
areas. N = 30/group. The upper and lower bars in box and whiskers plots show minimum
and maximum data points. ***p < 0.001.
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Figure 2.22. Golgi PI4P is required for PITPNC1-mediated invasion and endothelial
recruitment.
a. MDA-MB-231 cells expressing PITPNC1-Flag were transfected with Sac1K2A or
mock transfected and subjected to immunofluorescence analysis for Flag (green), p230
(red), and DAPI (blue). The intensity of Flag immunoreactivity in areas positive for p230
was considered as the PITPNC1 Golgi signal. The Golgi signal was normalized to total
cellular levels of PITPNC1 to control for differences in expression levels among
individual cells. N=30/group.
b, c. MDA-MB-231 cells overexpressing PITPNC1 or a control vector were transfected
with Sac1K2A or mock transfected and subjected to the Matrigel invasion assay (b) and
endothelial recruitment assay (c). N = 4/group.
Data are represented as mean ± S.E.M. The upper and lower bars in box and whiskers
plots show minimum and maximum data points. *p < 0.05, ***p < 0.001.
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Functional Significance of PITPNC1’s Binding partners, 14-3-3 and RAB1B
To gain further mechanistic insights into the cellular function of PITPNC1, we
next sought to identify potential PITPNC1 binding proteins. To accomplish this, I
expressed Flag-tagged PITPNC1 in MDA-MB-231 breast cancer cells and performed
immunoprecipitation of the Flag epitope followed by in-solution trypsin digestion and
mass spectrometry quantification. Mass spectrometry revealed several proteins that were
significantly bound to PITPNC1 (Figure 2.23). Our findings were validated by the
inclusion of the previously identified binding partners of PITPNC1, the 14-3-3 proteins
(Garner et al., 2011). Additionally, we identified a novel binding partner for PITPNC1,
the small GTPase RAB1B.

Figure 2.23. PITPNC1 co-immunoprecipitates with 14-3-3 proteins and RAB1B.
Lysates from MDA-MB-231 cells expressing Flag-tagged PITPNC1 or control vector
were subjected to immunoprecipitation by anti-Flag beads. The eluate was trypsin
digested in solution and the liquid chromatography-tandem mass spectrometry (LCMS/MS) spectra were analyzed by label free quantification. Comparison proteins in the
empty vector condition (horizontal axis) and the PITPNC1-Flag condition (vertical axis)
revealed PITPNC1, several 14-3-3 protein forms, and RAB1B to be significantly
different (p < 0.05) between the two samples. N=3/group.
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We first investigated the role of 14-3-3 proteins in PITPNC1-mediated metastasis.
The 14-3-3 proteins are scaffolding proteins able to bind many functionally diverse
signaling proteins. 14-3-3 proteins are involved in a multitude of cellular processes
including signal transduction, apoptosis, and cell cycle control (Fu et al., 2000). 14-3-3
was found to bind phosphorylated PITPNC1 on serine-274 and serine-299. This binding
shielded a PEST degradation sequence within PITPNC1, thus preventing the protein from
being degraded (Garner et al., 2011). The previous studies of PITPNC1-14-3-3
interaction were performed in COS-7 cells, a monkey kidney cell line. To verify that
PITPNC1 binds 14-3-3 through phosphorylated S274 and S299 in breast cancer cells, I
performed site-directed mutagenesis to mutate the putative phosphorylated serine
residues to the non-phosphorylatable alanine residues (Figure 2.24). Western blot
analysis of immunoprecipitated PITPNC1WT and PITPNC1S274A, S299A protein from breast
cancer cell lysate confirmed that the interaction of PITPNC1 and 14-3-3 proteins is
dependent on serine phosphorylation, as the non-phosphorylatable mutant did not coimmunoprecipitate with 14-3-3 (Figure 2.24).

Figure 2.24. 14-3-3 binding to PITPNC1 requires phosphorylated serine residues.
Western blot analysis of input and immunoprecipitated Flag-tagged PITPNC1WT and
PITPNC1S274A/299A from MDA-MB-231 cells using anti-Flag and anti-14-3-3 antibodies.
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We next asked if binding of 14-3-3 was required for the metastatic function of
PITPNC1. I transduced cells with retroviral stable overexpression of either PITPNC1WT,
PITPNC1S274A, S299A, or a control vector and found that only PITPNC1WT was sufficient to
promote invasion and endothelial recruitment (Figure 2.25a, b). As expected, these
effects are likely explained by the shorter half-life of the PITPNC1S274A, S299A (Figure
2.25c). The significantly shorter half-life of the mutant protein generates a reduced
steady-state quantity of PITPNC1 protein in these cells compared to overexpression of
wild-type protein, and thus decreased metastatic capacity.

Figure 2.25. 14-3-3 binding is required for PITPNC1’s phenotypes and stability.
a, b. MDA-MB-231 cells expressing empty control vector, wild-type PITPNC1, or
S274A/299A mutant PITPNC1 were subjected to invasion (a) and endothelial
recruitment assays (b). N=4/group. Data are represented as mean ± S.E.M. *p < 0.05,
**p < 0.01 ***p < 0.001.
c. The half-lives of wild-type PITPNC1 and S274A/299A mutant PITPNC1 in MDAMB-231 cells were determined by treating cells with 100μg/ml cycloheximide over 24
hours and analyzing PITPNC1 protein abundance in cellular lysates by western blotting.
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We next turned our attention to the novel PITPNC1 binding partner identified in
our screen, RAB1B. I verified that PITPNC1 co-immunoprecipitates with RAB1B by
western blot analysis (Figure 2.26a). Additionally, by conducting immunofluorescence
experiments Halberg found that PITPNC1-Flag and RAB1B co-localize predominantly in
the Golgi region of the breast cancer cells (Figure 2.26b). RAB1B is known to localize to
the TGN and is required for proper Golgi structure and function (Dugan et al., 1995;
Haas et al., 2007; Plutner et al., 1991).

Figure 2.26. RAB1B binds to and co-localizes with PITPNC1.
a. Western blot analysis of input and immunoprecipitated Flag-tagged PITPNC1WT and
PITPNC1S274A/299A from MDA-MB-231 cells using anti-Flag and anti-RAB1B antibodies.
b. MDA-MB-231 cells in (a) were immunostained for Flag (Green), RAB1B (red), and
DAPI (blue).
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Depletion of RAB1B has been previously found to cause vesiculation and
breakdown of the Golgi structure, impairing secretion. Given our finding that PITPNC1
localization to the Golgi is required for its ability to promote metastasis, and that RAB1B
regulate Golgi function, we next investigated whether PITPNC1 promotes metastasis by
enhancing the abundance of RAB1B in the Golgi. Immunofluorescence analysis revealed
a 2-fold reduction of endogenous RAB1B in the TGN upon knockdown of PITPNC1,
without a change in the total cellular RAB1B protein levels as measured by western blot
analysis of whole cell lysate (Figure 2.27a, b). Conversely, over-expression of wild-type
PITPNC1 led to a significant increase in RAB1B localized to the Golgi (Figure 2.27c).
Consistent with PITPNC1’s ability to bind PI4P as requisite for its Golgi localization,
lipid-binding mutant PITPNC1 did not increase localization of RAB1B to the Golgi
(Figure 2.27c).
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Figure 2.27. PITPNC1 recruits RAB1B to the Golgi.
a. LM2 breast cancer cells transfected with two independent siRNAs targeting PITPNC1
or a control siRNA were analyzed by immunofluorescence for RAB1B (red), p230
(green), and DAPI (blue). Right, quantification of RAB1B signal in the trans Golgi
network (TGN) as marked by p230-positive areas. N=30/group.
b. Western blot analysis of RAB1B levels in whole cell lysate from LM2 cells in (a).
c. MDA-MB-231 cells overexpressing PITPNC1WT or PITPNC1N88F were analyzed by
immunofluorescence microscopy as in (a). N=30/group. The upper and lower bars in box
and whiskers plots show minimum and maximum data points. ***p < 0.001.
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These above findings suggest that PITPNC1 regulates RAB1B Golgi localization
to drive metastasis. To functionally test this relationship, we performed epistasis
experiments wherein we depleted RAB1B in the setting of PITPNC1 overexpression
(Figure 2.28a). Depletion of RAB1B strongly inhibited PITPNC1-mediated enhancement
of Matrigel invasion and endothelial recruitment abilities (Figure 2.28b, c). Notably,
depletion of RAB1B reduced these metastatic capacities more strongly in the setting of
PITPNC1 overexpression than in control cells, indicating that the effects of RAB1B on
these metastatic phenotypes are downstream of PITPNC1, rather than via a separate
pathway. These epistasis and co-localization experiments support a pathway in which
RAB1B acts as a downstream effector of PITPNC1-mediated metastasis.
Taken together, our findings identify PITPNC1 as a promoter of metastasis in
melanoma, breast, and colon cancer through enhancing invasion and endothelial
recruitment phenotypes. PITPNC1 binds to PI4P in the Golgi, recruiting its binding
partner RAB1B to the Golgi. The role of the RAB1B/PITPNC1 protein complex in the
Golgi and in driving metastasis will be further explored in Chapter III.
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Figure 2.28. RAB1B is required for PITPNC1-mediated invasion and endothelial
recruitment phenotypes.
a. Western blot analysis of RAB1B, RAB5, and RAB7 levels in LM2 cells transfected
with 3 independent siRNAs targeting RAB1B either 72 hours or 24 hours posttransfection. GAPDH was used as a loading control. siRNA depletion of RAB1B was
specific for RAB1B as expression levels of Rab5 and Rab7 were unchanged.
b, c. Matrigel invasion (b) and endothelial recruitment (c) by MDA-MB-231 cell
overexpressing control vector or PITPNC1. 48 hours prior to the experiments both the
control and PITPNC1-overexpressing cells were transfected with control siRNA or
siRNA targeting RAB1B. N=4/group. Data are represented as mean ± S.E.M. **p < 0.01,
***p < 0.001.
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CHAPTER III: CHARACTERIZATION AND FUNCTIONAL
INSIGHTS INTO METASTATIC SECRETION REGULATED BY
PITPNC1

Mechanism of Action of PITPNC1-RAB1B Complex in Metastatic Secretion
Through immunofluorescence, biochemical, and cell-biological experiments, we
established a critical role for Golgi-localized RAB1B and PITPNC1 in driving metastasis.
To identify the direct molecular effects between this protein complex, the Golgi, and
metastasis, we first explored the role of PITPNC1 and RAB1B on Golgi structure and
function.
Several studies have established a direct link between normal structure of the
Golgi’s membrane-bound stacks and proper Golgi secretory function. Addition of
Brefeldin A, an antibiotic which blocks endoplasmic reticulum-to-Golgi transport induces
fragmentation of the Golgi ribbon structure and leads to improper localization of
secretory cargo (Fujiwara et al., 1988). Similarly, after addition of actin depolymerizing
toxins such as cytochalasin D and latrunculin B, cells exhibit Golgi fragmentation and
halted secretion (Lazaro-Dieguez et al., 2006). While a fragmented and diffuse Golgi
inhibits secretion, an excessively condensed Golgi structure also prevents optimal
vesicular budding. In actively secreting cells, enhanced vesicular budding results in an
extension of the TGN as visualized by electron microscopy and immunofluorescence
(Dippold et al., 2009). This extension is due to the protein GOLPH3, which bridges PI4P
in the TGN to MYO18A, an actin cytoskeletal protein, inducing tensile forces on the
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Golgi. The elongated Golgi structure facilitates vesicular budding and subsequently
augmented secretion (Dippold et al., 2009).
The regulated release of secreted factors is known to orchestrate multiple steps of
the metastatic cascade. Work by previous members of the laboratory has supported this
requirement for metastatic secretion in multiple cancer types. Png and Halberg previously
identified IGFBP2 and MERTK as proteins secreted by highly metastatic breast cancers
to recruit endothelial cells and enhance metastasis (Png et al., 2012). Work by Jiamin Loo
revealed highly metastatic colorectal cancer cells secrete creatine kinase brain-type
(CKB) to augment metabolic energetics and enhance liver metastasis, although this
protein is not secreted through the classical secretory pathway (Loo et al., 2015). We
questioned whether highly metastatic cells would display changes in Golgi morphology
consistent with their requirements for optimal secretion. We performed
immunofluorescence experiments to compare Golgi extension between poorly metastatic
parental cell populations and their in vivo-selected highly metastatic derivative sublines.
Remarkably, we found that in breast, colon, and melanoma cancer, the highly metastatic
sublines exhibited significantly increased Golgi length compared to the poorly metastatic
parental cell population (Figure 3.1). This identifies a correlation between metastatic
capacity and Golgi morphology and supports a role for extended Golgi structure and
increased secretion in enhanced metastatic capacity.
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Figure 3.1. Golgi extension correlates with metastatic capacity in multiple cancer
types.
Highly metastatic derivatives of the poorly metastatic MDA-MB-231 breast, LS174T
colon, and MeWo melanoma cancer cells developed previously (Loo et al., 2015; Minn et
al., 2005; Pencheva et al., 2012) and their parental cell populations were immunostained
for p230 and DAPI. Golgi extent was quantified as the fraction of the nucleus
circumference that was covered by p230-positive Golgi signal. N=40/group. Upper and
lower bars in box and whiskers plots show minimum and maximum data points.
***p < 0.001.

Previous studies have identified an essential role for RAB1B in maintaining Golgi
structure and thus secretory function (Haas et al., 2007; Romero et al., 2013). Similar to
previous findings, Halberg observed that breast cancer cells acutely depleted of RAB1B
exhibited a condensed Golgi structure compared to control cells by immunofluorescence
(Figure 3.2a). In a time course experiment, extended depletion of RAB1B generated
complete Golgi breakdown and fragmentation (Figure 3.2b).
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Figure 3.2. RAB1B is required for proper Golgi morphology.
a. LM2 cells transfected with either control or siRNAs targeting RAB1B were
immunostained for p230 (green) and DAPI (blue) 24 hours post-transfection. Golgi
extent was quantified as the fraction of the nucleus circumference covered by p230
positive Golgi signal. N= 40/group. Data are represented as mean ± S.E.M. ***p < 0.001.
b. Immunofluorescence images of cells in (a). Cells were imaged 24 hours, 48 hours, and
72 hours post-transfection.
I next questioned if PITPNC1 also regulates such Golgi morphology. I conducted
immunofluorescence experiments on breast cancer cells with acute depletion of PITPNC1
and observed a similar condensation of the Golgi structure (Figure 3.3a). We further
confirmed this immunofluorescence data with ultrastructural data. Transmission electron
microscopy experiments performed by Kunihiro Uryu in The Rockefeller University
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Electron Microscopy Facility also revealed a condensed Golgi morphology in cells with
acute PITPNC1 depletion (Figure 3.3b).

Figure 3.3. PITPNC1 is required for the extended ribbon Golgi morphology.
a. Golgi extent was analyzed by immunofluorescence in LM2 breast cancer cells
transfected with siRNAs targeting PITPNC1 or a control siRNA. N=50/group.
b. Golgi structure was analyzed in transmission electron microscopy (TEM) images of
LM2 cells transfected with siRNAs targeting PITPNC1 or a control siRNA. N=50/group.
Upper and lower bars in box and whiskers plots show minimum and maximum data
points. ***p < 0.001.
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Notably, these effects were not restricted to breast cancer cells, as depletion of
PITPNC1 in the MeWo melanoma cells and LvM-3B metastatic colon cancer cells also
reduced Golgi extent compared to control cells (Figure 3.4). These results suggest that
PITPNC1 regulates Golgi morphology in multiple cancer types.

Figure 3.4. PITPNC1 regulates Golgi morphology in multiple cancer types.
MeWo melanoma cells and LS174T-LvM3 colon cancer cells were transduced with a
short hairpin targeting PITPNC1 or a control hairpin and immunostained for p230 (green)
and DAPI (blue). Right, quantification of Golgi extent. N=25/group. Upper and lower
bars in box and whiskers plots show minimum and maximum data points. ***p < 0.001.

Conversely, breast cancer cells with PITPNC1 overexpression displayed an
extended Golgi morphology by both electron microscopy and immunofluorescence,
similar to that seen in actively secreting cells (Figure 3.5a-c). However, the lipid-binding
mutant form of PITPNC1, PITPNC1N88F, was unable to elongate the Golgi structure
(Figure 3.5a, b). This indicates that PITPNC1’s role in Golgi structure is dependent upon
its localization to the Golgi through binding PI4P in the TGN. Together these effects led
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us to hypothesize that PITPNC1 and RAB1B may promote metastasis via mediating
Golgi morphology and consequently secretory capacity.

Figure 3.5. PITPNC1 promotes Golgi extension.
a. MDA-MB-231 breast cells overexpressing control vector, wild-type, T58E, or N88F
mutant forms of PITPNC1 were immunostained for p230 (green) and DAPI (blue).
b. Quantification of Golgi extent in cells from (a). N=20/group.
c. TEM images of MDA-MB-231 cells overexpressing PITPNC1 or a control vector.
N=50/group.
Upper and lower bars in box and whiskers plots show minimum and maximum data
points. ***p < 0.001.
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We next sought to investigate how the PITPNC1-RAB1B complex regulates
Golgi structure. Given that Golgi extension requires binding of GOLPH3 to Golgi PI4P,
we speculated that PITPNC1-RAB1B may induce Golgi elongation through increasing
Golgi PI4P levels. Indeed, RAB1B has been previously shown to recruit the PI4-kinase
PI4KA (also known as PI4KIIIα) from the plasma membrane to the TGN, which
increases local PI4P abundance (Dumaresq-Doiron et al., 2010; Monetta et al., 2007). To
determine whether PI4P levels in the TGN were mediated by PITPNC1, we performed
co-immunofluorescence imaging experiment using p230 to mark the TGN and FAPP1PH to mark PI4P. Quantification of these images revealed that PITPNC1 depletion
significantly reduced TGN PI4P abundance, whereas PITPNC1 overexpression
significantly increased TGN PI4P levels (Figure 3.6a, b). We further confirmed this result
by repeating these experiments using a PI4P-specific antibody in place of the PH domain
(Figure 3.6c). These findings suggest that TGN PI4P abundance is governed by PITPNC1
in cancer cells.
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Figure 3.6. PITPNC1 governs PI4P abundance in the Golgi.
a, b. LM2 cells transfected with siRNAs targeting PITPNC1 or a control siRNA (a) or
MDA-MB-231 cells overexpressing PITPNC1 or control vector (b) were stained for PI4P
using FAPP-PH domain (red), p230 (green) and DAPI (blue). PI4P levels in the Golgi
were quantified as mean fluorescence intensity of FAPP1-PH signal in p230-positive
regions. N=50/group.
c. LM2 cells as in (a) were immunostained for PI4P using anti-PI4P antibody (red), p230
(green), and DAP1 (blue). N=40/group.
Upper and lower bars in box and whiskers plots show minimum and maximum data
points. **p < 0.01, ***p < 0.001.
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To further explore whether PI4KA was the kinase responsible for the observed
increase in PI4P levels in the breast cancer cells, we performed epistatic experiments with
the four PI4Ks expressed in mammalian cells: PI4K2A, PI4K2B, PI4KB, and PI4KA.
Unlike PI4KA, PI4K2A, PI4KB, and PI4K2B are all constitutively Golgi-resident PI4kinases (Balla, 2013). I depleted each of these kinases using siRNA specific to each
kinase and found that depletion of PI4K2A and PI4KB dramatically reduced the ability of
cancer cells to invade through Matrigel in both PITPNC1 overexpression cells and
control cells (Figure 3.7). This suggests that both of these kinases are critical for general
Golgi function, but that this effect is independent of PITPNC1. Depletion of PI4K2B
revealed a minimal effect on either control cells or cells with PITPNC1 overexpression.
The negligible effect of depleting PI4K2B is likely due to its much lower kinase activity
compared to PI4K2A and PI4KB (Balla, 2013), and thus is not likely to be involved in
PITPNC1-mediated secretion. However, depletion of PI4KA entirely ablated the effects
of PITPNC1-induced invasion but did not affect the invasive capacity of control cells
(Figure 3.7). Taken together, these findings suggest that PI4KA is recruited to the Golgi
from either the cytoplasm or plasma membrane by PITPNC1-RAB1B to increase TGN
PI4P and facilitate secretion.
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Figure 3.7. Modulation of PI4K isoforms in PITPNC1-mediated invasion.
MDA-MB-231 cells overexpressing PITPNC1 or a control vector were transfected with
siRNA targeting PI4KA, PI4KB, PI4K2A, PI4K2B, or a control siRNA and subjected to
the Matrigel invasion assay. N=4/group. Data are represented as mean ± S.E.M. ***p <
0.001.

Our model predicts that increased PI4P levels in the TGN driven by PITPNC1RAB1B would recruit additional GOLPH3 to the Golgi, allowing for increased Golgi
extension and metastatic secretion. We tested this hypothesis by quantifying the amount
of GOLPH3 in the Golgi by immunofluorescence analysis. Depletion of either PITPNC1
or RAB1B led to a 2-fold reduction in GOPH3 abundance in the Golgi, as measured by
p230-positive areas of the cell (Figure 3.8a). These changes in localization were not due
to changes in GOLPH3 expression, as protein levels in whole cell lysate were unchanged
(Figure 3.8b). Correspondingly, overexpression of PITPNC1 correlated with an increase
in GOLPH3 Golgi levels (Figure 3.8c).
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Figure 3.8. The PITPNC1-RAB1B complex recruits GOLPH3 to the Golgi.
a. LM2 cells transfected with either control siRNA or siRNAs targeting PITPNC1 or
RAB1B were immunostained for endogenous GOLPH3 and p230. Right, quantification
of GOLPH3 levels in the trans-Golgi. N=40/group.
b. Western blot analysis of GOLPH3 levels in whole cell lysate from LM2 cells
transfected with siRNA targeting PITPNC1 or a control siRNA.
c. MDA-MB-231 cells expressing PITPNC1 or control vector were analyzed for transGolgi GOLPH3 levels as in (a). Upper and lower bars in box and whiskers plots show
minimum and maximum data points. **p < 0.01, ***p < 0.001.
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We next asked if PITPNC1-dependent recruitment of GOLPH3 to the Golgi is
required for PITPNC1-mediated phenotypes. I depleted GOLPH3 using siRNA, and
verified the efficiency of knockdown by western blot analysis (Figure 3.9a). Knockdown
of GOLPH3 reversed the extended Golgi phenotype induced by PITPNC1 overexpression
by 63% (Figure 3.9b).

Figure 3.9. GOLPH3 is necessary for PITPNC1-mediated Golgi extension.
a. Western blot analysis of GOLPH3 and GOLPH3L levels in LM2 cells transfected with
siRNAs targeting GOLPH3 or a control siRNA. GADPH is used as loading control.
b. MDA-MB-231 cells transfected with GOLPH3 siRNA or control siRNA in the setting
of PITPNC1 or control overexpression were immunostained for p230 (green) and DAPI
(blue). Right, analysis of Golgi extent. N=30/group. Upper and lower bars in box and
whiskers plots show minimum and maximum data points. *p<0.05, ***p < 0.001.
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Lastly, we performed epistasis experiments to confirm that GOLPH3 is
functionally downstream of PITPNC1’s pro-metastatic phenotypes. Depletion of
GOLPH3 abrogated PITPNC1-mediated increases in invasion and endothelial
recruitment capacities, indicating GOLPH3 is required for PITPNC1’s promotion of
these effects (Figure 3.10a, b). Depletion of GOLPH3 in control cells also reduced the
ability of these cells to invade and recruit endothelial cells but to a significantly lesser
extent than in PITPNC1 overexpression cells, verifying that these effects are dependent
upon PITPNC1.

Figure 3.10. GOLPH3 is required for PIPTNC1-mediated metastatic phenotypes.
a, b. MDA-MB-231 cells were transfected with GOLPH3 siRNA or control siRNA in the
setting of control or PITPNC1 overexpression and subjected to the invasion (a) and
endothelial recruitment (b) assays. N=4/group. Data are represented as mean ± S.E.M.
**p < 0.01, ***p < 0.001.
We have demonstrated that PITPNC1 recruits RAB1B to the Golgi, which in turn
recruits PI4KA. Increased TGN-localized PI4KA increases PI4P TGN levels, recruiting
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GOPLPH3 to the TGN to induce Golgi extension. Given the effects of PITPNC1
depletion and overexpression on the structure of the Golgi network, the role of RAB1B in
regulating Golgi structure and secretion, and that Golgi extension reflects enhanced
vesicular release, we speculated that PITPNC1’s pro-metastatic effects are mediated
through increased secretory capacity. We previously demonstrated that PITPNC1
promotes cancer cell invasion and endothelial recruitment. These phenotypes both require
the secretion of specific factors: proteases for successful invasion and chemoattractants
for successful recruitment of endothelial cells. Additionally, cancer cell secretion has
been established as necessary in other steps of the metastatic cascade, including immune
evasion and metastatic niche colonization (Joyce and Pollard, 2009; Psaila and Lyden,
2009). This model is also consistent with previous work by Png and Halberg identifying
PITPNC1 as an upstream effector of secreted IGFBP2 in breast cancer metastasis (Png et
al., 2012).
To test whether PITPNC1 expression directly impacted cancer cell secretion, I
performed a set of Golgi exit assay experiments (Bonazzi et al., 2005). In this assay,
cells are placed at 20°C to halt secretion. Cells are then placed back at 37°C and secretion
resumes. Vesicular release is tracked by fixing and staining cells at various time points
after the return to 37°C. I conducted this assay by tracking vesicular release by
quantifying the amount of PI4P-containing vesicles in the cytoplasm. Since vesicular
budding requires PI4P (Hama et al., 1999; Wang et al., 2003), vesicles traveling to the
plasma membrane contain PI4P. To demonstrate that PI4P in the cytoplasm marks
secreted vesicles, I generated an MMP14-Flag construct to label secretory cargo. MMP14
is a transmembrane matrix metalloproteinase that is sorted through Golgi to the plasma
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membrane (Apte et al., 1997). MMP14-Flag and PI4P in the cytoplasm exhibited colocalization, indicating PI4P present in the cytoplasm is predominantly located in
secretory vesicles (Figure 3.11).

Figure 3.11. Validation of an MMP14-Flag construct to label secretory vesicles.
Left, diagram of MMP14-Flag construct labeling secretory vesicles. Right, cancer cells
expressing MMP14-Flag were immunostained for DAPI (blue), MMP14-Flag (green),
and FAPP-PH (PI4P marker, red). Arrows indicate signal overlap between MMP14-Flag
and FAPP-PH.

Interestingly, breast cancer cells with PITPNC1 depletion revealed significantly
reduced release of vesicles from the Golgi (Figure 3.12a). Importantly, PITPNC1
overexpression induced increased vesicular release in this assay, consistent with a role for
PITPNC1 in driving metastatic secretion (Figure 3.12b). These effects were dependent
upon RAB1B, as depletion of RAB1B abrogated the effects of PITPNC1 overexpression
on increased vesicular release (Figure 3.12b).
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Figure 3.12. PITPNC1 facilitates vesicular secretion.
a, b. Golgi exit assay analysis of LM2 cells transfected with control or PITPNC1targeting siRNA (a) and MDA-MB-231 cells overexpressing PITPNC1 or control vector
and transfected with siRNA targeting RAB1B or control siRNA (b). Cells were
immunostained for PI4P (FAPP-PH, red), p230 (green), and DAPI (blue) at time 0, 10,
and 30 minutes. The abundance of PI4P-containing vesicles released to the cytoplasm
was determined by subtracting Golgi-localized PI4P from the total cellular PI4P signal.
N=10/time point/group. Significance was determined by Fisher’s method. ***p<0.001.
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Development of a Method to Profile the Secretome of Breast Cancer Cells
We next sought to identify a set of secreted proteins regulated by PITPNC1 and
capable of mediating the pro-metastatic effects of PITPNC1. I developed a method to
isolate secreted proteins and quantify their relative amounts using stable isotope labeling
by amino acids in cell culture (SILAC) and mass spectrometry. We chose to use SILAC
since the incorporation of stable isotope-labeled amino acids into proteins allowed for the
quantification of small differences in protein amounts. SILAC has previously been used
for characterizing the secretome in pancreatic cancer and glioblastoma (Formolo et al.,
2011; Gronborg et al., 2006). We were interested in identifying secreted proteins whose
secretion changed upon PITPNC1 depletion, thus acting as downstream mediators of
metastasis. Utilizing mass spectrometry provides unbiased profiling of all proteins
secreted from the cell, enabling identification of novel secreted promoters of metastasis.
Cells secrete proteins in low abundance compared to the overall cellular
proteome, and thus it is necessary to maximize secreted protein recovery for mass
spectrometry while also minimizing contamination from cytosolic proteins and proteins
found in cell culture media. Conditioned media from the cancer cells was collected,
concentrated, and subjected to tandem liquid-chromatography mass spectrometry. The
initial attempts at this method were performed in media containing fetal bovine serum
(FBS), a standard component of cell culture media. However the large quantity of serum
proteins interfered with MS analysis by causing incomplete tryptic digestion of secreted
proteins (Figure 3.13a). However, the absence of serum in the cell culture media alters
cellular processes, including secretion. Prolonged serum starvation leads to cellular death,
releasing cellular proteome contents into the media. Contamination of conditioned media
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with cytosolic proteins impedes the detection of the low abundance secreted proteins.
Given these factors, it was necessary to optimize the time period of serum starvation prior
to media collection to maximize secreted protein recovery while minimizing cell death.
LM2 cells and CNLM1a cells were cultured in serum-free media for 24 hours, and the
number of cells counted every 4 hours (Figure 3.13b). Based on this data, 12 hours was
chosen as the duration of serum starvation prior to collection of conditioned media.

Figure 3.13. Optimization of conditions for cellular secretome profiling.
a. Gel electrophoresis of secreted media collected from MDA-MB-231 cells seeded in
triplicate. The prominent band at 75kD corresponds to albumin, a component of FBS.
b. One million MDA-MB-231 cells were seeded in serum-free media and counted every
four hours. Data are represented as mean ± S.E.M.
To verify this technique and identify potential pro-metastatic secreted proteins, I
first performed secretome analysis on the MDA-MB-231 parental cell line compared to
the LM2 metastatic derivative cell line, as well as the CN34 cell line compared to the
CNLM1a derivative cell line to identify secreted proteins more abundant in conditioned
media collected from the highly metastatic derivative sublines (Table 3.1, 3.2).
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Table 3.1. Secretome profiling of LM2 cells compared to MDA-MB-231 cells.
Unique
Peptides
Identified

Fold Difference
(LM2/MDA)

Gene
Symbol

Gene Name

20

6.2581

MMP1

Matrix metalloproteinase 1

23

4.4413

COL6A1

18

3.3526

PSAT1

Collagen alpha-1(VI) chain
Phosphohydroxythreonine
aminotransferase

5

2.8698

IARS

Isoleucine tRNA ligase

8

2.6846

VIM

9

2.3586

HNRNPC

22

2.1874

IQGAP1

Vimentin
Heterogeneous nuclear
ribonucleoproteins C1/C2
p195;Ras GTPase-activatinglike protein

4

2.158

PARP1

Poly [ADP-ribose] polymerase 1

14

2.1391

SERPINE2

Glia-derived nexin

Table 3.2. Secretome profiling of CNLM1a1 cells compared to CN34 cells.
Unique
Peptides
Identified

Fold Difference
(CNLM1a1/
CN34)

Gene
Symbol

Gene Name

8

167.9701

IGFBP1

6

30.0580

NARC1

Insulin-like growth factorbinding protein 1
Neural apoptosis-regulated
convertase 1

12

18.4200

MMP1

Matrix metalloproteinase 1

11

14.9509

MFGE8

Breast epithelial antigen

35

13.2840

VPO1

10

10.6790

PLAT

Vascular peroxidase 1
Tissue-type plasminogen
activator

25

8.2782

LAMB2

Laminin subunit beta-2

9

7.8866

CDH4

Cadherin-4

9

6.8671

CKB

Creatine kinase B-type
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Of the secretome profiling experiments, only one protein was highly abundant in
both the LM2 and CNLM1a1 conditioned media compared to conditioned media from the
parental cell populations—MMP1, a matrix metalloproteinase. The MMPs are
established regulators of metastasis. MMP activity increases in almost all human cancers
compared to non-cancerous surrounding tissue and this activity increase correlates with
cancer stage (Egeblad and Werb, 2002). MMPs breakdown extracellular matrix
components such as collagens, proteoglycans, and laminins to facilitate cancer cell
invasion with the local tissue, intravasation into the circulatory system, and extravasation
into a distal organ for metastatic colonization. The identification of MMP1 in the analysis
of secreted proteins from the metastatic cell lines validated the developed method for
secretome analysis of breast cancer cells. Additional secreted proteins previously
demonstrated to promote metastasis include IGFB1, which increases cancer cell
proliferation and survival (Vu and Werb, 2000), PLAT, which enhances metastatic
invasion through activating plasminogen to degrade the ECM (Andreasen et al., 1997),
and CKB, which aids cancer cell energetics (Loo et al., 2015). Components of the ECM
that promote cancer cell invasion were also identified, including the collagen COL6A1
(Lu et al., 2012; Naba et al., 2014), and the laminin LAMB2 (Patarroyo et al., 2002).
Optimization of the liquid chromatography/tandem mass spectrometry (LC/MSMS) protocol by Henrik Molina in The Rockefeller University’s Proteomics Resource
Center improved the sensitivity of the data collected from the CN34 and CNLM1a1
experiment. In this data set, more proteins were identified (990 proteins compared to 505
proteins in the LM2/MDA experiment) with improved quantification of proteins in the
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conditioned media allowing for a broader range of fold difference. We utilized this
optimized protocol in all further secretome profiling studies.

Identification and Validation of Secreted Proteins Regulated by PITPNC1
Having validated SILAC and MS for the identification of pro-metastatic secreted
proteins, we next sought to identify secreted proteins regulated by PITPNC1 and
downstream of PITPNC1-mediated metastasis. PITPNC1-depleted cells and control cells
were grown in SILAC media, and conditioned media was collected, concentrated, and
subjected to mass spectrometry. Proteomic analysis revealed six proteins that were at
least two-fold less abundant in conditioned media from PITPNC1-depleted cells relative
to control cells (Figure 3.11a). These proteins were matrix metalloproteinase 1 (MMP1),
platelet-derived growth factor A (PDGFA), platelet-derived growth factor receptor L
(PDGFRL), A Disintegrin and metalloproteinase domain-containing protein 10
(ADAM10), High temperature requirement protease 1 (HTRA1), and Family with
Sequence Similarity 3 (FAM3C, also called ILEI) (Figure 3.14).

Figure 3.14. Identification of secreted proteins regulated by PITPNC1.
Conditioned media was collected from SILAC-labeled LM2 control and PITPNC1knockdown cells and subjected to liquid chromatography-mass spectrometry (LCMS/MS) to identify proteins underrepresented in PITPNC1 knockdown media.
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We next verified the reduced abundance of these proteins in secreted media by
performing western blot analysis, and confirmed that the protein levels of all of these
factors except PDGFRL decreased significantly upon PITPNC1 knockdown (3.15a, b).

Figure 3.15. PITPNC1-regulated secreted proteins in cellular conditioned media.
a. Western blot analysis for FAM3C, MMP1, HTRA1, PDGFA, and ADAM10 in
conditioned media from LM2 cells expressing short hairpins targeting PITPNC1 or a
control hairpin.
b. Densitometry analysis of western blots in (a).
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Importantly, the reduced secretion of these proteins was not due to reduced
expression of these proteins. Gene expression levels of FAM3C, MMP1, ADAM10, and
PDGFA were not decreased in PIPTNC1-knockdown cells compared to control cells
(Figure 3.16a). For HTRA, gene expression was reduced by 50% in PITPNC1
knockdown cells, but its secreted protein level was reduced by 80%, indicating that
PITPNC1 in part regulates the secreted level of this protein. However, although the
mRNA levels of these genes are unchanged, any post-transcriptional regulation of mRNA
could affect intracellular protein levels. To ensure that the differences in secreted protein
levels were due to secretion and not differences in intracellular protein levels, I conducted
western blot analysis on lysate from control and PITPNC1-depleted cells to measure
intracellular protein levels of the secreted factors and found that the levels of MMP1,
ADAM, FAM3C, and PDGFA were similar (Figure 3.16b). For HTRA, the intracellular
protein level in PITPNC1 knockdown cells was decreased, however this decrease was
again less than the reduction in secreted levels consistent with the role of PITPNC1 in
secretion of this factor. These findings are consistent with a model wherein these secreted
factors are not released from the Golgi upon PITPNC1 knockdown as a consequence of
impaired PI4P/GOLPH3 function.
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Figure 3.16. Intracellular expression levels of PITPNC1-regulated secreted factors.
a. ADAM10, FAM3C, HTRA1, MMP1, and PDGFA expression levels were determined
by qRT-PCR in LM2 cells transduced with short hairpins targeting PITPNC1 or a control
vector. N= 3/group. Error bars represent S.E.M.
b. Western blot analysis of FAM3C, MMP1, HTRA1, PDGFA, and ADAM10 in whole
cell lysate from cells as in (a). Western blot analysis of GAPDH was used as a loading
control.
To show that loss of PITPNC1 impaired secretion of one of these specific
secreted factors, in I generated a red fluorescent protein (RFP)-tagged version of MMP1
as a marker for metastatic secretion, and tracked localization of this marker in a Golgi
exit assay. PITPNC1 depletion significantly reduced MMP1-RFP release from the TGN
(Figure 3.17), indicating secretion of MMP1 is impaired in the absence of PITPNC1.
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Figure 3.17. PITPNC1 is required for secretion of MMP1.
Golgi exit assay of control and PITPNC1 knockdown cells tracking RFP-labeled MMP1.
Cells were immunostained for MMP1-RFP (red), TGN46 (green), and DAPI (blue) at
time 0, 10, and 30 minutes. Right, MMP1 signal was analyzed in TGN46-postive regions.
N=25/timepoint/group. Significance was determined by Fisher’s method. ***p < 0.001.
Error bars represent S.E.M.

I further verified the role of PITPNC1 in regulating the secretion of these factors
by measuring the levels of these proteins in conditioned media collected from control
MDA-MB-231 cells and cells overexpressing PITPNC1. Western blot analysis of
conditioned media from cells with increased PITPNC1 revealed increased levels of all
secreted factors to varying degrees (Figure 3.18a). The intracellular levels of these
secreted proteins were unchanged upon overexpression of PITPNC1 (Figure 3.18b). This
funding is consistent with our model wherein increased PITPNC1 levels in highly
metastatic cells acts to increase only the secretion of these proteins, but not their
intracellular levels.
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Figure 3.18. PITPNC1 enhances secretion of pro-invasive and pro-angiogenic genes.
a. Western blot analysis for PDGFA, HTRA1, MMP1, ADAM10, and FAM3C in
conditioned media from MDA-MB-231 cells overexpressing PITPNC1 or a control
vector.
b. Western blot analysis of FAM3C, HTRA1, PDGFA, MMP1, ADAM10, and GAPDH
in whole cell lysate from cells as in (a). GAPDH was used as a loading control.
Having established that PITPNC1 regulates the secretion of these proteins, we
next sought to determine if each of these factors functionally promotes metastatic
phenotypes. We depleted each secreted factor individually in PITPNC1-overexpressing
cells using lentiviral-based shRNA, and subjected these cells to the invasion and
endothelial recruitment assays. Cells with knockdown of each secreted factor reduced the
capacity of PITPNC1 overexpression to increase invasion and endothelial recruitment
capacities compared to control cells to varying degrees (Figure 3.19a-c). Since each
factor was important for this phenotype, this suggests that the breast cancer cells are
optimized for maximal invasion and endothelial recruitment capacity through the
enhanced secretion of factors that act cooperatively in these processes.
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Figure 3.19. PITPNC1-mediated secreted factors are required for invasion and
endothelial recruitment phenotypes.
a. MDA-MB-231 cells were transduced with a control shRNA or shRNAs targeting
ADAM10, FAM3C, HTRA, PDGFA or a siRNA targeting MMP1 in the setting of
PITPNC1 overexpression. Expression levels for each knockdown were measured by
qRT-PCR.
b, c. Cells in (a) were subjected to the Matrigel invasion assay (b) and endothelial
recruitment assay (c). N=4/group. Data are represented as mean ± S.E.M. *p < 0.05,
**p < 0.01, ***p < 0.001.
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We further tested the functional significance of these secreted factors in an in vivo
lung colonization experiment. We depleted each secreted factor in the setting of
PITPNC1 overexpression and found that while overexpression of PITPNC1 was
significant to increase lung colonization compared to control cells, knockdown of each
secreted factor reduced the ability of these cells to form lung metastatic nodules (Figure
3.20). The effects of depleting the secreted factors on invasion, endothelial recruitment,
and metastatic colonization indicate that these secreted factors cooperatively impact
metastatic progression mediated by PITPNC1. Taken together, these epistatic
experiments reveal PITPNC to promote metastasis through increasing the cellular release
of ADAM10, FAM3C, HTRA1, MMP1, and PDGFA, which act as secreted prometastatic proteins.

83

Figure 3.20. PITPNC1 promotes metastasis by facilitating secretion of a set of
proteins.
a. Bioluminescence imaging quantification of lung metastatic colonization by 40,000
MDA-MB-231 cells transduced with a control shRNA or shRNAs targeting ADAM10,
FAM3C, HTRA, PDGFA or a siRNA targeting MMP1 in the setting of PITPNC1
overexpression. N=6/group. Data are represented as mean ± S.E.M. *p<0.05.
b. Representative bioluminescence images.
c. H&E staining of representative lung sections.
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CHAPTER IV: PTPRN2 AND PLCβ1 PROMOTE METASTATIC
BREAST CANCER CELL MIGRATION

Functional validation of PTPRN2 and PLCβ1 as Promoters of Metastasis
Given the importance of phosphatidyl inositides (PIs) in regulating cellular
processes needed for metastasis and the dramatic effects of PITPNC1 in regulating
metastatic secretion (Chapter III), we were interested in identifying the mechanisms of
additional protein regulators of other PIs as potential novel drivers of metastasis. We
were particularly interested in proteins that regulate PI(4,5)P2, given the role of this lipid
in regulating several cellular processes including endocytosis, exocytosis, signal
transduction, and cell motility (Balla, 2013; Vicinanza et al., 2008).
Using previously conducted microarray transcriptional profiling of the MDA-MB231 breast cancer cells and their in vivo-selected highly metastatic derivative subline
(Minn et al., 2005; Tavazoie et al., 2008) we were intrigued to find two genes, PTPRN2
and PLCB1, that possess known enzymatic activity against PI(4,5)P2 to be both upregulated in highly metastatic LM2 cells. I validated the up-regulation of these genes in
these cells as well as in a second independent breast cancer cell line, CNLM1a1,
compared to the parental MDA-MB-231 cell line. Both genes exhibited markedly
increased expression in the metastatic CNLM1a1 derivative subline relative the parental
CN34 population at both the gene expression and protein levels (Figure 4.1a-d).
Additionally, the levels of both proteins were lowest in MCF 10A cells, a mammary
epithelial cell line, consistent with the non-invasive and non-tumorigenic characterization
of these cells.
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Figure 4.1. PTPRN2 and PLCβ1 expression increases with malignant
transformation in breast cell lines.
a, b. PTPRN2 (a) and PLCB1 (b) expression levels were determined by qRT-PCR.
c, d. Western blot analysis of PTPRN2 (c) or PLCβ1 (d) levels in MCF 10A, MDA-MB231, LM2, CN34, and CNLM1a1 cells. GAPDH was used as a loading control. Right,
densitometry analysis of PTPRN2 or PLCβ1 levels normalized to GAPDH.
*p < 0.05, **p < 0.01.
I next sought to test the functional significance of this up-regulation in highly
metastatic cells by determining if expression of these genes was necessary for breast
cancer metastasis. I depleted PTPRN2 or PLCβ1 in highly metastatic LM2 cells and
performed tail vein metastatic colonization assays. Knockdown of these genes
significantly reduced lung metastatic colonization (Figure 4.2a-d).
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Figure 4.2. Functional validation of PTPRN2 and PLCβ1 as promoters of breast
cancer metastasis.
a, c. Western blot analysis of PTPRN2 (a) or PLCβ1 (b) levels in LM2 cells expressing
short hairpins targeting PTPRN2, PLCβ1, or a control hairpin. GAPDH was used as a
loading control.
b, d. Bioluminescence imaging quantification of lung colonization by 40,000 LM2 cells
as in (a, c). N=5 mice/group. Right, H&E staining of representative lung sections.
Data are represented as mean ± S.E.M. *p < 0.05, ***p < 0.001.
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To show that these effects were not specific to the MDA-MB-231/LM2 system, I
depleted PTPRN2 and PLCβ1 in a second highly metastatic derivative subline,
CNLM1a1. Depletion of either PTPRN2 or PLCβ1 in the CNLM1a1 cells also decreased
the ability of these cells to form lung metastatic nodules (Figure 4.3a, b).

Figure 4.3. Functional validation of PTPRN2 and PLCβ1 in an independent
metastatic breast cancer cell line.
a, b. Bioluminescence imaging quantification of lung colonization by 40,000 CNLM1a1
cells with depletion of PTPRN2 (a) or PLCβ1 (b). N=5 mice/group. Below, H&E
staining of representative lung sections. Data are represented as mean ± S.E.M. *p < 0.05.
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Interestingly, cells with depletion of either PTPRN2 or PLCβ1 exhibited
significantly reduced signal in the lungs of mice as early as 24 hours post-injection
compared to control cells (Figure 4.4). This suggests that knockdown of these genes
impacts early stages of metastatic progression, such as migration and invasion, rather
than later stages of metastatic growth such as angiogenesis (Chiang and Massague, 2008).

Figure 4.4. Depletion of PTPRN2 or PLCβ1 affects metastatic colonization at early
time points.
Bioluminescence imaging quantification of lung colonization one day after injection of
40,000 LM2 cells with knockdown of PTPRN2, PLCβ1, or control cells. Data are
represented as mean ± S.E.M. *p < 0.05, **p<0.01, ***p<0.001.

Clinical Significance of PTPRN2 and PLCβ1 in Breast Cancer Metastasis
Having demonstrated the requirement for expression of PTPRN2 and PLCβ1 for
breast cancer metastasis, I next asked if expression of the genes correlated with patient
outcomes. To investigate the clinical importance of PTPRN2 and PLCβ1 in breast cancer
progression, I quantified their expression levels from cDNA samples of patients with
89

varied stages of breast cancer. Notably, expression levels of both genes increased
significantly in tumors of patients with advanced stage IV metastatic disease (Figure 4.5a,
b).
I next analyzed data from The Cancer Genome Atlas (TCGA) and found that
patients whose primary tumors possessed higher levels of PTPRN2 and PLCB1
demonstrated significantly worse overall survival compared to patients whose tumors
possessed lower levels of these genes (Cancer Genome Atlas, 2012) (Figure 4.5c).
Additionally, PTPRN2 and PLCB1 expression correlated with worse distal metastasisfree survival in a second large cohort of breast cancer patients (Figure 4.5d) (Gyorffy et
al., 2010). These findings establish PTPRN2 and PLCβ1 as clinically relevant promoters
of metastasis in breast cancer.
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Figure 4.5. PTPRN2 and PLCB1 expression correlates with worse clinical outcomes
in breast cancer.
a, b. PTPRN2 (a) and PLCB1 (b) levels were analyzed in human breast cancers (stages IIV) and normal breast tissue from TissueScan qPCR Array Breast Cancer Panels II and
III (Origene, N = 97). Expression levels were normalized to levels in normal tissue for
each gene. Data are represented as mean ± S.E.M. *p < 0.05, **p<0.01.
c. Kaplan-Meier curve representing overall survival of a cohort of breast cancer patients
(N = 528) as a function of their primary tumor’s PTPRN2 and PLCB1 expression levels
(data from the TCGA Research Network). Patients whose primary tumors’ PTPRN2 and
PLCB1 expression levels were higher or lower than the median of the population were
classified as low (blue) or high (red) expression.
d. Kaplan-Meier curve representing distal metastasis-free survival of a cohort of breast
cancer patients (N = 1609) as a function of their primary tumor’s PTPRN2 and PLCB1
expression levels (Data from KMPlot) Patients’ primary tumors’ PTPRN2 and PLCB1
expression levels were classified as low (blue) or high (red) expression.
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Metastatic Phenotypes Mediated by PTPRN2 and PLCβ1
We investigated several cellular metastatic phenotypes to identify the mechanisms
by which PTPRN2 and PLCβ1 mediate metastasis. Similar to the action of PITPNC1,
depletion of either PTPRN2 or PLCβ1 reduced the ability of cells to invade through
Matrigel (Figure 4.6a). However, unlike PITPNC1, cells with knockdown of either gene
revealed reduced ability to migrate through a porous trans-well insert in a migration assay
(Figure 4.6b). While the requirement for PITPNC1 in invasion was through release of
secreted proteases to degrade the Matrigel and enable cell movement, the defects in
invasion capacity shown by PTPRN2 and PLCβ1-kncockdown cells appeared to be
secondary to a defect in migratory capacity.
To further test a role for PTPRN2 and PLCβ1 in migration, I tested these cells in
a scratch assay. Cells with knockdown of either gene and control cells were grown to
confluency and a scratch was made through the cell monolayer, clearing the scratch area
of cells. Cells were allowed to migrate back into the scratch area. Depletion of either
PLCβ1 or PTPRN2 significantly decreased the ability of cells to migrate back into the
scratch area over a 24-hour period, confirming the reduced migratory capacity of these
cells (Figure 4.6c).
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Figure 4.6. PTPRN2 and PLCβ1 are required for metastatic migration and invasion.
a. Matrigel invasion by 50,000 LM2 cells transfected with siRNA targeting PTPRN2,
PLCβ1, or control siRNA. Data normalized to control values. N = 6 inserts/group.
b. Migration assay by 100,000 LM2 cells transfected with siRNA targeting PTPRN2,
PLCβ1, or control siRNA. Data normalized to control values. N = 6 inserts/group. Right,
representative images of the migration assay. Scale bar, 100 μm.
c. Quantification of area covered by cells 24 h after a scratch was made through confluent
cells transfected with siRNA targeting PTPRN2, PLCβ1, or control siRNA. N = 5
wells/group. Right, representative images of the scratch assay.
Data are represented as mean ± S.E.M. **p<0.01, ***p<0.001.
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To demonstrate that these effects were not limited to LM2 cells, I depleted
PTPRN2 or PLCβ1 in four other breast cancer cells: BT-459, CNLM1a1, HCC-1806, and
MDA-MB-468, and subjected these cells to the migration assays. Knockdown of either
gene significantly reduced metastatic migration (Figure 4.7a-d).

Figure 4.7. PTPRN2 and PLCβ1 are required for metastatic migration in multiple
breast cancer cell lines.
a-d. Migration assay by 100,000 BT-549 (a), CNLM1a1 (b), HCC-1806 (c), and MDAMB-468 (d) cells transfected with siRNA targeting PTPRN2, PLCβ1, or control siRNA.
N = 5 inserts/group. Data are represented as mean ± S.E.M. *p<0.05, **p<0.01,
***p<0.001.
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To ensure that the defects observed in metastatic colonization, Matrigel invasion,
and migration capabilities in the setting of PTPRN2 or PLCβ1 knockdown were not due
to changes in proliferation capacity of these cells, I conducted a five-day proliferation
assay. Cellular growth rates were not affected by either gene in this assay (Figure 4.8a,
b). Together these findings indicate that PTPRN2 and PLCβ1 are required for metastatic
invasion and migration, and these effects are not secondary to growth defects induced by
these genes.

Figure 4.8. Depletion of PTPRN2 or PLCβ1 does not affect cellular proliferation.
a, b. Proliferation of 20,000 LM2 cells expressing siRNAs targeting PTPRN2 (a), PLCβ1
(b), or a control hairpin. N=3/group. Error bars represent S.E.M.

Both PTPRN2 and PLCβ1 have been previously demonstrated to possess
enzymatic activity for the substrate PI(4,5)P2 (Caromile et al., 2010; Rebecchi and
Pentyala, 2000), and we questioned whether this enzymatic activity was necessary for the
pro-metastatic effects of PRPN2 or PLCβ1. To test this, I mutated the catalytic domain of
each protein to generate enzymatically inactive versions and tested these versions in the
metastatic phenotypes. PTPRN2 contains a C(X)5R catalytic domain common to protein
96

tyrosine phosphatases (PTPs), where C is the catalytic cysteine (Barford et al., 1998). In
canonical PTP domains, the motif also contains an alanine residue (CXAXXXR).
However, the PTP domain of PTPRN2 contains an aspartic acid residue at this position
(CXDXXXR), rendering it catalytically inactive against phosphorylated tyrosine resides
but enabling its activity to dephosphorylate PI(4,5)P2 (Caromile et al., 2010; Wasmeier
and Hutton, 1996). In both conserved PTP domains and PTPRN2’s PTP domain, a
catalytic cysteine residue mediates the enzymatic phosphate monoester hydrolysis. A
previous study had demonstrated that mutation of PTPRN2’s catalytic cysteine residue,
C945, to a serine residue abrogates the protein’s ability to dephosphorylate PI(4,5)P2
(Caromile et al., 2010). Serine is commonly used in mutation of cysteine residues, since it
is structurally similar but does not possess nucleophilic activity. The PTP catalytic
mechanism involves the formation of a phospho-enzyme intermediate that is hydrolyzed
to restore the free enzyme and generates inorganic phosphate, but the cysteine to serine
mutation renders this intermediate non-hydrolyzable, trapping the substrate and rendering
the enzyme catalytically dead. To dissect the influence of PTPRN2’s catalytic activity
independent of trapping the substrate or reducing total active enzyme, I instead mutated
C945 to an inactive alanine residue. I found that while wild-type PTPRN2 overexpression
was sufficient to increase invasion, migration, and metastatic lung colonization in mice,
equivalent overexpression PTPRN2C945A was not sufficient to enhance these effects
(Figure 4.9a-d). Thus PTPRN2 is sufficient to enhance metastatic capacity and its
catalytic activity is required for its promotion of metastatic phenotypes.
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Figure 4.9. PTPRN2’s catalytic activity is required for its pro-metastatic effects.
a. Western blot analysis of MDA-MB-231 cells transduced with PTPRN2, PTPRN2C945A,
or control vector. GAPDH was used as a loading control.
b, c. Cells in (a) were subjected to the Matrigel invasion (b) and migration assays (c).
N = 5 inserts/group.
d. Bioluminescence imaging quantification of lung colonization by 40,000 MDA-MB231 cells as in (a). N = 5 mice/group. Right, representative lung histology.
Data are represented as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.
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PLCβ1 contains the high conserved catalytic domain shared by all phospholipase
C (PLC) enzymes. The phospholipase mechanism involves hydrolyzing the
phosphodiester bond linking the inositol ring (in this case, inositol phosphorylated at the
4’ and 5’ positions) to the glycerol backbone with two fatty acid chains acylated to it.
The mechanism first involves attack by the hydroxyl group on the inositol ring adjacent
to the phosphodiester bond, which forms a cyclic intermediate and releases diacyl
glycerol, the first product of this reaction. The cyclic intermediate then undergoes
nucleophilic attack by a water molecule coordinated by PLC’s catalytic histidine,
generating inositol triphosphate, the second product of this reaction (Rebecchi and
Pentyala, 2000). Mutation of PLCβ1’s catalytic histidine residue, H331, has been
previously shown to abrogate its ability to hydrolyze PI(4,5)P2 (Ramazzotti et al., 2008).
I overexpressed PLCβ1H331Q and PLCβ1WT in the MDA-MB-231 cells, and found that the
wild-type enzyme was capable of increasing invasion, migration, and metastasis.
However, the catalytically inactive mutant failed to promote these effects (Figure 4.10ad). These findings establish the enzymatic activity of PLCβ1 as necessary for its prometastatic effects.
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Figure 4.10. PLCβ1’s catalytic activity is required for its pro-metastatic effects.
a. Western blot analysis of MDA-MB-231 cells transduced with PLCβ1, PLCβ1H331Q, or
control vector. GAPDH was used as a loading control.
b, c. Cells in (a) were subjected to the Matrigel invasion (b) and migration assays (c).
N = 5 inserts/group.
d. Bioluminescence imaging quantification of lung colonization by 40,000 MDA-MB231 cells as in (a). N = 5 mice/group. Right, representative lung histology.
Data are represented as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.
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Functional characterization of PI(4,5)P2 Levels in Metastatic Migration
Given that the enzymatic activities of both PTPRN2 and PLCβ1 were required to
enhance migration and invasion, we next sought to determine the role of their enzymatic
substrate (PI(4,5)P2 in metastasis. PI(4,5)P2 is predominantly present in the inner leaflet
of the cellular plasma membrane (Martin, 2001; Vicinanza et al., 2008). Interestingly,
both PTPRN2 and PLCβ1 also demonstrated prominent localization to the plasma
membrane in breast cancer cells (Figure 4.11). A role for PLCβ1 in the nuclei to regulate
cellular growth has been previously described, but PLCβ1 did not show nuclear
localization in the MDA-MB-231 breast cancer cells, although it did show some
cytoplasmic localization. PTPRN2 exhibited additional perinuclear staining in the Golgi
region. PTPRN2 is a transmembrane protein, and has been previously observed to be
recycled from the plasma membrane to the Golgi, where it is again exported to the
plasma membrane.
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Figure 4.11. PTPRN2 and PLCβ1 localize to the cytoplasm and plasma membrane
of breast cancer cells.
Representative images of MDA-MB-231 cells retrovirally transduced with PTPRN2FLAG, PLCβ1-FLAG, or control vector and immunostained with anti-FLAG (red) and
DAPI (blue). Scale bar, 10 μm.

As described above, these enzymes act to reduce the levels of PI(4,5)P2 through
two independent mechanisms. PLCβ1 hydrolyzes PI(4,5)P2 to generate IP3 and DAG,
while PTPRN2 dephosphorylates the lipid. To determine if these enzymes were affecting
the levels of PI(4,5)P2 in breast cancer cells, I first quantified the abundance of PI(4,5)P2
in the plasma membrane of cancer cells using immunofluorescence. I followed an
immunocytochemical technique previously demonstrated to accurately reflect changes in
PI(4,5)P2 mass (Hammond et al., 2012; Hammond et al., 2009a). This method utilizes a
gentle detergent, saponin, and is performed at low temperature to preserve the lipids in
the plasma membrane for detection. Consistent with the increased levels of PTPRN2 and
PLCβ1 in highly metastatic breast cancer cells and the enzymatic activity of these
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proteins against PI(4,5)P2, LM2 cells exhibited lower levels of PI(4,5)P2 in their plasma
membranes relative to their less metastatic parental cell population (Figure 4.12).

Figure 4.12. Plasma membrane levels of PI(4,5)P2 varies with metastatic capacity.
Mean fluorescence intensity of membrane PI(4,5)P2 was analyzed in MDA-MB-231 and
LM2 cells immunostained with PI(4,5)P2 antibody (red) and DAPI (blue) using
fluorescence microscopy. N = 50 cells/group. Scale bar, 10 μm. Data are represented as
mean ± S.E.M. ***p<0.001.

I next tested whether membrane PI(4,5)P2 levels functionally affected metastatic
capacity. I added exogenous PI(4,5)P2 to LM2 cells using the PIP carrier system. In this
system, a positively charged carrier is incubated with the negatively charged
phospholipid to allow the carrier to coordinate the lipid. The carrier-lipid complex is
added to cells, and the phospholipid is incorporated into its correct location in the cell
(Ozaki et al., 2000). I first confirmed that exogenously added PI(4,5)P2 was incorporated
into the inner leaflet of the plasma membrane. Cells were transfected with a construct
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encoding the GFP-tagged PH domain of PLCdelta, which binds to PI(4,5)P2 with high
affinity. The expression of this construct enables tracking of this lipid within living cells.
GFP-PLCdelta-PH showed some membrane localization and diffuse cytoplasmic staining
in control cells. In cells treated with exogenous PI(4,5)P2, GFP-PLCdelta-PH showed
strongly increased membrane localization (Figure 4.13a). The translocation of the
construct to the plasma membrane indicates that exogenous PI(4,5)P2 incorporates into
the inner leaflet of the plasma membrane in treated cells.
Addition of exogenous PI(4,5P)2 to the breast cancer cells increased their
membrane PI(4,5)P2 levels by 22%, and reduced the ability of the cells to colonize the
lungs of mice by 80% compared to cells treated with carrier alone (Figure 4.13b, c).
These findings indicate that increased membrane abundance of PI(4,5)P2 reduces
metastatic capacity.
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Figure 4.13. Addition of exogenous PI(4,5)P2 abrogates metastatic capacity.
a. MDA-MB-231 cells were transfected with GFP-PLCdelta-PH (green) and treated with
carrier incubated with PI(4,5)P2 or carrier alone. Scale bar, 10 μm.
Mean fluorescence intensity of membrane PI(4,5)P2 was analyzed in LM2 cells treated
with carrier incubated with PI(4,5)P2 or carrier alone. Cells were immunostained with
PI(4,5)P2 antibody (red) and DAPI (blue) and analyzed using fluorescence microscopy.
N = 50 cells/group. Scale bar, 10 μm.
b. Bioluminescence imaging quantification of lung colonization by 40,000 LM2 cells
treated with carrier incubated with PI(4,5)P2 or carrier alone. Right, H&E staining of
representative lung sections. N=6 mice/group.
Data are represented as mean ± S.E.M. *p<0.05, ***p<0.001.
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We next asked if PTPRN2 and PLCβ1 enhance metastasis by regulating
membrane PI(4,5)P2 levels in breast cancer cells. Consistent with the enzymatic activities
of PLCβ1 and PTPRN2 as decreasing the abundance of PI(4,5)P2, overexpression of
either enzyme reduced membrane levels of the lipid (Figure 4.14a). Conversely, depleting
either enzyme in cancer cells increased the membrane levels of PI(4,5P)2 (Figure 4.14b).
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Figure 4.14. PTPRN2 and PLCβ1 modulate PI(4,5)P2 abundance in the plasma
membrane.
a, b. MDA-MB-231 cells overexpressing PTPRN2, PLCβ1, or a control vector (a) or
LM2 cells transfected with siRNA targeting PTPRN2, PLCβ1, or a control siRNA (b)
were immunostained for PI(4,5)P2 levels and analyzed by fluorescence microscopy.
Mean fluorescence intensity of plasma membrane levels of the lipid was quantified.
N = 50 cells/group. Right, representative immunofluorescence images of cells stained
with anti-PI(4,5)P2 antibody (red) and DAPI (blue). Scale bar, 10 μm.
Data are represented as mean ± S.E.M. **p<0.01, ***p<0.001.
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I further confirmed these changes in PI(4,5)P2 abundance by measuring the levels
of this lipid using an independent method, a PI(4,5)P2 enzyme-linked immunosorbent
assay (ELISA). In this assay, PI(4,5)P2 is extracted from cells, incubated with PI(4,5)P2
detector protein and then added to a PI(4,5)P2-coated plate for competitive binding. A
peroxidase-linked secondary detection reagent and colorimetric substrate is used to detect
PI(4,5)P2 detector protein bound to the plate. The colorimetric absorbance signal is thus
inversely proportional to the amount of lipid extracted (Figure 4.15a). I performed
extracted PI(4,5)P2 from cancer cells with overexpression or depletion of PTPRN2 and
PLCβ1 and observed changes in PI(4,5)P2 mass consistent with the immunofluorescence
data (Figure 4.15b). Together these results suggest that PTPRN2 and PLCβ1 govern the
plasma membrane levels of this lipid in breast cancer cells.

Figure 4.15. PI(4,5)P2 mass quantification upon modulation of PTPRN2 or PLCβ1.
a. ELISA absorbance values were obtained for known concentrations of PI(4,5)P2. The
standard curve was generated using non-linear regression analysis.
b 1 x 106 LM2 cells with knockdown of PLCB1, PTPRN2, or a control siRNA or MDAMB-231 cells with overexpression of PLCB1, PTPRN2, or a control vector were
subjected to PI(4,5)P2 extraction. Extracted lipid was quantified by ELISA.
Data are represented as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.
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I next investigated the functional significance of PI(4,5)P2 plasma membrane
levels in metastatic migration, the phenotype mediated by PTPRN2 and PLCβ1. I
manipulated the levels of PI(4,5)P2 in cancer cells using two methods. First, I decreased
plasma membrane lipid levels to determine whether this could rescue the migratory
defect induced by PTPRN2 or PLCβ1 depletion. To selectively deplete plasma membrane
PI(4,5)P2, I utilized rapamycin-inducible dimerization constructs previously developed
for this purpose (Hammond et al., 2012). In this system, PI(4,5)2 levels are reduced by
the enzyme inositol polyphosphate-5-phosphatease (INPP5E), which dephosphorylates
the lipid. Cells are transfected with constructs encoding INNP5E fused to FKBP and
membrane-inserted protein Lyn11 fused to FRB. Addition of rapamycin induces
dimerization of FRB and FKBP, consequently recruiting INPP5E to the plasma
membrane. Breast cancer cells transfected with these constructs and treated with
rapamycin exhibited reduced plasma membrane PI(4,5)P2 staining compared to cells
treated with DMSO (Figure 4.16a). PTPRN2-depleted and PLCβ1-depleted cells, which
possess greater levels of plasma membrane PI(4,5)P2, were transfected with these
constructs. Addition of rapamycin significantly enhanced their migratory capacity
relative to cells treated with DMSO. Control cells treated under the same conditions also
exhibited increased migration but to a lesser extent, indicating these effects are partially
dependent on PTPRN2 and PLCβ1 (Figure 4.16b, c).
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Figure 4.16. Selective depletion of PI(4,5)P2 at the plasma membrane partially
rescues PTPRN2 and PLCβ1 depletion.
a. MDA-MB-231 cells transfected with Lyn11-FRB and INPP5E-FKBP, treated with either
DMSO or 100 nm rapamycin, and immunostained with anti-PI(4,5)P2 antibody (green) and DAPI
(blue). Left, quantification of membrane PI(4,5)P2 mean fluorescence intensity. Right,
representative images. N = 50 cells/group. Scale bar, 10 μm.
b, c. LM2 cells transfected with siRNA targeting PTPRN2 (b), PLCβ1 (c) or a control siRNA
were transfected with Lyn11-FRB and INPP5E-FKBP, treated with either DMSO or 100 nm
rapamycin and subjected to the migration assay. N = 5 inserts/group.

Data are represented as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.
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Given that decreasing plasma membrane PI(4,5)P2 increased migratory capacity,
I questioned whether increasing PI(4,5)P2 levels would abrogate the enhanced migratory
capacity induced by PTPRN2 or PLCβ1 overexpression. In a complementary set of
experiments, I increased levels of the lipid by adding exogenous PI(4,5)P2 to the breast
cancer cells (Ozaki et al., 2000). Increasing PI(4,5)P2 prevented the effects of PTPRN2
and PLCβ1 overexpression on migration (Figure 4.17a, b). These effects were specific to
PI(4,5)P2, since addition of exogenous PI4P, another lipid present in the plasma
membrane (D'Angelo et al., 2008), had no effect on migration capacity for either control
cells or cells with overexpression of PTPRN2 or PLCβ1 (Figure 4.17c). These findings
establish that PTPRN2/PLCβ1-mediated reduction in plasma membrane PI(4,5)P2 levels
correlates with increased metastatic migration capacity.
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Figure 4.17. Addition of PI(4,5)P2 abrogates PTPRN2 or PLCβ1-mediated
metastatic migration.
a, b. MDA-MB-231 cells overexpressing PTPRN2 (a), PLCβ1 (b) or control vector were
treated with carrier alone or carrier incubated with PI(4,5)P2 and subjected to the
migration assay. N = 5 inserts/group.
c. MDA-MB-231 cells overexpressing PTPRN2 or a control vector were treated with
carrier incubated with PI(4,5)P2, carrier incubated with PI4P, or carrier alone and
subjected to the migration assay. N = 5 inserts/group.
Data are represented as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.
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Clinical and Functional Studies of PIP5K as a Driver of Metastatic Migration
Based on the importance of PI(4,5)P2 plasma membrane abundance on metastatic
capacity, I questioned whether the enzyme that generates this lipid, phosphatidyl inositol
5-phosphate kinase (PIP5K), would also affect metastasis in breast cancer. PIP5K
phosphorylates PI4P in the plasma membrane, producing PI(4,5)P2 (van den Bout and
Divecha, 2009). Interestingly, breast cancer patients whose tumors exhibited high levels
of the three forms of PIPK (PIP5K1A, PIP5K1B, and PIP5K1C) showed dramatically
better relapse-free survival and distal metastasis-free survival compared to patients whose
tumors expressed low levels of PIP5K (Gyorffy et al., 2010) (Figure 4.18a, b).
I next investigated a role for PIP5K in metastatic phenotypes, I focused on
PIP5K1A as it is the dominant isoform in MDA-MB-231 and has been shown to localize
to the plasma membrane in membrane ruffles (van den Bout and Divecha, 2009;
Yamaguchi et al., 2010). Overexpression of PIP5K1A in LM2 cells reduced the invasion
and migration abilities of these cells (Figure 4.18c-e). Taken together, these data suggest
that plasma membrane PI(4,5)P2 abundance negatively correlates with metastatic
capacity.
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Figure 4.18. PIP5K is a clinically relevant suppressor of metastatic invasion and
migration.
a, b. Kaplan-Meier curve representing relapse-free survival (a) or distal metastasis free
survival (b) of a cohort of breast cancer patients as a function of their primary tumor’s
mean PIP5K1A, PIP5KB, and PIP5KC expression levels. Patients’ primary tumors’
PIP5K expression levels were classified as low (blue) or high (red) expression.
c. PIP5K1A levels in LM2 cells overexpressing PIP5K1A or control vector were
measured by qRT-PCR.
d, e. Migration (c) and Matrigel invasion (d) of LM2 cells overexpressing PIP5K1A or
control vector. Data normalized to control values. N = 5 inserts/group.
Data are represented as mean ± S.E.M. *p<0.05, ***p<0.001.
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PTPRN2 and PLCβ1 Modulate Cofilin Localization
PI(4,5)P2 regulates cellular processes through binding to effector proteins, either
to recruit these proteins to the plasma membrane or to modulate their activity. Given the
effects of PTPRN2 and PLCβ1 on metastatic migration through altering PI(4,5)P2
abundance, I questioned whether these effects were mediated through actin dynamics.
Multiple proteins involved in actin dynamics are known to be inhibited by plasma
membrane PI(4,5)P2 , including gelsolin, profilin, twinfilin, capping proteins, and cofilin
(Saarikangas et al., 2010). I first investigated whether any of these genes was clinically
significant in breast cancer metastasis. Of these genes, only the increased expression of
cofilin was found to significantly correlate with worse distal metastasis-free survival in a
cohort of breast cancer patients (Gyorffy et al., 2010) (Figure 4.19a-f). Increased cofilin
expression has previously been implicated in breast cancer progression, as well as in oral
squamous cellular carcinoma, renal cell carcinoma, and ovarian cancer (Martoglio et al.,
2000; Turhani et al., 2006; Unwin et al., 2003; Wang et al., 2007; Wang et al., 2004).
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Figure 4.19. Expression of PI(4,5)P2 binding proteins in clinical metastasis-free
survival.
a-f. Kaplan-Meier curves representing distal metastasis-free survival of a cohort of breast
cancer patients (N = 1609) as a function of their primary tumor’s indicated gene
expression levels (Data from KMPlot). Patients’ primary tumors’ indicated gene
expression levels were classified as low (blue) or high (red) expression. CFL1 (a), TWF1
(b), GSN (c), PFN1 (d), CAPZA1 (e), CAPZB (f).
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Cofilin binds to plasma membrane PI(4,5)P2, and this binding prevents cofilin’s
ability to bind actin (Gorbatyuk et al., 2006; Ojala et al., 2001; Yonezawa et al., 1991).
Previous studies have shown that when PI(4,5)P2 is hydrolyzed, cofilin is released from
the plasma membrane and acts in the cytoplasm as an actin severing protein to promote
migration (Andrianantoandro and Pollard, 2006; Ghosh et al., 2004; van Rheenen et al.,
2007). Plasma membrane PI(4,5)P2 levels consequently regulate the localization and
activation state of cofilin. Given that PLCβ1 and PTPRN2 alter the levels of plasma
membrane PI(4,5)P2, I questioned whether cofilin localization could also change upon
depletion or overexpression of PTPRN2 or PLCβ1. Cells depleted of either of these
enzymes exhibited higher levels of plasma membrane PI(4,5)P2, and thus would be
expected to contain increased levels of membrane-associated cofilin. To test this
hypothesis, I sought to purify membrane fractions containing membrane and membraneassociated proteins from cancer cells and quantify the amount of cofilin in these fractions.
Western blots from MDA-MB-231 cells showed clean separation between the membrane
and cytoplasmic cellular compartments, as epidermal growth factor receptor (EGFR), a
transmembrane protein, was present predominantly in the membrane fraction, while
tubulin, a component of microtubules in the cytoplasm, was present only in the
cytoplasmic fraction (Figure 4.20).
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Figure 4.20. Separation of cytoplasmic and membrane proteins.
Membrane and membrane-associated proteins (MEM) and cytoplasmic proteins (CYTO)
were collected from MDA-MB-231 cells overexpressing PTPRN2 or a control vector.
Protein fractions were subjected to Western blot analysis for PTPRN2, EGFR, and
Tubulin.

Having demonstrated effective separation of membrane and cytoplasmic cellular
fractions, I next measured membrane cofilin content in the setting of altered PLCβ1 or
PTPRN2 expression. Western blot analysis of membrane fractions from metastatic cells
depleted of either PLCβ1 or PTPRN2 contained significantly more cofilin (CFL1) protein
compared to control cells (Figure 4.21a, b). Conversely, cells overexpressing either of
these enzymes contained less cofilin in their membrane fraction relative to control cells
(Figure 4.21c, d).
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Figure 4.21. PTPRN2 and PLCβ1 regulate the cellular localization of cofilin.
a, b. Membrane and membrane-associated proteins were purified from cells transfected
with siRNA targeting PTPRN2 (a) or PLCβ1 (b) or control siRNA. Fractions were
subjected to western blot analysis for CFL1 and EGFR levels. Below, densitometry
analysis of CFL1 levels normalized to EGFR levels.
c, d. Membrane and membrane-associated proteins were purified from cells
overexpressing PTPRN2 (c), PLCβ1 (d) or a control vector. Fractions were subjected to
western blot analysis for CFL1 and EGFR levels. Right, densitometry analysis of CFL1
levels normalized to EGFR levels. Data are represented as mean ± S.E.M. *p<0.05.
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These changes in cofilin membrane quantity were independent of changes in total
cofilin protein content, as western blot analysis for cofilin whole cell lysate from these
cells revealed no difference in cofilin abundance (Figure 4.22a, b). This indicates that the
differences in cofilin membrane quantity were due to changes in cofilin localization
rather than changes in cofilin expression upon manipulation of PTPRN2 or PLCβ1
expression levels.

Figure 4.22. Total cofilin and actin protein abundance in cancer cells with
modulated PTPRN2 and PLCβ1 expression.
a. Western blot analysis of cofilin and actin in whole cell lysate of LM2 cells transfected
with a control siRNA or siRNAs targeting PTPRN2 or PLCβ1.
b. Western blot analysis of cofilin and actin in whole cell lysate of MDA-MB-231 cells
overexpressing PTPRN2, PLCβ1, or a control vector.
Western blot analysis of GAPDH was used as a loading control.
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To further test the change in cofilin localization upon PTPRN2 or PLCβ1
modulation, I performed immunofluorescence experiments to visualize CFL1
localization. Cells depleted of PTPRN2 or PLCβ1 exhibited significantly increased
membrane localization of CFL1 relative to control cells (Figure 4.23a, b). Conversely,
overexpression of PTPRN2 or PLCβ1 revealed reduced cofilin membrane localization,
and increased cytoplasmic staining (Figure 4.23c). Taken together, these data indicate
that PTPRN2 and PLCβ1 act upstream of CFL1 localization. By decreasing plasma
membrane PI(4,5)P2 levels, these enzymes reduce cofilin’s association with the plasma
membrane, increasing the level of cytoplasmic cofilin.
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Figure 4.23. Immunofluorescence visualization of cofilin localization governed by
PLCβ1 or PTPRN2.
a, b. LM2 cells transfected with siRNA targeting PTPRN2 (a), PLCβ1 (b), or a control
siRNA were immunostained for CFL1 (red) and DAPI (blue). Top, representative
images. Bottom, quantification of membrane mean fluorescence intensity of CFL1.
N = 50 cells/group. Scale bar, 10 μm.
c. MDA-MB-231 cells overexpressing PTPRN2, PLCβ1, or a control vector were
immunostained for CFL1 (red) and DAPI (blue). Left, representative images. Right,
quantification of membrane mean fluorescence intensity of CFL1. N = 50 cells/group.
Scale bar, 10 μm.
Data are represented as mean ± S.E.M. ***p<0.001.
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PTPRN2 and PLCβ1 Promote Migration through Actin Remodeling by Cofilin
I next explored whether the cofilin localization changes observed upon depletion
of PLCβ1 or PTPRN2 result in altered cofilin activity. Cofilin regulates migration by
severing F-actin filaments to generate free barbed ends. The production of free barbed
ends by cofilin is a necessary precursor for the assembly of actin filaments driving
membrane protrusion, and enhanced abundance of free barbed ends correlates with
increased actin polymerization (Carlsson, 2006; Chan et al., 2000). Cofilin is only able to
bind and sever actin when not bound to PI(4,5)P2, as the binding sites for actin and
PI(4,5)P2 overlap and are mutually exclusive. To determine whether the decreased
cytoplasmic cofilin I observed in cancer cells with depletion of PTPRN2 and PLCβ1 led
to a reduction in cellular cofilin activity, I performed barbed end assays. In the barbed
end assay, cells are partially permeabilized and incubated with labeled actin monomers.
The actin monomers are only able to incorporate into free barbed ends. Unbound actin
monomers are washed away, and cells are fixed and stained for immunofluorescence. The
amount of free barbed ends can be quantified by measuring the amount of labeled actin
monomer present in the cells. Measurement of the number of free barbed ends in the
breast cancer cells revealed that cells depleted of PTPRN2 or PLCβ1 contained
significantly fewer free barbed ends relative to control cells, as quantified by the
incorporation of labeled actin monomers (Figure 4.24). These results suggest that PLCβ1
and PTPRN2 regulate breast cancer cell actin polymerization through decreased
membrane PI(4,5)P2 abundance and increased cofilin activity.
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Figure 4.24. PTPRN2 and PLCβ1 mediate cofilin activity.
LM2 cells transfected with siRNA targeting PTPRN2, PLCβ1, or control siRNA were
partially permeabilized and incubated with biotin-actin monomers. Cells were stained for
incorporated biotin-actin monomers using Streptavidin-555 (red) and DAPI (blue). Right,
quantification of mean fluorescence intensity of incorporated biotin-actin monomers.
N = 100 cells/group. Scale bar, 20 μm. Data are represented as mean ± S.E.M. *p<0.05,
***p<0.001.

Given the changes in cofilin localization and activity observed upon PLCβ1 and
PTPRN2 modulation, we next asked whether these changes in cofilin localization alter
the actin cytoskeleton in cancer cells. Interestingly, cells depleted of PTPRN2 or PLCβ1
exhibited reduced F-actin signal as visualized by immunofluorescence (Figure 4.25a).
This change in staining intensity was independent of total actin protein abundance as
measured by western blotting (Figure 4.22), suggesting that these cells possessed similar
quantities of actin monomers, but less filamentous actin in the setting of PTPRN2 or
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PLCβ1 knockdown. Conversely, PTPRN2 or PLCβ1 overexpression significantly
increased cellular F-actin staining intensity (Figure 4.25b). The weak actin filament
network seen upon PTPRN2 or PLCβ1 depletion is consistent with the migration defects
observed in these cells, since actin filament polymerization capacity at the leading edge is
necessary for cellular migration and invasion (Ghosh et al., 2004). These findings are also
consistent with the increased membrane-associated (inactive) cofilin in these cells, since
cofilin activity is necessary for the generation of new actin filaments.
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Figure 4.25. PTPRN2 and PLCβ1 expression affects actin polymerization.
a, b. LM2 cells transfected with siRNA targeting PTPRN2, PLCβ1, or control siRNA (a)
and MDA-MB-231 cells overexpressing PTPRN2, PLCβ1, or a control vector (b) were
stained with phalloidin (red) and DAPI (blue) and analyzed using fluorescence
microscopy. Right, mean fluorescence intensity quantification of whole cell phalloidin
signal. N = 40 cells/group. Scale bar, 10 μm. Data are represented as mean ± S.E.M.
**p<0.01, ***p<0.001.
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The above findings reveal PTPRN2 and PLCβ1 to regulate actin dynamics,
decreasing the levels of plasma membrane PI(4,5)P2 to increase active cytoplasmic
cofilin to drive metastatic migration. To test whether cofilin acts downstream of
PLCβ1/PTPRN2-mediated PI(4,5P)2 dynamics and metastatic migration, I performed
epistasis experiments. Partial knockdown of cofilin using RNA-interference abrogated
the effects of PTPRN2-mediated enhancement of migration and metastatic colonization,
consistent with cofilin being necessary for the effects (Figure 4.26a-c). In the setting of
PTPRN2 overexpression, cofilin depletion decreased migration by cancer cells by greater
than 70%. Similarly, cofilin depletion prevented enhanced migration capacity induced by
PLCβ1 overexpression (Figure 4.26d). Consistent with cofilin as necessary for cell
motility, depletion of cofilin reduced the ability of control cells to migrate, but to a lesser
extent than cells with PTPRN2 or PLCβ1 overexpression, indicating that cofilin is acting
in part through the PTPRN2/PLCβ1 pathway.
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Figure 4.26. Cofilin is required for PTPRN2- and PLCβ1-mediated metastasis.
a. Western blot analysis of CFL1 in MDA-MB-231 cells transfected with siRNAs
targeting CFL1. GAPDH was used as a loading control.
b, c. MDA-MB-231 cells were transfected with siRNAs targeting CFL1 or a control
siRNA in the setting of control or PTPRN2 (b) or PLCβ1 (c) overexpression and
subjected to the migration assay. N = 5 inserts/group.
c. Bioluminescence imaging quantification of 40,000 MDA-MB-231 cells as in (b).
Right, representative lung histology. N = 5 mice/group.
Data are represented as mean ± S.E.M. *p<0.05, ***p<0.001.
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I hypothesized that PTPRN2 and PLCβ1 act upstream of cofilin by regulating
cofilin’s localization through modulating plasma membrane PI(4,5)P2 levels. Cells
depleted of either enzyme exhibited increased levels of plasma membrane PI(4,5)P2 and
increased membrane-associated cofilin. Given that the activation of cofilin depends on its
release from PI(4,5)P2, a constitutively membrane-associated mutant of cofilin should
not be able to respond to changes in plasma membrane PI(4,5)P2 levels mediated by
PLCβ1 or PTPRN2. To generate a continuously membrane-associated form of cofilin, I
fused the N-terminal sequence of Lck, a Src tyrosine kinase to cofilin. This sequence is
myristoylated and inserted into the plasma membrane (Zlatkine et al., 1997). Addition of
this sequence has been demonstrated as sufficient to target proteins to the plasma
membrane. Cells transfected with cofilin-Lck exhibited increased cofilin localization to
the plasma membrane relative to cells transfected with wild-type cofilin (Figure 4.27). In
cells overexpressing either PLCβ1 or PTPRN2, endogenous cofilin was depleted using
siRNA targeting the 3’UTR, and cofilin was re-expressed as either wild-type cofilin or
membrane-anchored cofilin-Lck. Cells with replacement expression of wild-type cofilin
exhibited PTPRN2 and PLCβ1-mediated increases in migration. However, restoring
cofilin expression with membrane-anchored cofilin-Lck abolished the ability of PTPRN2
or PLCβ1 to increase migration (Figure 4.27a, b). These findings indicate that metastatic
migration driven by PTPRN2 and PLCβ1 is accomplished through active, non-PI(4,5)P2
membrane-associated cofilin.
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Figure 4.27. Membrane-fused cofilin abrogates PTPRN2 and PLCβ1 effects.
a. MDA-MB-231 were transfected with siRNA targeting the 3’UTR of CFL1 to deplete
endogenous CFL1 and further transfected with plasmids encoding either GFP-CFL1-WT
or GFP-CFL1-Lck (green) and immunostained with DAPI (blue). Left, quantification of
membrane GFP-CFL1. Right, representative images. N=50 cells/group. Scale bar, 10 μm.
b, c. MDA-MB-231 cells overexpressing PTPRN2 (b) or PLCβ1 (c) were transfected as
in (a) and subjected to the migration assay. N = 5 inserts/group.
Data are represented as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.
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Our findings support a model wherein PTPRN2 and PLCβ1 abundance increases
in highly metastatic breast cancer cells. PTPRN2 and PLCβ1 convergently reduce the
levels of PI(4,5)P2 in the plasma membrane, dissociating cofilin from the membrane and
enabling it to sever cytoplasmic actin to drive actin assembly, metastatic migration, and
colonization.
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CHAPTER V: DISCUSSION

Overview of Findings
Phosphoinositide regulator proteins may drive cancer progression by
manipulating the lipids governing the cellular processes that give rise to metastatic
phenotypes. In this thesis, I describe the molecular mechanisms of three proteins,
PITPNC1, PTPRN2, and PLCβ1, which regulate the levels of PIs in cancer cells to
promote metastasis. In the final chapter of this thesis, I summarize the findings from
Chapters II-IV, address additional considerations on the mechanisms of these proteins,
synthesize findings from both projects, and discuss the therapeutic potential of targeting
these pathways.
We first identified PITPNC1 as a robust driver of metastasis in melanoma, breast,
and colon cancer through functional studies and clinical data analysis. Notably, PITPNC1
expression increased significantly in triple negative breast cancer, a subtype of breast
cancer for which targeted adjuvant therapy is currently lacking. We furthermore
identified multiple pathways by which PITPNC1 expression may be increased in cancer
cells. PITPNC1 was initially identified as a target of the metastasis suppressor miRNA,
miR-126, and we discovered PITPNC1 was also targeted by a second metastasis
suppressor miRNA, miR-335. Additionally, PITPNC1 is amplified in nearly half of
breast tumors due to a common amplification within chromosome 17q where it is located.
We then investigated the molecular mechanism of PITPNC1-mediated metastasis,
and found that PITPNC1 binds to PI4P in the trans Golgi network (TGN), bringing its
binding partners, RAB1B and 14-3-3 proteins to the Golgi. The PITPNC1/RAB1B
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protein complex increases PI4P abundance in the Golgi, and we propose this occurs
through the recruitment of PI4KA to the TGN by RAB1B. PI4KA increases the TGN
abundance of PI4P, and GOLPH3 binds to the additional PI4P, inducing tensile forces on
the Golgi through GOLPH3’s binding to MY018A and the actin cytoskeleton. The
elongated Golgi ribbon induced by these forces facilitates secretion, leading to enhanced
release of secreted factors. We identified a set of pro-metastatic genes whose secretion
required PITPNC1: ADAM10, FAM3C, HTRA1, MMP1, and PDGFA (Figure 5.1).

Adapted from Halberg, N*, Sengelaub, CA*, et al. In Revision at Cancer Cell.
Figure 5.1. PITPNC1-mediated metastatic secretion though recruitment of RAB1B
to the trans Golgi.
PITPNC1 expression is augmented in highly metastatic cells due to genomic
amplification and loss of miR-126- and miR-335-mediated repression. PITPNC1 binds
14-3-3 and RAB1B, and localizes to the Golgi due to its binding of PI4P. Recruitment of
RAB1B to the Golgi enhances PI4P abundance, increasing tensile stretching of the Golgi
by GOLPH3. The elongated Golgi morphology enhances secretion of a set of proantigenic and pro-metastatic factors.
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PTPRN2 and PLCβ1 were initially identified as putative targets of a metastasis
suppressor miRNA, miR-335. Increased expression of PTPRN2 and PLCβ1 was found to
clinically correlate with metastatic relapse and worse overall survival in breast cancer in
breast cancer patients. PTPRN2 and PLCβ1 convergently target PI(4,5)P2 in the plasma
membrane of breast cancer cells. These enzymes act in two independent manners:
PTPRN2 dephosphorylates PI(4,5)P2 while PLCβ1 hydrolyzes the lipid. The action of
these enzymes decreases the abundance of PI(4,5)P2 in the plasma membrane, releasing
cofilin from the membrane to the cytoplasm. Cofilin in the cytoplasm binds and severs
actin, generating increased actin polymerization and enhancing cellular motility.
Enhanced cellular motility driven by PTPRN2 and PLCβ1 promotes metastatic
migration, especially at early stages in the metastatic cascade (Figure 5.2).
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Adapted from Sengelaub, CA et al. In Revision at EMBO J.
Figure 5.2. PTPRN2- and PLCβ1-mediated metastatic migration through PI(4,5)P2dependent actin remodeling.
PTPRN2 and PLCβ1 expression is increased in highly metastatic breast cancer cells due
to loss of translational repression by miR-335. PTPRN2 and PLCβ1 deplete PI(4,5)P2 in
the plasma membrane. PI(4,5)P2 binds cofilin to inhibit its activity, and loss of PI(4,5)P2
increases cofilin actin-severing activity to promote metastatic migration.

Considerations on the Mechanism of PITPNC1-mediated Metastasis
PITPNC1 belongs to the RdgB class of PITP transfer proteins (PITP family class
II), which is generally less well characterized than the class I proteins, PITPα and PITPβ.
PITPα and PITPβ have been found to bind and transfer unmodified phosphoinositide (PI)
and phosphatidyl choline (PC). Previous work by other researchers implicated PITPNC1
as binding and transferring phosphatidic acid (PA) (Garner et al., 2012). The
physiological implication of this activity is unclear; although the researchers suggest that
PITPNC1 may transfer PA to the endoplasmic reticulum for synthesis of PI. In our
biochemical and cellular analyses, we did not detect binding of PITPNC1 to PA.
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Additionally, PITPNC1 exhibited localization to the TGN in breast cancer cells, an
organelle enriched in PI4P. PITPNC1 localization to the TGN was dependent upon PI4P,
as depletion of PI4P by Golgi-localized SAC1 reduced PITPNC1 abundance in the Golgi
and increased PITPNC1 in the cytoplasm. Furthermore, the defects in secretion we
observe upon depletion of PITPNC1 are consistent with a role for PITPNC1 in the Golgi.
PI4P thus represents a new substrate for the PITP domain, as previous PITP domain
substrates have been limited to PI, PC, and PA.
Future studies will be required to determine what role, if any, the lipid transfer
capacity of PITPNC1 serves in metastatic cells. Nils Halberg previously observed that
recombinant PITPNC1 is capable of transferring PI4P between vesicles in vitro, however
with much lower efficiency relative to the transfer of PI by PITPα. Several possible
functions of PITPNC1 transfer of PI4P are considered as follows. First, it is possible that
PITPNC1 may localize PI4P to proposed “microdomains” within the TGN where
exocytic budding is thought to occur (De Matteis and Luini, 2008). PI4P recruits proteins
required for vesicle budding at these sites in the TGN. Another possibility is that
PITPNC1 maintains PI4P localization in the TGN. The Golgi is a dynamic organelle
undergoing continual anterograde and retrograde transport of cargo. PITPNC1 may bind
to PI4P to prevent PI4P retrograde transport to the cis Golgi, maintaining enrichment of
PI4P in the TGN. Lastly, a new role for lipid transfer domains as lipid-presenting proteins
has recently been suggested. The lipid transfer protein TIPE3 was demonstrated to not
only transfer PI(4,5)P2, but also present PI(4,5)P2 to PI3K, increasing the generation of
PIP3 through optimal orientation of the substrate (Fayngerts et al., 2014). This suggests
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that PITPNC1 could also present PI4P to PI4P-binding proteins, although the
physiological role of this activity would need to be determined.

In our proposed mechanism of PITPNC1-mediated secretion, PITPNC1 binds and
recruits RAB1B to the Golgi. RAB1B in turn recruits PI4KA to the Golgi, increasing the
abundance of PI4P in the TGN. In addition to its role in recruiting PI4KA, RAB1B also
enhances secretion through activating ADP ribosylation factor 1 (ARF1). Secretory
vesicles are formed by the recruitment of various cytoplasmic proteins, a process that is
initiated by ARF1. ARF1 is activated by conversion from a GDP-bound form to GTPbound state by the guanine nucleotide exchange factor (GEF) GBF1. RAB1B has been
found to recruit GBF1 from the cytoplasm to the Golgi where it activates ARF1, inducing
vesicle formation at the TGN (Dumaresq-Doiron et al., 2010; Monetta et al., 2007).
Consequently, PITPNC1-mediated recruitment of RAB1B to the TGN may promote
metastatic secretion through two methods: RAB1B recruiting PI4KA and RAB1B
activating ARF1. Interestingly, 14-3-3 proteins have also been shown to recruit BARS
and PI4KB to the Golgi to regulate Golgi carrier formation and vesicular budding and
fission (Valente et al., 2012). In addition to bringing RAB1B to the Golgi, PITPNC1 may
also increase 14-3-3 Golgi abundance to facilitate secretion.

Considerations on the Mechanism of PTPRN2 and PLCβ1-mediated Metastasis
PTPRN2 and PLCβ1 deplete PI(4,5)P2 from the plasma membrane, which
promotes actin remodeling and migration. This is accomplished through the activation of
cofilin, which is inhibited as a result of its binding to membrane PI(4,5)P2. Loss of
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PI(4,5)P2 allows cofilin to move to the cytoplasm where it modifies actin filaments.
Through fluorescence recovery after photobleaching (FRAP) experiments, cofilin has
been shown to bind PI(4,5)P2 transiently, with fast on- and off-rates (van Rheenen et al.,
2007). Therefore, the increase in cytoplasmic cofilin upon PI(4,5)P2 depletion is not the
result of direct release of cofilin by PTPRN2 or PLCβ1, but rather the lower on-rate of
cofilin binding to PI(4,5)P2 as a result of the lower PI(4,5)P2 concentration at the plasma
membrane. Cofilin activation is highly sensitive to alterations in PI(4,5)P2 levels by
PTPRN2 and PLCβ1.
Cofilin activity must be carefully temporally and spatially controlled to promote
optimal formation of plasma membrane protrusions and subsequent migration. Indeed,
excess cofilin activation can inhibit actin dynamics (Wang et al., 2007). Although the
mechanisms by which PTPRN2 and PLCβ1 enzymatic activities are controlled were not
studied in this thesis, several modes of regulation are possible. First, we noted that both
PTPRN2 and PLCβ1 frequently localize to one edge of the plasma membrane, potentially
corresponding to the leading edge of the cancer cell. Restricted localization of these
proteins would thus generate restricted cofilin activation, promoting directional
migration. However, future work will be required to determine how the localization of
PTPRN2 and PLCβ1 to the leading edge is established.
In addition to polarized localization of PTPRN2 and PLCβ1, the enzymatic
activity of each protein may be temporally restricted. As a transmembrane protein,
PTPRN2 is transported to the plasma membrane and then recycled back to the Golgi in a
cyclical manner. Since PTPRN2 is not constitutively localized to the plasma membrane,
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it is only able to dephosphorylate PI(4,5)P2 during one part of its cellular trafficking
cycle, restricting its activity.
PLCβ1 activity is temporally restricted by its requirement for external activation.
The PLCβ family is activated by heterotrimeric G proteins, and PLCβ1 is specifically
activated by the Gqα subunits. In order to activate PLCs, heterotrimeric G proteins must
first be activated by G protein-coupled receptors (GPCRs) which act as GEFs to
exchange GDP to GTP bound to the G protein. GPCRs are activated by small molecules
such as hormones, cytokines, and peptides. Gqα -coupled GPCRs are activated by several
molecules that have been implicated in cancer, including CXC chemokines (implicated in
metastatic angiogenesis), bradykinin (identified as a growth factor in multiple cancer
types), angiotensin II (promotes migration and proliferation in breast and lung cancer),
and endothelin-1 (overexpressed in multiple cancer types, promotes survival and
migration) (Rhee, 2001). The fact that these molecules must be present to activate PLCβ1
restricts its enzymatic activity. The localization of these activating molecules in the
microenvironment may perhaps also provide a chemotactic directional effect on cellular
migration.
PLCβ1 activity is further temporally restricted by the length of G protein
activation. Activated G proteins contain intrinsic GTPase activity, quickly inactivating
the signaling cascade. Interestingly, PLCβ enzymes possess GTPase stimulating activity,
or the ability to increase the rate of inactivation of the G protein to prevent constitutive
activation of enzymatic activity (Rebecchi and Pentyala, 2000). Thus PLCβ1 limits its
own activity, consistent with the need for temporal control of PI(4,5)P2 depletion and
cofilin activation. In PLCδ, a homolog of PLCβ1, decreasing concentrations of PI(4,5)P2
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reduced enzymatic activity in vitro, indicating that the PI(4,5)P2 substrate itself may also
serve to modulate the activity of the enzyme (Cifuentes et al., 1993). This represents an
additional route by which the enzymatic activity of PLCβ1 may be limited, to allow for
controlled activation of cofilin without depleting membrane PI(4,5)P2 necessary for other
cellular processes.

A recent study on PTPRN2 suggested a role for PTPRN2 in resistance to
apoptosis, specifically in the setting of high cell density (Sorokin et al., 2015). We did not
observe changes in the cellular proliferation rates of cancer cells with either depletion or
overexpression of PTPRN2. However, staining for caspase markers and Ki67 in these
cells will be required to conclusively eliminate this hypothesis. Nuclear-localized PLCβ1
has also been implicated in cell proliferation. Products of the PLC reaction, DAG and
IP3, activate PKC, which in turn activates cell cycle proteins (Faenza et al., 2000).
However we did not observe PLCβ1 localization to the nucleus in the breast cancer cells
utilized in this work, nor did we observe changes in cellular proliferation rates upon
PLCβ1 depletion or overexpression.

miR-126 and miR-335 Regulation of PITPNC1, PTPRN2, and PLCB1
PITPNC1, PTPRN2, and PLCB1 were initially identified as putative targets of
miR-126 and miR-335. These miRNAs are silenced in highly metastatic breast cancer
cells, and reconstituting their expression reduces metastatic colonization capacity
(Tavazoie et al., 2008). Expression of these miRNAs is repressed by independent
mechanisms. Work by Kim Png, a previous graduate student in the laboratory, revealed
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that miR-335 is silenced by two independent mechanisms in highly metastatic breast
cancer cells. Copy number analysis demonstrated that one allele is genetically deleted in
multiple metastatic derivative sublines, while methylation-specific PCR showed that the
miR-335 is also epigenetically silenced through promoter hypermethylation (Png et al.,
2011).
Png did not find evidence of genomic deletion or promoter hypermethylation in
the silencing of miR-126 in highly metastatic breast cancer cells. Work by Png and
Claudio Alarcon, a postdoctoral fellow in the laboratory, determined that miR-126
expression is silenced in part due to a defect in its processing. Although highly metastatic
cells exhibit low levels of mature miR-126, they possess an increased quantity of pri- and
pre-miR-126. The pri form of a microRNA is the initial transcript transcribed by RNA
polymerase II. The pri-miRNA is bound by DCGR8 and cleaved by the ribonuclease
Drosha to generate the pre-miRNA. The pre-miRNA is then exported from the nucleus.
In the cytoplasm, the pre-miRNA is cleaved by Dicer to generate the mature miRNA
(Kim, 2005). The expression of pre-miR-126 but not mature miR-126 in the metastatic
cells suggests defects in nuclear export of pre-miR-126 or in recognition and cleavage by
Dicer. Further work is needed to precisely determine the underlying cause of this
processing defect.
Png, Halberg, and I established PITPNC1 as targeted by both miR-126 and miR335. Future studies will be required to determine if PTPRN2 and PLCB1 are directly or
indirectly targeted by miR-335. Analysis of the coding sequences and 3’UTRs of
PTPRN2 and PLCB1 did not reveal any sequences with the required 6-nucleotide
complementarity to the 3p arm of miR-335, however several regions showed 5- and 4-
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nucleotide complementarity. The miRNA 6-nucleotide seed sequence must be entirely
complimentary to the target gene transcript in order for the RISC complex to degrade the
transcript (Grimson et al., 2007). However, 4- and 5-nucleotide sequence
complementarity is still sufficient for miRNA binding that can inhibit translation through
steric hindrance, reducing protein levels of a target gene. Several regions of 6-nucleotide
complementarity in both PTPRN2 and PLCB1 were identified for the 5’ arm of miR-335.
Heterologous luciferase reporter assays in conjunction with mutational analysis will be
required to determine if miR-335-5p directly targets these genes. Additionally, it cannot
be excluded that miR-335 is indirectly regulating expression of these genes through
modulation of an RNA binding protein or transcription factor.

Implications for Lipid Regulators in Metastatic Progression
Given the requirement for careful regulation of PIs, it is notable that the
expression of PITPNC1, PTPRN2, and PLCB1 are all regulated by miRNA-induced
translational repression in metastatic breast cancer cells, which results in modulation of
gene expression, but not complete depletion or aberrant activation. Cancer cells
frequently exhibit dramatic changes that lead to gene silencing, including genetic
deletions or epigenetic silencing such as DNA methylation or chromatin modification, or
gene activation, such as promoter hypermethylation or gene copy number amplification.
Additionally, cancer cells undergo frequent mutations which may repress gene product
expression by inducing nonsense-mediated decay of gene transcripts, or increase gene
product effects by constitutively activating protein activity. In contrast, miRNA
overexpression or silencing decreases or increases gene expression within a small
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dynamic range. This modulation of gene expression is particularly important for PI
regulator proteins, since the abundance and localization of PIs is tightly controlled within
cells.

We have shown that although PITPNC1 binds to PI4P, its binding capacity is
weaker than other PI4P binding proteins, such as FAPP1. This potentially allows
PITPNC1 to recruit RAB1B to the Golgi without preventing the binding of secretion
effector proteins to PI4P, which would disrupt cellular secretion and eventually lead to
cell death. Essentially, PITPNC1’s weak binding capacity enables it to facilitate secretion
without permanently affecting the abundance, localization, or action of PI4P.

Conversely, PTPRN2 and PLCβ1 both deplete PI(4,5)P2. As described above, the
enzymatic activity of these proteins must be restricted since PI(4,5)P2 is crucial in other
cellular processes. For example, PI(4,5)P2 is the precursor to PI(3,4,5)P3, a key PI in
cancer proliferation (Bunney and Katan, 2010). We have shown that PTPRN2 and
PLCβ1 deplete PI(4,5P)2 by approximately 30%, leaving remaining lipid for other
cellular activities. However, it cannot be excluded that PTPRN2 and PLCβ1-mediated
depletion of this lipid may impact other processes in addition to cofilin activation.
PI(4,5)P2 is involved in membrane trafficking through both exocytosis and endocytosis
(Martin, 2001; Zoncu et al., 2007). PI(4,5)P2 serves as a docking site for proteins
involved in Ca2+-triggered vesicle exocytosis, however depletion of this lipid has also
been demonstrated to be necessary for secretion in mast cells (Hammond et al., 2006). A
similar process has been reported to occur in endocytosis, where PI(4,5)P2 recruits

144

clathrin or other coat proteins, but the lipid must be removed for vesicle fission to
complete (Chang-Ileto et al., 2011). While our findings focus on the role of PTPRN2 and
PLCβ1-mediated depletion of PI(4,5)P2 on actin dynamics and migration, they do not
exclude other effects on the above cellular processes, which may also contribute to
metastatic phenotypes.

Metastatic Secretion
Secretion is a required phenotype in multiple steps of the metastatic cascade,
including secretion of proteases to degrade the ECM allowing for cancer cell invasion,
and secretion of attractive factors for cancer cell proliferation and angiogenesis.
PITPNC’s ability to promote metastasis in melanoma, breast, and colon cancers is
surprising given the diversity of tissues in the primary site and metastatic site of these
cancers. However, the ability to invade, colonize a metastatic niche, and induce
angiogenesis is required for metastasis in all solid tumor cancers. In addition to
establishing PITPNC1 as a robust mediator of metastatic secretion, we identified Golgi
elongation as a previously un-described morphological feature of highly metastatic cells.
Given the importance of secretion in the metastatic cascade, enhanced secretion is likely
a feature of highly metastatic subpopulations in other solid tumor types, and future
studies are needed to determine if Golgi elongation correlates with metastatic capacity
across a broad spectrum of cancers.

We identified a set of five proteins that exhibited PITPNC1-dependence for their
secretion. However, given the effects of PITPNC1 on Golgi morphology, it is likely that
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PITPNC1 affects global secretion in metastatic cells and is not limited to the secretion of
a subset of proteins. MMP1, ADAM10, FAM3C, PDGFA, and HTRA were identified in
our SILAC secretome as exhibiting the greatest change in secreted abundance upon
depletion of PITPNC1, but mass spectrometry identified 40 proteins whose abundance
changed by at least 1.5-fold. As this data was collected three years ago, repeating this
experiment with improved mass spectrometry protocols and equipment could reveal
novel pro-metastatic secreted factors. Furthermore, it would be interesting to determine
whether these five proteins serve pro-metastatic functions in melanoma and colon cancer
cells, or whether secretome profiling in these cells would reveal a novel set of secreted
pro-metastatic proteins.

Golgi elongation is mediated through the actin cytoskeleton, suggesting a
secondary role for PTPRN2 and PLCβ1 in mediating metastatic secretion. The weak
actin cytoskeleton observed upon depletion of PTPRN2 or PLCβ1, reflecting defects in
actin polymerization, would affect tensile forces on the Golgi leading to a condensed
Golgi and impairing secretion. Future experiments are needed to measure the length of
the Golgi upon PTPRN2 or PLCβ1 depletion and overexpression to determine if Golgi
morphology and secretory capacity is a consequence of PI(4,5)P2-mediated actin
dynamics. PTPRN2 has been previously demonstrated to regulate insulin secretion in
pancreatic beta cells, although the molecular mechanism is unknown (Wasmeier and
Hutton, 1996). A possible explanation is that PTPRN2 regulates actin dynamics in these
cells through PI(4,5)P2 depletion, altering Golgi morphology to enhance insulin
secretion.

146

Potential for Therapeutic Targeting of PITPNC1, PTPRN2, and PLCβ1
PITPNC1, PTPRN2, and PLCβ1 have the potential to be therapeutically targeted
at three levels: restoring miRNA-126 or miR-335 expression, inhibiting the activities of
these enzymes, or inhibiting effector proteins downstream of these enzymes. The clinical
application of miRNA-based therapies is hindered by the short half-life of miRNAs in
vivo and difficulties in delivering miRNAs to targeted tissues (Broderick and Zamore,
2011). Even if the miRNA were successfully delivered to target cells, a single dose would
not be sufficient to restore sustained miRNA expression and tumor suppression. Instead
viral delivery of miRNAs represents a more promising avenue of therapeutic
development, as it would allow for continuous restoration of expression. Several studies
have demonstrated efficacy of using adeno-associated virus (AAV) to drive expression of
a given miRNA, restoring miRNA expression and preventing tumor growth in murine
models of liver and lung cancer, as well as preventing metastatic colonization by colon
cancer (Kota et al., 2009; Loo et al., 2015; Miyazaki et al., 2012). Viral delivery of
miRNAs has the potential to deliver specific and continuous level of expression, however
AAV as a delivery vehicle for therapeutic treatments is currently still under clinical
development and testing.
Targeting the PITPNC1, PTPRN2, or PLCβ1 directly with small molecular
inhibitors represents an additional option for therapeutic targeting. For PITPNC1, a small
molecule inhibitor could bind within its PITP domain, preventing PITPNC1’s ability to
bind PI4P in the Golgi. As we showed in our cell biological experiments, PITPNC1’s
ability to bind PI4P is critical for its pro-metastatic effects. A study recently identified a
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class of small molecules, nitrophenyl(4-(2-methoxyphenyl)piperazin-1yl)methanones (NPPMs), with the ability to inhibit the PI transfer activity of the major
yeast PITP, Sec14 (Nile et al., 2014). In silico docking studies projected that the NPPMs
bind within Sec14’s hydrophobic lipid binding pocket, and NPPM binding would prevent
binding of PI or PC. This study represented the first validated inhibitors against PITP
domains and established the PITP domain as pharmacologically targetable. Future studies
are needed to determine if NPPMs are capable of inhibiting PITPNC1 PI4P-binding
activity, but this study creates promise for future drug discovery targeting PITPNC1.
An alternate method of targeting PITPNC1 would be through inhibiting its
interaction with 14-3-3 proteins. 14-3-3 proteins bind to PITPNC1, blocking a PEST
degradation sequence within PITPNC1’s cytoplasmic tail. In the absence of 14-3-3
binding, PITPNC1 has a much shorter half-life in cells. Protein-protein interactions may
be inhibited by peptides, but use of peptides as therapeutics faces many challenges
including poor metabolic stability, poor cell permeability, and rapid clearance. Inhibiting
protein-protein interactions by a small molecule is highly difficult due to the complex
structure of proteins compared to the relatively simple structure of small molecules.
Surprisingly, one study identified a compound, BV02 (2-(2,3-Dihydro-1,5-dimethyl-3oxo-2-phenyl-1H-pyrazol-4-yl)-2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid),
which is able to inhibit the interaction between 14-3-3 and Bcr-Abl protein kinase
(Mancini et al., 2011). Screening for compounds that block the PITPNC1-14-3-3
interaction may reveal additional therapeutic targets against PITPNC1.
One possible method to identify small molecule inhibitors of the PITPNC1/14-3-3
interaction in a high-throughput format is an in-cell western assay, which is allows for
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quantification of protein levels in whole cells using immunofluorescence. In this assay,
cancer cells would be seeded in microtiter plates and incubated with various compounds.
After treatment, cells would be fixed, permeabilized, incubated with anti-PITPNC1 and a
control antibody, and finally incubated with infrared-conjugated secondary antibodies.
An infrared imaging system would measure PIPTNC1 protein levels and control protein
levels for normalization. A small molecule that inhibits the 14-3-3 binding to PITPNC1
would be expected to decrease PITPNC1 levels, without changing levels of a control
protein or changing cell viability. This screen would identify a set of primary hits, which
would be validated for their ability to directly disrupt the PITPNC1/14-3-3 interaction in
a biochemical secondary assay. In the secondary assay, we would combine hits from the
first screen with purified 14-3-3 protein and a rhodamine-labeled peptide comprising
PITPNC1’s 14-3-3 binding sequence and measure fluorescence polarization (FP). In
cases where a small molecule inhibitor successfully disrupts the PITPNC1 peptide/14-3-3
interaction, the free peptide would exhibit lower FP compared to the larger FP of the
peptide/14-3-3 complex.
PITPNC1 regulates the secretion of a set of pro-metastatic and pro-angiogenic
proteins, and these proteins also represent potential therapeutic targets. Secreted proteins
are therapeutically advantageous compared to intracellular proteins since they may be
targeted by systemically administered antibodies. Although antibodies are expensive to
produce, they possess a longer half-life and higher specificity than non-biological drugs.
One example of a therapeutic antibody targeting a secreted protein is bevacizumab,
which binds vascular endothelial growth factor A (VEGF-A) to prevent angiogenesis.
However bevacizumab has demonstrated mixed efficacy, prolonging survival in patients
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with metastatic colon, lung, or renal cancers, but not breast cancer (Ferrara et al., 2004;
Montero et al., 2012). Since PITPNC1 facilitates the secretion of multiple proteins, this
treatment approach would require multiple therapeutic antibodies.
Although there are many drugs that inhibit kinases, the discovery of cell
permeable and orally bioavailable phosphatase and phospholipase inhibitors has proven a
much more difficult task. Several compounds have been discovered that inhibit PTP and
PLC domains, although no specific in vivo inhibitors for PTPRN2 or PLCβ1 currently
exist. Small molecule inhibitors of PTP domains typically mimic the structure of
phosphotyrosine, the natural substrate of PTP domains, but are rendered nonhydrolyzable. A popular target for drug discovery is PTP1B, a PTP found to promote
Type II diabetes (Johnson et al., 2002). The catalytic site of PTP1B has so far proven
intractable to specific small molecule inhibitors due to the highly conserved nature of the
PTP domain. Since PTPRN2 contains a non-canonical PTP domain, it may be easier to
identify specific inhibitors.
Prior to the discovery of PTPRN2’s activity against PI(4,5)P2, one research group
“back mutated” several residues in the PTPRN2 catalytic domain to the canonical PTP
residues. These mutations created PTP activity, which was used as the readout in a screen
for catalytic inhibitors. The group identified derivatives of 2-(oxalylamino)benzoic acid
as inhibitors of mutant PTPRN2 recombinant protein (Drake et al., 2003). Future
experiments are needed to determine if these compounds inhibit wild-type PTPRN2’s
lipid phosphatase activity and thus would be candidates for optimization for use in vivo.
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A potent inhibitor of PLCy, U73122 (1-(6-((17β-3-methoxyestra-1,3,5(10)-trien17-yl)amino)hexyl)-1H-pyrrole-2,5-dione), has been used in many studies to dissect the
role of this enzyme in cellular processes. However, U73122 has little activity against
PLCβ1 (Hou et al., 2004), suggesting that the divergence among the PLC family could
sufficiently allow for an inhibitor specific to PLCβ1.
Given the importance of cofilin in many cell types, targeting cofilin would be
clinically unfeasible. Cells must maintain a balance of cofilin activity in order to
maintain their actin cytoskeletons and thus structural integrity. However, our clinical and
experimental findings suggest that increasing plasma membrane PI(4,5)P2 may prevent
metastasis. One method to achieve this is increasing the activity of PIP5K, although the
mechanisms by which PIP5K isoforms are regulated are not well characterized. Overall,
PITPNC1, PTPRN2, and PLCβ1 represent viable novel targets for the development of
anti-metastatic treatments.
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MATERIALS AND METHODS

Animal Experiments
All animal experiments were conducted in accordance to a protocol approved by
the Institutional Animal Care and Use Committee at The Rockefeller University. Mice
were housed 5 mice/cage at a 12-hour day-night cycle with free access to tap water and
food pellets. Six- to eight-week old age-matched female NOD-SCID mice were used for
lung and liver metastasis assays. For lung metastatic colonization assays, luciferase
reporter-labeled cells at the number indicated were suspended in 100μL PBS and injected
via the tail vein. For liver metastasis assays, luciferase reporter-labeled breast cancer cells
were resuspended in 50μl of a 1:1 ratio of Matrigel and PBS and injected into the spleens
of six-week old age-matched female NOD-SCID mice. After injection into the spleen, a
splenectomy was then performed to prevent the growth of a tumor in the spleen. Sevento eight- week old age-matched female Balb/c mice were used for 4T1 lung metastasis
assay.
Lung or liver colonization was measured once per week by non-invasive
bioluminescence imaging. Mice were anesthetized and injected retro-orbitally with
100μL luciferin (15 mg/mL). Imaging was performed between 2 and 5 minutes after
injection with a Xenogen IVIS system and analyzed with Living Image software
(Xenogen).
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Cell Lines
The MDA-MB-231 breast cancer cell line and its metastatic derivatives, 293T
cells, LS174T-LvM3 colorectal cells, and 4T1 cells were cultured with Dulbecco’s
modified Eagles’ medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS).
LS174T-LvM3 subline was derived from the human LS174 colon cancer line through
rounds of in vivo selection (Loo et. al., 2015). The MeWo melanoma cell line (ATCC)
was maintained according to ATCC guidelines in DMEM supplemented with 10% FBS.
BT-549 and HCC-1806 cell lines (ATCC) were maintained according to ATCC
guidelines in RPMI medium supplemented with 10% FBS. MDA-MB-468 cells (ATCC)
were cultured in DMEM medium containing 10% FBS. Human umbilical vein
endothelial cells (HUVEC) (ATCC) were maintained according to ATCC guidelines in
EGM-2 media (Lonza) supplemented with 2% FBS.

Cell Transfections
Transient transfection of siRNAs (Integrated DNA Technologies, sequences in
Table 6.1) was performed using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol. Cells were seeded for invasion and migration assays or
subjected to the tail vein metastasis assay 48 hours post-transfection.
Immunofluorescence was conducted 72 hours post-transfection.
Transient transfection of plasmids into cells was conducted using Lipofectamine
2000 according to the manufacturer’s protocol. Cells were used for immunofluorescence,
migration, or invasion assays 24 hours post-transfection.
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Table 6.1. siRNA Sequences
Control

CGUUAUCGCGUAUAUACGCGAU

PITPNC1 #1

CCACAGACGCACCCGAAUU

PITPNC1 #2

CGAUGAAAUUCCAGAGCGC

GOLPH3

GCUUGUGGAAUGAGACGUA

MMP1

GGAGGUAUGAUGAAUAUAA

RAB1B

GCCAGCGAGAACGUCAAU

PTPRN2 #1

CCUACUGAGCGGACAGAAAGAAGCC

PTPRN2 #2

GGCAUUGAGCAAGCUAUGAGGGUCC

PLCB1 #1

CGCUAAGAAAUAAUUGAUGGAGCCA

PLCB1 #2

GGCGUUAAUCAUAAAGAAGCAAGAA

CFL1 #1

GCAAGCAAACUGCUACGAGGAGGUC

CFL1 #2

ACGACAUGAAGGUGCGUAAGUCUUC

CFL1 #3 (3’UTR targeting) CUCAUGGAAGCAGGACCAGUAAGGG

Generation of Constructs for Knockdown and Overexpression Cell Lines
For generation of retrovirus, 293T cells were seeded onto a 10cm plates. 12µg of
Gag/Pol vector, 6µg of VSVG vector, and 12µg of the appropriate plasmid were then cotransfected into the 293T cells using 60µL of Lipofectamine 2000 transfection reagent
(Life Technologies) according to the manufacturer’s protocol. After 5 hours, the media
was replaced with fresh antibiotic-free DMEM supplemented with 10% FBS. At 72 hours
post-transfection, the virus was harvested by spinning for 5 min at 400 x g to pellet
cellular debris. The supernatant was decanted through a 0.45µm filter.
For generation of lentivirus, 293T cells were transfected using the third generation
lentiviral packaging system (Dull et al., 1998). 3µg of each of the 3 packaging vectors
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and 9µg of the appropriate shRNA plasmid were transfected into cells using 60µl of
Lipofectamine 2000 transfection reagent according to the manufacturer’s protocol. The
virus was collected as above for lentiviral production.
Cancer cells were transduced with virus in the presence of 10µg/mL of polybrene
(Millipore). After 16 hours, the media was changed to DMEM supplemented with 10%
FBS and the appropriate antibiotic was added for selection.
Primers used to clone overexpression constructs are listed in Table 6.2. shRNA
sequences are listed in Table 6.3. Mutagenesis was performed using QuikChange
Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies) according to the
manufacturer’s protocol. Mutagenesis primer sequences are listed in Table 6.4.
The Sac1-K2A construct was a gift from Dr. Peter Mayinger, University of
Oregon (Rohde et al., 2003). For PI(4,5)P2 depletion experiments, LYN11-FRB-mcherry
(Addgene plasmid # 38004) and PJ-INPP5E (Addgene plasmid # 38001) were gifts from
Robin Irvine (Hammond et al., 2012). For cofilin replacement experiments, pEGFP-N1
human cofilin WT was a gift from James Bamburg (Addgene plasmid # 50859)
(Garvalov et al., 2007).
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Table 6.2. Cloning Primers
PITPNC1

F: CCGGCCTACGTAATGCTGCTGAAAGAGTACCG

Vector: pBABE-puro

R: CCGGCCGAATTCTTACTCAGATTTGGGCCGACA

PITPNC1-GFP

F: CCGGCCAAGCTTATGCTGCTGAAAGAGTACCGG

Vector: pBABE-puro

R: CCGGCCCTCGAGCTCAGATTTGGGCCGACA

PITPNC1-GST

F: CCGGCCGAATTCCTGCTGAAAGAGTACCGGATC

Vector: pGEX-6p-1

R: CCGGCCCTCGAGTTACTCAGATTTGGGCCGACA

PITPNC1-Flag

F: CCGGCCTACGTAATGCTGCTGAAAGAGTACCG

Vector: pBABE-puro

R:CCGGCCGAATTCTTACTTGTCGTCATCGTCTTTGT
AGTCCTCAGATTTGGGCCGACATG

FAPP1-PH

F: CCGGCCGAATTCATGGAGGGGGTGTTGTACAA

Vector: pGEX-6p-1

R:CCGGCCCTCGAGTCACCTTGTATCAGTCAAACAT
G

PTPRN2

F: CCGGCCGAATTCGGGCCGCCGCTCCCGCTGCTG

Vector: pBABE-puro

R: CCGGCCCTCGAGTCACTGGGGAAGGGCCTTGAG

PLCB1

F: CCGGCCTACGTAATGGCCGGGGCTCAACCCGGA

Vector: pBABE-puro

R: CCGGCCGTCGACTCACAGAGGAGTATCAAATTC

CFL1-Lck

F:CCGGCCGAATTCATGGGATGCGTCTGCTCAAGCG

Vector: pEGFP-N1

CCTCCGGTGTGGCTGTC
R:CCGGCCGGATCCCGGGATAACAAAGGCTTGCCCT
CCAGGGAG

PIP5K1A

F: CCGGCCTACGTAATGGCGTCGGCCTCCTCCGGG

C-terminal FLAG

R:CCGGCCGTCGACTTACTTGTCGTCATCGTCTTTGT

Vector: pBABE-puro

AGTCATGGGTGAACTCTGACTCTGC
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Table 6.3. shRNA Sequences
Control

CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCT
TCATCTTGTTGTTTTT

PITPNC1#1

CCGGCGGGTGTATCTCAACAGCAAACTCGAGTTTGCTGTTG
AGATACACCCGTTTTTG

PITPNC1#2

CCGGCAATGGATGAAGTCCGAGAATCTCGAGATTCTCGGAC
TTCATCCATTGTTTTTG

ADAM10

CCGGGCAGGTTCTATCTGTGAGAAACTCGAGTTTCTCACAG
ATAGAACCTGCTTTTT

FAM3C

CCGGGATGCAAGTTTAGGAAATCTACTCGAGTAGATTTCCT
AAACTTGCATCTTTTTG

HTRA

CCGGCGGTGAAGTGATTGGAATTAACTCGAGTTAATTCCAA
TCACTTCACCGTTTTTG

PDGFA

CCGGGAATCCGGATTATCGGGAAGACTCGAGTCTTCCCGAT
AATCCGGATTCTTTTTTG

PTPRN2 #1

CCGGAGGTGCTAAAGAGATTGATATCTCGAGATATCAATCT
CTTTAGCACCTTTTTT

PTPRN2 #2

CCGGCGACGATGATAGACTTTACCACTCGAGTGGTAAAGTC
TATCATCGTCGTTTTT
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Table 6.4. Mutagenesis Primers
PITPNC1 T58E

F:CCCTCACCATGGCAATGGGCAGTTCGAAGAGAAGCG
GGTGTATCTCAACAGCA
R:TGCTGTTGAGATACACCCGCTTCTCTTCGAACTGCCC
ATTGCCATGGTGAGGG

PITPNC1 N88F

F:ATTTTATGTGACAGAGAAGGCTTGGTTCTATTATCCC
TACACAATTACAGAAT
R:ATTCTGTAATTGTGTAGGGATAATAGAACCAAGCCTT
CTCTGTCACATAAAAT

PITPNC1 S274A

F:TCTTCCGTCCGCAGTGCGCCTTCTGCCGCTCCATCCA
CCCCTCTCTCCACA
R:TGTGGAGAGAGGGGTGGATGGAGCGGCAGAAGGCG
CACTGCGGACGGAAGA

PITPNC1 S299A

F:CCCAAAGATCGGCCCCGGAAAAAGGCCGCCCCAGAA
ACTCTCACACTTCCA
R:TGGAAGTGTGAGAGTTTCTGGGGCGGCCTTTTTCCGG
GGCCGATCTTTGGG

PTPRN2 C945A

F:GCCGTTCTTGTCCAATAATTGTTCATGCCAGTGACGG
TGCAG
R:CTGCACCGTCACTGGCATGAACAATTATTGGACAAG
AACGGC

PLCB1 H331Q

F:ATTTCATTAATTCCTCGCAAAACACCTACCTCACAGC
TG
R:CAGCTGTGAGGTAGGTGTTTTGCGAGGAATTAATGA
AAT

RNA Extraction and Real-Time Quantitative PCR (RT-qPCR)
Total RNA was collected from cells using the Total RNA Purification Kit
(Norgen Biotek) according to the manufacturer’s protocol. For quantification of mRNA,
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1µg of total RNA was reverse transcribed using the cDNA First-Strand Synthesis Kit
(Life Technologies). Approximately 50ng of the resulting cDNA was then mixed with
SYBR green PCR Master Mix (Applied Biosystems) and appropriate primers.
Quantitative mRNA expression data was obtained using an ABI Prism 7900HT RealTime PCR System (Applied Biosystems). HPRT was used as an endogenous control for
normalization. Primer sequences are listed in Table 6.5.

Table 6.5. Quantitative PCR Primers
PITPNC1

F: GCGCTACTACAAAGAATCTGAGG
R: GAGCACATGATAGGCTGATGAC

ADAM10 F: AGCAACATCTGGGGACAAAC
R: CCCAGGTTTCAGTTTGCATT
FAM3C

F: ATCTCAAAAGCTTGCCCTGA
R: AAATGGTGCCACATCTCCTC

MMP1

F: AGGTCTCTGAGGGTCAAGCA
R: AGTTCATGAGCTGCAACACG

HTRA1

F: TGGAATCTCCTTTGCAATCC
R: CCTTCAGCTCTTTGGCTTTG

PDGFA

F: ACACGAGCAGTGTCAAGTGC
R: ACCTCACATCCGTGTCCTCT

PTPRN2

F: GGCCAAAGGTGCTAAAGAGA
R: TGTCAGCGCGAACTCAAA

PLCB1

F: TCTGGAATGCAGGTTGTCAG
R: GCCACTCTTCCCGTTGTATT

CFL1

F: TGTCAAGATGTGCCAGATAA
R: GCCCAGAAGATAAACACCAGAT

PIP5K1A

F: CGGCCCGATGATTACTTGTAT
R: CGTCGCTGGACACATAGAATAG
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Matrigel Invasion Assay
Cancer cells were grown to 70% confluence and then the medium was changed to
0.2% FBS DMEM for 16 hours. BioCoat Matrigel invasion chambers (Corning) were
hydrated with 0.2% DMEM media for 2 hours prior to use. Cells were seeded into
invasion chambers at 50,000 cells per well in quintuplicate and incubated at 37°C for 20
hours. Inserts were rinsed in PBS, and the apical side of the insert was gently scraped to
remove non-invaded cells. Inserts were fixed in 4% paraformaldehyde in PBS for 15
minutes at 37°C. The inserts were excised and mounted with VECTASHIELD HardSet
Mounting Medium with DAPI (Vector Laboratories). Invaded cells were imaged using an
inverted fluorescence microscope (Zeiss Axiovert 40 CFL). Four images at 10X
magnification were taken for each insert and quantified using Fiji software.

Endothelial Recruitment Assay
50,000 cancer cells were seeded into 24-well plates approximately 24 hours prior
to the start of the assay. HUVEC cells were serum-starved in EGM-2 media (Lonza)
supplemented with 0.2% FBS for 20 hours. Cancer cells were washed with PBS and 1
mL 0.2% FBS EGM-2 medium was added to each well. Each well was then fitted with a
3.0µm HTS Fluoroblock trans-well migration insert (BD Falcon). 80,000 HUVECs,
resuspended in 0.5 mL of starvation media, were seeded into each insert and incubated at
37°C for 20 hours. The inserts were processed and analyzed as described above for the
Matrigel invasion assay.
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Trans-well Migration Assay
Cancer cells were grown to 70% confluence and medium changed to 0.2% FBS
DMEM media for 16 hours. Cells were seeded into 3.0μm PET trans-well migration
inserts (Corning) in quintuplicate at 100,000 cells per well in 0.2% FBS DMEM. Inserts
were processed and analyzed as described above for the Matrigel invasion assay.

Scratch Assay
Cancer cells seeded in triplicate were grown to 90% confluence in 6-well plates
and then starved for 16 hours in 0.2% FBS DMEM. A scratch through the cell monolayer
was made using a 1000μL pipet tip. Four images of each well were taken after the scratch
was made (0 h) and 24h later. Images were analyzed using ImageJ (NIH) to quantify the
scratch area covered by cancer cells.

Proliferation Assay
20,000 cancer cells were seeded in triplicate for each time point in 6-well plates
and counted after 1, 3, and 5 days using a hemocytometer.

Luciferase Reporter Assay
The full-length 3’UTR’s and CDS’s of PITPNC1, PTPRN2, and PLCB1 were
cloned into the psiCheck2 dual luciferase reporter vector (Promega). MDA-MB-231
cells were transfected with the respective specific reporter construct. 30 hours after
transfection, the cells were lysed and the ratio of renilla to firefly luciferase expression
was determined using the dual luciferase assay (Promega).
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Flag Immunoprecipitation
MDA-MB-231 cells retrovirally transduced to express Flag-tagged PITPNC1
were lysed in TNET buffer (50mM Tris, 150mM NaCl, 1mM EDTA, 1% Triton X-100,
pH 7.4). Following centrifugation at 20,000 x g for 15 minutes the supernatant was mixed
with magnetic anti-flag beads (Sigma) and left to rotate end over end at 4°C for 5 hours.
Immunoprecipitated material was washed twice in PBS before eluting the bound protein
complexes by addition of 3X Flag peptide (Sigma). Immunoprecipitated material was
analyzed by mass spectrometry and western blotting.

Protein Production
cDNA of human PITPNC1 and the FAPP-PH domain was cloned into the pGEX6P-1 vector (GE Healthcare Biosciences) and transformed into BL21(DE3) cells (Agilent
Technologies). Cells were grown in LB medium supplemented with 100μg/mL
ampicillin to OD600 = 0.6 at 37°C. Isopropyl-B-D-thiogalactaside (IPTG, Sigma) was
added to 0.2mM and incubation was continued at 18°C overnight. Cells were collected
by centrifugation and resuspended in 50mM Tris-HCl, 150mM NaCl, 2mM DTT, pH 7.5
plus protease inhibitors (Roche). The lysate was sonicated and spun down at 6,000 x g
for 20 minutes at 4°C. Protein was further purified from the supernatant using the Pierce
GST Spin Purification kit (Thermo Scientific) according to the manufacturer’s
instructions.
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Lipid Overlay Assay
Nitrocellulose membranes were spotted with the indicated lipids (Echelon
Biosciences). The membranes were blocked in 3% FFA-free BSA (Sigma-Aldrich) and
incubated with 1μg recombinant PITPNC1 protein overnight at 4°C. PITPNC1 was
detected using anti-GST antibody (Cell Signaling Technologies) and HRP-conjugated
anti-rabbit antibody (Invitrogen).

Liposome Pull-Down Assay
The assay was performed as previously described (He et al., 2009). Solutions of
phosphatidylcholine, phosphatidylethanolamine and phosphoinositides (65/24/4) were
dried under argon. The lipids were resuspended in lipid transfer buffer (10mM HEPES
pH 7.4, 150mM NaCl) for a total 4mM total lipid and incubated at 65°C for 1 hour. The
lipids were frozen in liquid nitrogen and thawed at 37°C three times. Resulting liposomes
were pelleted by centrifugation at 25,000 x g for 20 minutes at 22°C. Pelleted liposomes
were resuspended in lipid transfer buffer and mixed with 4μg recombinant protein. After
a 30 minute incubation at room temperature the liposomes were collected by
centrifugation (25,000 x g for 20 minutes at 22°C) and levels of PITPNC1 in the
supernatant and pellet were detected by SDS-PAGE followed by SimplyBlue staining
(Invitrogen). The liposome-bound fraction was determined as PITPNC1 protein levels in
the pellet compared to the supernatant.
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Immunofluorescence
Immunocytochemical detection of PI4P was performed as previously described
(Hammond et al., 2009b). Cells were fixed in 4% paraformaldehyde/PBS for 15 minutes
at room temperature, washed, and permeabilized for 5 minutes with 20μM digitonin.
Blocking and all subsequent staining steps were carried out in 5% goat serum/PBS. The
following primary antibodies were also used: anti-p230 (BD Biosciences), FAPP-PHGST (recombinant protein), anti-GM130 (BD Biosciences), anti-GOLPH3 (Abcam), antiRAB1B (Proteintech), anti-TGN46 (AbD Serotec), anti-Flag (Sigma) and anti-GST (Cell
Signaling). Cells were rinsed, stained with DAPI (4',6-diamidino-2-phenylindole), and
mounted with ProLong Gold (Life Technologies).
Immunocytochemical detection of PI(4,5)P2 was performed as previously
described (Hammond et al., 2009b). Cells were fixed in 4% paraformaldehyde, 0.2%
glutaraldehyde in PBS for 15 minutes at room temperature, washed, and then chilled on
ice. Cells were blocked and permeabilized for 45 minutes in 5% goat serum, 50mM
NH4Cl, 0.5% saponin, 20mM Pipes pH 6.8, 137mM NaCl, 2.7mM KCl. Subsequent
steps were carried out in this buffer with reduction of saponin to 0.1%. Cells were
incubated with anti-PI(4,5)P2 IgM antibody (Echelon Biosciences), followed by
Biotinylated anti-IgM antibody (Vector Laboratories), and detected using Streptavidin
Alexa Fluor-labeled tertiary antibody (Life Technologies). Cells were post-fixed in 2%
paraformaldehyde for 10 minutes on ice, before warming to room temperature. Cells
were rinsed, stained with DAPI, and mounted with ProLong Gold (Life Technologies).
For immunocytochemical detection of CFL1 or FLAG, cells were fixed in 4%
paraformaldehyde/PBS for 15 minutes at room temperature, rinsed, and permeabilized for
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5 minutes with 0.3% Triton-X. Blocking and incubation with antibodies was conducted in
5% goat serum/PBS. Anti-CFL1 antibody (Cell Signaling Technologies) or anti-FLAG
(Sigma) was detected using the appropriate Alexa Fluor-labeled secondary antibody (Life
Technologies). Cells were stained with DAPI and mounted in ProLong Gold (Life
Technologies).
Immunofluorescence of phalloidin was performed using Alexa Fluor-555 and
Alexa Fluor-647 Phalloidin (Life Technologies) according to the manufacturer’s
protocol.

Microscopy
Fluorescence images were acquired on an inverted TC5 SP5 laser scanning
confocal microscope. Image analysis was performed using Fiji software.
To measure lipid/protein contents in the trans Golgi compartments, the trans
Golgi markers (p230, TGN46) were thresholded and the magic wand tool (ImageJ) was
used to demarcate the trans-Golgi compartments. Mean signal intensity of the
lipid/protein was then measured in the demarcated compartment.
Golgi extent was calculated as the length of p230-covered nucleus relative to the
nuclear circumference multiplied by 100.
For quantification of released PI4P-containing vesicles in the Golgi exit assay,
trans Golgi PI4P abundance was subtracted from whole cellular PI4P abundance and
divided by the cell area. The data was then normalized to the time 0 value.
To measure mean signal intensity in the membrane compartment, the cell was
thresholded and the outline of the cell selected using the magic wand tool. The outline
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was reduced by 1μm to form an inner band, and mean signal intensity of this area
between the outer and inner band was recorded.
For whole cell phalloidin content, the cell was thresholded and the outline of the
cell selected using the magic wand tool. The mean signal intensity of the signal over the
area of the cell was recorded.
To measure incorporation of biotin-actin monomers in the barbed end assay, the
cell was thresholded in the phalloidin signal channel and the outline of the cell selected
using the magic wand tool. The mean signal intensity of the streptavidin signal over the
area of the cell was recorded.

Transmission Electron Microscopy
Cells were fixed in 4% paraformaldehyde and 2.5% glutaraldehyde in 0.075M
sodium cacodylate buffer pH 7.4 for 30 minutes. Subsequently, cells were washed in the
buffer, post-fixed with 1% osmium tetra-oxide for 1 hour, stained en bloc with 2% uranyl
acetate for 30 minutes, dehydrated by a graded series of ethanol, depletion of ethanol
with propylene oxide, infiltrated with a resin (Electron Microscope Sciences) and
embedded with the resin. After polymerization at 60°C for 48 hours, ultra-thin sections
were cut, post-stained with 2% uranyl acetate and 1% lead citrate and visualized by
electron microscopy (100CX JEOL) with the digital imaging system XR41-C (Advantage
Microscopy Technology).
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Stable Isotope Labeling of Amino acids in Culture (SILAC) LC-MS/MS Experiment
Cells were grown in DMEM-Flex media contained in the SILAC Protein ID &
Quantitation Kit (Invitrogen) for 7 days according to the manufacturer’s instructions.
Media was changed to serum-free DMEM-Flex media 16 hours prior to collection of
conditioned media. Conditioned media was 0.2μM-filtered to remove dead cells, and
concentrated 100x using Amicon Ultra-15 centrifugal filter units (Millipore). Reduced
and alkylated proteins were separated by 1D gel electrophoresis, stained by SimplyBlue
(Invitrogen), and protein bands were excised and trypsinized (Promega), following
published protocol (Shevchenko et al., 1996). Extracted peptides were desalted on a trap
column following separation using a 12cm/75μm reversed phase C18 column (Nikkyo
Technos Co., Ltd.). The resolving gradient, increasing from 10% B to 45% B in 45
minutes (A: 0.1% Formic Acid, B: Acetonitrile/0.1% Formic Acid), was delivered at 300
nL/min. The liquid chromatography setup (Dionex) was connected to an Orbitrap XL
(Thermo Scientific) operated in CID top-7-mode. Acquired data was searched against a
forward and a reversed (Elias et al., 2005) human data base (ipi.HUMAN v3.87)
appended with common contaminants (Bunkenborg et al., 2010) and quantified using
MaxQuant version 1.2.2.5 (Cox et al., 2011). Tandem MS data were queried using full
tryptic constraint allowing for a maximum of 3 missed cleavages. Oxidation of methiones
and N-terminal acetylation of protein was allowed. Cysteines were treated as being fully
carbamidomethylated. Matched peptides fulfilling a False Discovery Rate of 1% or lower
were accepted as valid matches.
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Label Free Quantification LC-MS/MS experiment
Co-immunoprecipitated and 3x-FLAG eluted proteins were trypsinized insolution overnight. Peptides were desalted using homemade Empore C18 columns prior
to being analyzed by LC-MS/MS (Dionex 3000 HPLC coupled to Orbitrap XL, Thermo
Scientific). The mass spectrometer was operated in a high/low mode. Peptides were
separated at 300nL/min using a gradient increasing from 10% B to 45% B in 120 minutes
(A: 0.1% Formic Acid, B: Acetonitrile/0.1% Formic Acid). Generated LC-MS/MS data
were queried against UniProt’s complete Human Proteome (July 2014) and quantified
using MaxQuant 1.5.0.30. In short, Peptide Spectrum Match false discovery rate was set
to 1% while protein false discovery rate was set to 1%. A total of 563 proteins were
matched. Match between runs were used for the label free quantification. Generated label
free quantification values were analyzed using Perseus 1.5.0.9. All LFQ values were log2
transformed and filtered, requiring that a given protein was matched in two of the three
replicates. An excellent correlation was measured between replicate samples (r2 of 0.98
for each condition). Missing LFQ values were imputed (width: 0.3, down shift: 1.8).
Differences between the two conditions were assessed by a 2-sample t-test using a
permutation based FDR cut-off of p < 0.05. In addition to PITPNC1, several 14-3-3
protein isoforms and RAB1B were found to be significantly different between the two
samples. RAB1B was matched with 6, 8, and 9 peptide spectrum matches (PSMs) in bait
samples versus 2, 1 and 2 PSMs in control.
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Western Blot Analysis
Membrane and membrane-associated proteins were isolated from cells using the
ProteoExtract native membrane and membrane-associated protein extraction kit (EMD
Millipore) according to the manufacturer’s instructions. Whole cell lysate was prepared
by lysing cells in RIPA buffer containing protease and phosphatase inhibitors (Roche).
Conditioned media was collected from cell incubated in serum-free media for 16 hours.
Collected media was 0.2μm-filtered to remove dead cells and concentrated 20-fold using
spin filter columns (Millipore). Proteins were separated using SDS-PAGE gels (Life
Technologies) and transferred to PVDF membrane (Millipore). The following antibodies
were used for protein detection: anti-FAM3C (Abcam), anti-MMP1 (Acris Antibodies),
anti-HTRA1 (Sigma), anti-PDGFA (Acris Antibodies), anti-ADAM10 (Millipore), antiRAB1B (Proteintech), anti-GOLPH3 (Abcam), anti-CFL1 (Cell Signaling
Technologies,), anti-EGFR (Cell Signaling Technologies), anti-PTPRN2 (Sigma,), antiPLCB1 (Sigma), anti-β-actin (Sigma), anti-GAPDH (Cell Signaling Technologies). To
image loading control proteins, blots were stripped using Restore Western Blot stripping
buffer (Thermo Scientific) according to the manufacturer’s protocol followed by
incubation with appropriate primary antibodies. Bound antibody was detected using the
appropriate HRP-conjugated secondary antibodies (Life Technologies). Densitometry
analysis of blots was performed using ImageJ (NIH).

Addition of Exogenous PI(4,5)P2
Exogenous PI(4,5)P2 was performed using the Shuttle PIP kit (Echelon
Biosciences) according to the manufacturer’s instructions. PI(4,5)P2-diC16 and Carrier 2
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(Histone H1) were solubilized in water to 500μM concentration. Carrier 2 and PI(4,5)P2
were combined in a 1:1 ratio (100μM concentration each) and incubated for 15 minutes at
room temperature. The complex was added to cells for 1 hour at a final concentration of
10μM. Treated cells were then subjected to immunofluorescence, migration, or metastatic
colonization assays.

Barbed End Assay
Barbed end assay was performed with slight modifications as previously
described (Chan et al., 1998). Biotin-G-actin (Cytoskeleton, Inc.) was prepared as
monomers according to the manufacturer’s instructions. Permeabilizing buffer was
prepared as 20mM Hepes, 138mM KCl, 4mM MgCl2, 3mM EGTA, 0.04 g/L saponin,
1mM ATP, and 1% BSA. Cells were starved for 3 hours in 0% FBS DMEM. Cells were
treated with addition of serum for 5 minutes, and then incubated in permeabilizing buffer
containing 0.2μM biotin-G-actin for 1 minute at 37°C. Cells were rinsed in PBS and
fixed for 15 minutes in 4% paraformaldehyde/PBS. Cells were blocked in 5% goat
serum/PBS for 30 minutes, followed by incubation with Streptavidin-conjugated Alexa
Fluor-555 and Phalloidin Alex Fluor-647 (Life Technologies) in blocking buffer for 30
minutes. Cells were counter-stained with DAPI and mounted using Prolong Gold (Life
Technologies).
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Histology
Lungs were prepared by intravenous perfusion of PBS followed by 4%
paraformaldehyde/PBS and infusion of paraformaldehyde via the trachea. Removed lungs
were embedded in paraffin, sectioned in 5μm thick slices, and stained with hematoxylin
and eosin.

Analysis of clinical data sets
Published data generated by the TCGA Research Network
(http://cancergenome.nih.gov/)(Cancer Genome Atlas, 2012) was used to obtain RNASeq expression values for PTPRN2 and PLCB1 in breast cancer patients. Values were
converted to z-scores and averaged to determine the PTPRN2 and PLCB1 combined gene
signature. Each sample was classified as positive for the gene signature if the signal was
above the median signal for the population.
Published microarray data from GSE17536 was used to obtain probe-level
expression values for PITPNC1 in colorectal cancer patients. Each sample was classified
as PITPNC1 positive if the signal was above the median signal for the population.
KM Plot data from the breast cancer database (version 2014) (Gyorffy et al., 2010) was
analyzed using JetSet probes only (Li et al., 2011a). Expression of each gene was
calculated using the auto-selected best cutoff. Each sample was classified as positive for
the selected gene expression if the signal was above the designated cutoff.
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Statistical analyses and general methods
All statistical analysis was performed using Graphpad Prism 5. For each figure,
center bars represent the mean and error bars represent S.E.M. Populations were
determined to be normally distributed by the Kolmogorov-Smirnov normality test, and
unpaired Student’s one-tailed t-test was used to determine significance. F test was
performed to compare variances, and Welch’s correction was included for populations
where the variances differed significantly. For populations where N < 5 or populations
were not normally distributed, one-tailed Mann-Whitney test was used to determine
significance. For Kaplan-Meir survival analysis, a Log-rank (Mantel-Cox) test was used.
Symbols were used as follows: *P < 0.05, **P < 0.01, ***P < 0.001. P < 0.05 was
considered statistically significant.
For in vitro and cellular experiments, no statistical method was used to
predetermine sample size. The investigators were not blinded to allocation during
experiments and outcome assessment. In vitro experiments and imaging experiments
were performed a minimum of three independent times with separate culture preparations
and imaged in individual sessions. Western blots were conducted three times using
independent sample preparations.
For animal experiments, no statistical method was used to predetermine sample
size. The investigators were not blinded to allocation during experiments and outcome
assessment. Mice were randomized into groups prior to injection. Pre-established criteria
for exclusion included accidental death before completion of the experiment for causes
unrelated to the experiment or significant outlier as calculated by sample values greater
than two standard deviations from the mean.
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